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“I try to best every previous defining moment with a new one. In that
way you don’t live in the past, you live for the future.”
- Neil deGrasse Tyson
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Abstract
Atherosclerosis is characterised by the deposition of lipids in the arterial wall, which
triggers an inflammatory response. Leukocytes migrate into the area of injury and release
heme-peroxidase myeloperoxidase (MPO) into the extracellular matrix (ECM) milieu,
which converts hydrogen peroxide (H2O2) in the presence of halides or pseudohalides,
chloride (Cl-) and thiocyanate (SCN-), to generate oxidants hypochlorous acid (HOCl)
and hypothiocyanous acid (HOSCN), respectively. There is considerable evidence that
these oxidants, particularly HOCl, modify and damage surrounding cells and ECM
proteins at the site of inflammation, and therefore have been suggested to play a role in
the pathophysiology of cardiovascular disease (CVD). HOCl is a highly reactive oxidant
and has been observed to modify and oxidise lipids, proteins, DNA, and RNA, which
subsequently leads to cellular dysfunction. In contrast, HOSCN is much less reactive
compared to HOCl and has a high specificity for cysteine (Cys) residues. Oxidation
by HOSCN is generally reversible by endogenous antioxidant mechanisms but can be
irreversibly damaging at high concentrations. The ECM harbours several important
proteins including fibronectin (FN), which plays a role in matrix assembly, remodelling,
and assists in cell functions. FN possesses functionally important epitopes including:
cell binding fragment (CBF), heparin binding fragment (HBF), and extra domain A
(EDA). The proximity between FN and MPO-derived oxidants makes it a likely target
for oxidation and modifications. Therefore, this project aims to elucidate the effects of
HOCl, and HOSCN on ECM protein, FN, and whether SCN- concentrations can modulate
the extent of modifications causes by HOCl.
In the first study, commercially-derived human plasma FN was exposed to increasing
concentrations of reagent HOCl for 2 hr at 37°C. Human plasma FN exposed to
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HOCl resulted in fragmentation and aggregation (or formation of altered species) of
FN, particularly at greater than 50x molar ratios as seen with sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE), silver staining and Western blotting.
HOCl targets methionine (Met) and tryptophan (Trp) residues in a dose dependent
manner, but not tyrosine (Tyr) residues. Methionine sulfoxide (MetSO), a by-product
of Met oxidation, was observed to be present in native FN and treatment with HOCl.
MetSO was likely to be further oxidised with treatment of higher concentrations of HOCl.
The FN CBF and HBF epitopes were targeted and modified by HOCl as seen with loss
of antibody recognition using enzyme-linked immunosorbent assay (ELISA) and Western
blotting. Human coronary artery endothelial cells (HCAEC) exposed to HOCl-modified
FN were observed to lose adhesion with impaired cell spreading, and a reduction in cell
metabolic activity. Furthermore, HCAEC exposed to HOCl-modified FN were observed
to up- and down-regulate genes associated with ECM and adhesion molecules. HOCl was
also observed to target and modify cellular-derived FN in HCAEC-derived whole ECM
extract causing loss of antibody recognition for the CBF, HBF and cellular-derived FN
EDA epitopes. These data support the hypothesis that HOCl targets and modifies FN,
which subsequently leads to biological dysfunction of HCAEC exposed to HOCl-modified
FN.
In the second study, commercially-derived human plasma FN was exposed to increasing
concentrations of reagent HOSCN derived from lactoperoxidase (LPO)/SCN-/H2O2 and
incubated for 2 hr at 37°C. Modifications by HOSCN to human plasma FN were observed
to be less extensive than what was observed with HOCl. HOSCN was observed to
structurally modify human plasma FN starting at 10x molar ratio with minor formations
of fragments and aggregates (or altered species). HOSCN was observed to target and
oxidize Cys (thiol) residues as examined using a ThioGlo assay, which is in-line with the
knowledge that HOSCN has a specificity for Cys residues. The functional CBF epitope
on FN was observed to be modified by HOSCN but to a lesser extent compared to
HOCl. Subsequent biological functional assays for cell adhesion and metabolic activity
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for HCAEC exposed to HOSCN-modified FN showed no changes. However, these HCAEC
were observed to up- and down-regulate certain ECM and adhesion molecules, although
fewer changes were examined when compared to HCAEC exposed to HOCl-modified FN.
Exposure of HCAEC-derived whole ECM extract to HOSCN resulted in no significant
changes to the functional CBF, HBF, and EDA epitopes, and no major structural changes
were observed in Western blots. These data support the hypothesis that HOSCN does
modify FN but to a lesser extent compared to HOCl, suggesting that the presence of
HOSCN over that of HOCl may lead to less FN damage.
In the third study, human plasma FN was exposed to an enzymatic MPO/Cl-/H2O2
or MPO/SCN-/H2O2 system, which would better simulate the reaction that occurs in
vivo. Exposure of human plasma FN to the enzymatic MPO/Cl-/H2O2 system resulted
in extensive modifications to the structure of FN as observed with silver staining and
Western blotting. The functional CBF and HBF epitopes on FN were both observed
to be targeted and modified by the enzymatic MPO/Cl-/H2O2 system. Furthermore, a
HOCl-generated epitope was observed with increasing concentration of H2O2. A decrease
in HCAEC adhesion and proliferation were observed when HCAEC were exposed to FN
modified by the enzymatic MPO/Cl-/H2O2 system. In contrast, exposure of human
plasma FN to the enzymatic MPO/SCN-/H2O2 system resulted in minor modifications
to the protein structure and functional CBF, and HBF epitopes. HCAEC adhesion
and proliferation were not significantly affected when incubated on treated FN. These
data support that oxidants derived from the enzymatic MPO/Cl-/H2O2 modifies the
structure of human plasma FN resulting in loss biological function. The extent of
modification by MPO/SCN-/H2O2 system on human plasma FN was minor compared
to the MPO/Cl-/H2O2 system and resulted in no changes to cell adhesion or metabolic
activity.
The final study examined the competition between Cl- and SCN- as a substrates
for MPO and their modifications on human plasma FN. At physiologically relevant
concentrations of 100 mM of Cl- and absent or low concentrations of SCN-, FN is
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modified resulting in protein fragmentation and aggregation (or altered species), and loss
of antibody recognition of the functional CBF and HBF epitopes on FN. Furthermore,
a formation of HOCl-generated epitopes were also observed. Addition of increasing
concentrations of SCN- resulted in a shift of structural modifications that were specific to
MPO/Cl-/H2O2 to those observed with treatment using the enzymatic MPO/SCN-/H2O2
system. The addition of increasing concentration of SCN- also mitigated the loss of
antibody recognition, returning it back to levels similar to control. This supports the
hypothesis that addition of SCN- assists in mitigating damage derived from the enzymatic
MPO/Cl-/H2O2 system.
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Chapter 1
Introduction
1.1 General Overview
This chapter will provide background information on myeloperoxidase (MPO),
extracellular matrix (ECM), and their role in the immune response and in the basement
membrane. It will also include a literature review on the current knowledge of the
relationship between MPO and ECM proteins, and their role in the inflammatory disease
atherosclerosis.
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1.2 Chronic inflammatory disease and atherosclerosis
Atherosclerosis is a common chronic inflammatory disease that is characterized by
the accumulation of lipids in the arterial wall, in particular those derived from low
density lipoprotein (LDL) (Figure 1.1) [1]. LDL is necessary for lipid transport and
is derived endogenously in small quantities within the body, but high levels can occur
with poor dietary intake, leading to increased risk of cardiovascular disease [2]. Increased
circulating levels of LDL leads to increase occurrences of LDL deposits in the arterial walls
with evidence of extensive LDL modifications by enzymatic mechanisms (lipoxygenase,
myeloperoxidase, NADPH oxidases, and nitric oxide synthase), reactive nitrogen/oxygen
species, free radicals and two-electron oxidant [3–5]. Such modifications have been
suggested to contribute to LDL retention [3, 4, 6]. An inflammatory response occurs
against modified LDL, with un-regulated uptake by macrophages leading to formation
of foam cells [7–9]. Oxidised LDL is seen to express a number of pro-atherogenic and
atherosclerotic effects including changes to the arterial wall proteins [5].
MPO is a leukocyte-derived haem-peroxidase that produces reactive oxidants during
inflammation [11]. These oxidants are proposed to structurally modify the ECM of
the arterial wall basement membrane. Structurally modified ECM protein may lose its
function, which can alter metabolism and cause endothelial dysfunction. Further changes
can occur when MPO and its oxidants, interacts with smooth muscle cells (SMC) during
the development of atherosclerosis [12, 13]. Inflammatory cell and SMC infiltration [14],
accumulation of intracellular/extracellular lipids [1, 15], and endothelial dysfunctions [16]
are all hallmark characteristics of plaque formation in atherosclerosis.
Moreover, occlusion of the vessel in combination with arterial calcification results in
hardening and inflexibility in advanced lesions, which leads to an increased pressure
on arterial walls [17]. As with any wound healing or formation of lesions, the process of
fibrosis occurs, which is highly dependent on the basement membrane (and corresponding
ECM) to generate a fibrous cap for a more stable lesion. Mortalities and complications
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Figure 1.1: Schematic diagram demonstrating the progression of atherosclerosis. EL is extracellular
lipid, NC is necrotic core, FC is fibrous cap, and Th is luminal thrombi. Adapted from Virmani, 2000
[10]
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from chronic heart disease (CHD), as well as cerebrovascular disease (i.e. myocardial
infarction and stroke, respectively) have been associated with rupture of lesions and
subsequent stenosis of the blood vessels, rather than the presence of an atherosclerotic
lesion itself [18]. The likelihood of rupture is determined by the composition of the plaque;
thin fibrous caps with higher levels of inflammatory cells are more likely to rupture than
a plaque with a thick fibrous cap [1]. Thus, structural modifications and/or damage to
the basement membrane and the associated ECM can make the plaque prone to rupture.
Therefore, it is pertinent to understand how such modifications may come about and
there is substantial evidence that oxidants produced during inflammation (notably those
derived from MPO) contribute to this damage.
4
1.3 Myeloperoxidase and its oxidative reactions
During the ”respiratory burst”, activated leukocytes convert diatomic oxygen to
superoxide radical (O2•-) [19, 20]. O2•- can subsequently undergo spontaneous or catalytic
(by superoxide dismutase enzyme) dismutation to generate the antimicrobial agent
hydrogen peroxide (H2O2) (Figure 1.2) [19, 20]. MPO is also released extracellularly into
the extracellular milieu (via degranulation of activated leukocytes) or are transcytosed
from plasma through the endothelium, and has been found to co-localise with fibronectin
(FN) in the ECM [21, 22].
MPO is a dimeric protein of approximately 146 kDa, made up of two monomers of 73 kDa
linked by a disulfide bond. Each identical monomer are functionally independent and are
composed of a heavy (58.5 kDa) and a light (14.5) chain [23]. The active site on MPO is
only easily accessible to H2O2 and small anions [24]. Reaction between H2O2 and ferric
MPO converts the enzyme to compound I by two electron oxidation (Figure 1.3) [25].
MPO compound I, in the presence of H2O2 and halides (chloride - Cl-, bromide - Br-,
iodide - I-) or pseudohalides (thiocyanate - SCN-) catalytically converts these substrates
to hypohalous acids, hypochlorous (HOCl), hypobromous (HOBr), hypoiodous (HOI),
and hypothiocyanous (HOSCN) acid, respectively via a two electron reduction [26]. This
process reverts MPO back to the ferric enzyme state [26]. MPO have reactivity rates
for substrates in the preference order of I- ∼ SCN- > Br- > Cl- (Table 1.1) [27]. Other
heme enzymes also exist such as eosinophil peroxidase (EPO) and lactoperoxidase (LPO).
EPO is an eosinophil-derived granule that play a role in allergies and parasitic infections
[28], and LPO is found to be present in higher concentrations in saliva, milk and tears
[29]. LPO preferentially generates HOSCN, while EPO has previously been found to
preferentially generate both HOBr and HOSCN over HOCl [26, 30].
Hypohalous acids generated via the MPO halogenation cycle are one of many reactions
that can cause oxidation. MPO is also capable of generating radicals via its peroxidase
cycle to produce other reactive species. MPO compound I, via a one electron oxidation,
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Table 1.1: Second-order rate constant of halide and pseudohalide substrates.
Substrate Second-order rate constant
SCN- 9.6 ± 0.5 x 106 M-1 s-1
I- 7.2 ± 0.7 x 106 M-1
Br- 1.1 ± 0.7 x 106 M-1
Cl- 2.5 ± 0.3 x 104 M-1 s-1
converts to compound II, oxidizing free radical O2•- and nitric oxide (NO•). The MPO
peroxidase cycle generates nitrogen dioxide radical (NO2•) tyrosyl radicals from the
oxidation of nitrite (NO2-) and Tyr, respectively [26]. O2•- is particularly known to
react with Tyr residues (free or present on peptides) to form crosslinks such as di-Tyr
[31].
Figure 1.2: Schematic diagram demonstrating the synthesis of MPO-derived oxidants generated via the
two electron oxidation halogenation cycle. Superoxide is generated from NADPH oxidase, which converts
to H2O2 spontaneously or enzymatically via superoxide dismutase. H2O2 reacts with degranulated MPO
in the presence of physiological concentrations of halides to produce HOCl, HOSCN, and HOBr.
Generation of bactericidal oxidants occur in inflammation invoked against foreign
pathogens [32]. In cases of chronic inflammation, generation of high concentrations of
these reactive oxidants can be damaging to host cells and molecules (lipids, proteins,
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peptides, DNA), such as may occur in atherosclerosis [33]. The presence of MPO has
been associated with endothelial cell (EC) dimorphism and dysfunction [34]. Moreover,
the localisation of MPO and the release of oxidants within the endothelium has been
associated with ECM protein fragmentation, cross-linking [35], and modifications to
amino acids [33, 36].
Figure 1.3: Schematic diagram demonstrating the MPO catalytic cycle. Image from Davies, 2011 [26]
High levels of plasma MPO have been clinically correlated with a prevalence of coronary
artery disease (CAD) [37], with an even greater prevalence in individuals presenting with
diabetes [11], and a history of smoking and hypertension [38]. Moreover, deficiency in
MPO plasma levels have been correlated with a reduced rate of cardiovascular disease [39].
Previous studies have correlated high systemic levels of MPO with plaque erosion, which
is another mechanism that can lead to thrombus occlusion as opposed to the commonly
known plaque rupture [40, 41]. Plaques that are susceptible to erosion are associated with
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absent or small lipid cores and elevated SMC, whereas plaque ruptures are associated
with a lipid rich core, higher levels of migrated inflammatory cells, with greater evidence
of matrix degradation and formation of thinner fibrous caps [40, 41]. Plaque erosion
have been shown to primarily occur in premenopausal women with coronary thrombosis
[42, 43]. MPO, being a cationic compound, has been shown to co-localize in the sub-
endothelial matrix with negatively charged proteins such as glucosaminoglycans (GAG)
and also FN [21, 22]. Thus, MPO-derived oxidant damage may be one mechanism that
modifies the vessel, and is a contributor to unstable plaque formations in atherosclerosis.
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1.3.1 Hypochlorous Acid
The physiological concentration of Cl- is known to be around 100 mM in humans [44].
Due to higher concentrations of Cl- compared to other halides, cytoxic HOCl is the
key component generated in host anti-microbial defense [32]. HOCl is known to be
highly reactive and acts on several oxidisable groups including: unsaturated fatty acids,
sulfur-ethyl group, sulfhydryl groups, haem groups and iron-sulfur centers [8, 45–48];
by-products generated during oxidation of these groups have been observed in chronic
inflammatory diseases. HOCl has been shown to oxidize proteins, peptides, lipid, DNA,
RNA, carbohydrate chains and antioxidants [49, 50].
HOCl reacts with amino acid side chains in proteins with a kinetic preference order
of: Cysteine (Cys) > Methionine (Met) > Cystine ∼ Histidine (His) ∼ α-amino ∼ >
Tryptophan (Trp) > Lysine (Lys) > Tyrosine (Tyr) ∼ Arginine (Arg) > Glutamine (Gln)
∼ Asparagine (Asn) [49, 51]. The action of HOCl on Cys residues results in the formation
of unstable sulfenyl chloride intermediate, which can react with water to yield cysteic
acid (RSO3H) [49]. Furthermore, sulfenyl chloride can also form dilsulfide crosslinks by
reacting with other Cys residue or with other thiol groups [49]. Reaction between HOCl
and Met has been found to commonly generate methionine sulfoxide (MetSO), a common
oxidation species of Met and has been linked to oxidative stress [51, 52]. Depending on
the availability of other amino acids, it’s likely that HOCl will react with Tyr and Trp
residues [26]. This reaction has previously been shown to produce strong di-Tyr and
di-Trp crosslinks, which are known to form non-reducible aggregates [53, 54].
HOCl can react with nitrogen containing compounds, such as free α-amino groups or
lysine residues found on proteins to form chloramines. In the presence of biological
reductants (e.g. Met, ascorbates, and thiols), chloramines can revert back to their parent
amines but have also been shown to readily degrade in vivo to form aldehydes (Figure 1.4)
[55–57]. Decomposition by decarboxylation of chloramines tend to form unstable imines,
which can further lose their ammonia group via hydrolysis [49]. The ammonium ion can
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cycle back to react with HOCl to form monochloramines and further react with other
groups. Furthermore, chloramines can transfer chlorine to Tyr (also His and Lys) residues
[58], leading to formation of 3-chloroTyr and subsequently to 3,5-chloroTyr, which are
notably long-lived biomarkers of HOCl modifications [48, 59].
Figure 1.4: Mechanism of rearrangement in nitrogen-centred radicals. Image from Hawkins, 2003 [49]
These mechanisms of HOCl oxidation are commonly investigated to elucidate the reaction
of HOCl with ECM-derived proteins. Chlorinated Tyr residues, 3-chloroTyr and 3,5-
chloroTyr, have been used as biomarkers to indicate MPO activity (Figure 1.5) [48,
60–62]. Chlorinated Tyr are a minor product but are more stable (particularly in acidic
conditions) compared to chloramines, and thus can serve as a biomarker for HOCl-
mediated modifications [48, 56, 57]. These products can therefore be detected with
sensitive and quantitative analytical methods (although they are invasive and destructive
to cells and tissues) [57]. However, chlorination can occur in the stomach likely by Cl2,
which is in equilibrium with HOCl, thus chlorinated Tyr can form non-enzymatically
in these highly acidic conditions (Figure 1.5) [56]. Other analytical detection methods
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that have been used are immunohistochemistry (IHC) or Western blotting utilising an
antibody that was originally raised against HOCl-oxidized LDL, known as clone 2D10G9
[63]. This antibody is found to bind to an un-identified HOCl-generated epitope, and
has been detected in intermediate and advanced lesions. Localization of 2D10G9 was
associated with long thin cells, suggestive of SMC or fibroblasts supported by positive
staining of phosphotungstic acid haemotoxylin (PTAH), an SMC marker [8, 63].
In previous studies, it was also found that HOCl targets and modifies ECM proteins
as investigated in human atherosclerotic lesions and pig aortae [64]. ECM derived
from healthy pig aortae exposed to HOCl resulted in increased levels of oxidized amino
acids detected, such as increased formations of di-Tyr, o-Tyr, 3-chloroTyr, and L-3,4-
dihydroxyphenylalanine (DOPA) [64]. The exposure of SMC-derived ECM to HOCl
resulted in the rapid consumption of the oxidant and immediate formation of chloramines
and chloramides, which were found to degrade over time [65]. Furthermore, HOCl was
found to mediate fragmentation of SMC-derived ECM as seen with increasing detection
of radio-labeled amino acids released [65].
Figure 1.5: Chlorination of Tyr residues by HOCl to form 3-chloroTyr and 3,5-chloroTyr. Adapted
from Winterbourne and Kettle, 2003 [56].
GAGs, such as heparin/heparan sulfate (HS) and chondroitin sulfate (CS), are
polysaccharides that are covalently attached to a core protein to form proteoglycans.
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These GAGs have been previously shown to be modified and damaged by HOCl [66]. HS
such as found on proteoglycan perlecan, are an important protein ligand (as discussed
later in this chapter), and due to being highly anionic has been found to bind to MPO
[67]. HOCl was found to not directly modify HS chains despite its highly reactive (N-
unsubstituted) glucosamine (GlcNH2) residues. However, it was proposed to mediate
MPO-derived HOCl damage on the protein core of perlecan leading to loss of EC adhesion
[67]. This damage was found to be attenuated with the addition of heparin, which
blocked the binding of MPO [67]. GlcNH2 residues, GlcNAc (N-acetylglucosamine), and
GlcNSO3 (glucosamine-N-sulphate) have previously been found to form chloramines/di-
chloramines, and N-chlorosulfonamides and chloramides, thus it was interesting to see
that this was not the case with whole perlecan protein [68, 69]. Hyaluronic acid and CS
exposed to HOCl were also found to form chloramides [70]. These chloramides were found
to react with O2 and mediated fragmentation of the GAGs [71]. Moreover, exposure of
SMC-derived whole ECM to HOCl was found to release uronic acid, which is a sugar
acid found on GAGs [65]. This suggests that HOCl may react directly with GAGs but in
whole protein, it has been found to direct the damage to certain locations on the proteins
due to binding and proximity of MPO.
Deposition of fatty acids and cholesterol in the vascular wall is met with oxidation by
HOCl leading to formation of chlorohydrins, which has been detected in atherosclerotic
plaques [72, 73]. HOCl has a higher reactivity with proteins compared to fatty
acids/cholesterols, and therefore resulted in lower levels of chlorohydrins detected [73].
The formation of these species, particularly oxidized LDL, which exhibits proatherogenic
properties, can cause downstream effects inducing cellular changes [72], ATP depletion,
human myeloid cell toxicity [74], and promotes the development of atherosclerosis [75,
76]. Furthermore, oxidized LDL itself is deleterious within plaques, however it can be
taken up by cells, such as migrated leukocytes or EC, leading to damage to perinuclear
proteins [76, 77].
HOCl has been found to also oxidize DNA and RNA, in particular guanine, which has the
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lowest standard reduction potential compared to the other bases [78]. Oxidation of DNA
leads to formation of several products, such as 8-hydroxyguanine and 8-hydroxyadenine,
which have been detected in lesions [79]. Moreover, it can also lead to formations of semi-
stable chloramines (and subsequent radicals), which have been found to further react with
DNA to form crosslinks [49, 80]. Chloramine formation on DNA have been previously
shown to occur more rapidly with uridine and thymidine bases (3.0 x 104 M-1 s-1) [80].
The mechanism of oxidation are shared between DNA and RNA, whereby exposure of
RNA to oxidants commonly formed 8-hydroxyguanosine by-products [81]. The formation
of 8-hydroxyguanosine can lead to mutations on the transcription level if they pair with
adenine over cytosine in RNA [82]. Exposure of DNA and RNA may lead to defective
protein synthesis due to modifications on base pairs that may cause improper pairing and
this can be particularly deleterious in EC and SMC in the progression of atherosclerosis
[83–85].
Antioxidants generally scavenge or degrade oxidants and prevent further oxidation.
Antioxidants, such as glutathione (GSH), are highly reactive with oxidants, and thus
react rapidly to scavenge oxidants leading to formation of stable derivatives [86]. In
certain situations, antioxidants can be oxidized by HOCl to form chloramines, albeit
at a lower kinetic rate compared to Met and GSH residues [87]. GSH is a common
agent for preventing intracellular oxidative damage, and exposure of resting neutrophils
to HOCl was found to lead to loss a of both protein thiols and GSH levels [88]. Moreover,
exposure of human umbilical vein ECs (HUVECs) to low concentrations of HOCl was
found to have similar results with loss of protein thiols and GSH levels [89]. Flavonoids
are plant-derived polyphenol antioxidants [90], and the flavonol subclass has been found
to react with HOCl [91]. Exposure of flavonols to low or moderate concentrations of
HOCl was found to slightly increase the antioxidant activity; however exposure to high
concentrations of HOCl resulted in the loss of antioxidant activity by the flavonols [91].
As can be seen from these previous studies, HOCl is promiscuous and has been found
to react widely with many components of the sub-endothelium and plasma. This leads
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to modifications and damage, which can subsequently lead to cellular dysfunction. The
vascular environment is highly dependent on the healthy functioning of cells and proteins
and thus investigations into the effect of HOCl on ECM proteins would be highly valuable.
Current experiments were designed to expand and better shape our understanding of these
changes by characterising the mechanism of action of HOCl upon specific and key ECM
proteins.
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1.3.2 Hypothiocyanous Acid
HOSCN is produced by enzymatic reactions between MPO and SCN- [26], but can
spontaneously occur as a reaction between HOCl and SCN- [92, 93]. SCN- is present
in varying physiological concentrations within the body with high levels detected within
the oral cavity, which is converted to HOSCN by antimicrobial LPO despite substantial
excess of chloride [94]. The physiological plasma concentration of SCN- ranges between
20-40 µM (0.01-3 mM in other areas of the body [95], with elevated plasma concentrations
detected in smokers, which can range between 80-400 µM [96–99].
HOSCN has been found to be an effective antimicrobial agent against invading pathogens
due to its specificity for sulfhydryl/acidic thiol groups, such as Cys residues [100, 101].
However, in situations where thiol groups are depleted or inaccessible, HOSCN has been
found to react with Trp and Lys residues [26, 102]. The reaction between HOSCN
and thiol groups have been observed to form unstable thiosulfenyl thiocyanate (RS-
SCN), a transitory derivative that can further react with water to generate sulfenic
acid intermediates (RS-OH) [94, 103]. These intermediates have been implicated in
protein aggregation forming dilsulfide crosslinks and fragmentation [94, 104–107]. As a
consequence of the unstable nature of these products, there is a lack of useful biomarkers
that can be used to detect HOSCN-derived modifications, limiting investigations with
regards to clinical samples. However, fluorometric ThioGlo assay can be used as an
alternative in vivo method to investigate the loss of thiol groups [57, 108]. This method
utilizes a fluorometric compound that binds to free thiol groups that have not been
modified/oxidized [57].
The biochemistry of SCN-/HOSCN is complex, with conflicting studies suggesting that
SCN- can be damaging and others suggesting that it can act as an antioxidant in some
inflammatory diseases, such as cystic fibrosis or CVD [93, 99, 109]. MPO has a higher
specificity for SCN- than Cl- by almost 730 fold (Table 1.1) [98, 110]. Thus, it has been
proposed that at elevated levels of SCN-, up to 50% of H2O2 is converted to HOSCN
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with the remaining reacting with other halides such as Cl- [98, 110]. Young individuals
with highly elevated levels of plasma SCN- presented with greater deposition of LDL and
increased presence of fatty streaks in the aortae [111]. Furthermore, high plasma levels
of SCN- were associated with increased carbamylation leading to increased formations of
homocitrulline, which has been found to have damaging effects in atherosclerosis [112,
113]. However, with regards to CVD, increased plasma SCN- levels resulted in smaller
plaque formations compared to control in mice [114]. Moreover, moderate elevations of
SCN- in combination with low levels of MPO correlated with decreased mortality rate
[99].
The effects of HOSCN on ECM proteins are expected to be different to those examined
with HOCl due to the oxidants specificity for thiol groups. The mechanism has not been
characterized and thus further investigations can assist in elucidating the potential effects
of HOSCN on ECM-derived proteins. Furthermore, there is potential in SCN- acting as
an antioxidant and may be able to grant protection from the damaging effects of HOCl.
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1.3.3 Other potential oxidants
HOCl and HOSCN are primarily MPO-derived oxidants produced during inflammation.
However, other oxidative species exists that elicit their own specific modifications such as
seen with hydroxyl radicals (HO•), HOBr or HOI, radicals generated in the peroxidase
cycle (NO2• and TyrO•), and peroxynitrite (ONOO-/ONOOH) [26, 115, 116].
H2O2 is produced by the conversion of O2- by superoxide dismutaste [117, 118]. It has
previously been implicated as an oxidant and is suggested to interact with proteins as
well, and is readily broken down by catalase to oxygen and water [26, 119]. Activity of
H2O2 is linked with conversion to HO•, which is known to be highly reactive and is able
to damage proteins, amino acids, and lipids [115, 116, 120]. Generation of HO• occurs
either by a catalytic breakdown of H2O2, through photolysis or by a Fenton method
which uses a Fe(2+)-EDTA catalysis to simulate reduction by trace iron or copper irons
[26, 115, 116, 119, 121, 122]. However, there are low levels of trace ions. Thus, it is
likely that modifications are hypohalous acid-derived due to a high reaction rate between
MPO, halides, and H2O2 [26, 123]. It has been found that at least 40-70% of H2O2,
in the presence of Cl-, is converted to HOCl [26, 98, 124]. Furthermore, reactions with
H2O2 and O2•- are very slow [116], thus the major contribution of oxidation is likely from
hypohalous acids.
Plasma levels of Br- and I- have been found to be around 20-100 µM [44] and < 1 µM
[27], respectively. Due to the similarities between Cl- and Br-, the effects of HOBr has
been found to be on par with HOCl [26]. Both of these halides are known to have
higher second-order rate constants with MPO and thus have the potential to generate
HOBr/HOI over HOCl [27]. HOBr is known to be highly reactive with several oxidisable
group analogous to those examined with HOCl but also have been found to react with
functional thiol and amine groups [125, 126]. Treatment of GAGs with HOBr was found
to yield N -Bromo derivatives [127], similar to those found with HOCl treatment [68, 71].
With regards to HOI, there are limited studies investigating the generation and effects
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of HOI with early studies observing iodination on extracellular proteins [117]. A more
recent study has investigated the effects of I- as a species to mitigate damage from HOCl
[128].
The formation of ONOO-/ONOOH is due to a rapid reaction between NO• (derived from
nitric oxide synthase enzymes; e.g. iNOS/eNOS) and O2•- [129]. The oxidants ONOOH
and TyrO•/NO2• have both been found to mediate Tyr nitration resulting in formation of
nitrated Tyr, 3-nitroTyr or 6-nitroTyr [129, 130]. These nitrated Tyr residues have been
used as biomarkers to indicate nitration induced damage [129]. In recent studies, these
reactive species have been shown to modify key amino acids on ECM proteins leading to
cellular dysfunction [130–132].
The generation and modifications by different types of oxidants are broad and certain
mechanisms are favoured over others depending on the location and the type of
inflammation.
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1.3.4 Antioxidants
Oxidative damage can be minimized by various physiological antioxidants, which
scavenges oxidants by rapidly reacting with them and preventing damage to host cells
[86, 133]. There are many groups of antioxidants, both endogenous and taken up through
dietary supplementations [86, 133]. These include: enzyme inhibitors, limiting oxidant
production, MPO binding agents, and supplements of vitamins or other compounds.
There are various ways of removing oxidants, particularly H2O2, O2-, and
ONOO-/ONOOH; this is possible due to the endogenous antioxidants available within
the body. O2- can be consumed by superoxide dismutase and converted to H2O2, as seen
previously in section 1.3 [19, 20]. H2O2 can be scavenge and decomposed by catalase,
breaking down the oxidant into water and oxygen [134]. This can subsequently decrease
the conversion of H2O2 in the presence of physiological halides, to the more damaging
hypohalous acids [134].
There are currently no known antioxidant agent that can directly remove HOCl. This
poses a problem as HOCl is commonly generated in inflammation and is known to be
rather damaging to host cells and proteins [49, 50]. Oxidation by HOSCN has been found
to be reversible but can subsequently form non-reversible products [94, 103]. Other
than removing the upstream oxidants (H2O2 and O2•-), there has been some recent
studies examining reduction of HOSCN by thioredoxin reductase [135]. Thioredoxin is a
redox protein and in conjunction with thioredoxin reductase may be capable of reducing
HOSCN and mitigating subsequent damage [135, 136]. It was proposed that HOSCN
acts on the sulfur-thiol group on thioredoxin reductase, thus reducing the oxidant.
Furthermore, HOSCN has been observed to be reducible by mammalian thioredoxin
reductase but not bacterial thioredoxin reductase; this makes HOSCN less damaging
in humans particularly in areas with high concentrations of SCN- such as in the lungs
[135]. There is risk of inactivation of redox enzymes by these oxidants but it was been
observed that addition of seleno-compounds (e.g. selenocysteine) resulted in preventing
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the inactivation of thioredoxin reductase [137]. These selenocysteine residues are highly
advantageous as they are resistant to over-oxidation, whereas their sulphur counterparts
are more prone to overoxidation leading to formation of irreversible modifications [137,
138]. This suggests that during inflammation, antioxidants may help to mitigate the
oxidative damage induced by HOCl, HOSCN, and other oxidants.
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1.4 Extracellular Matrix Overview
The ECM is a complex network of multifunctional proteins with each playing an
important role in providing a versatile scaffold, and regulating functions between cell-
cells and cells-protein (Figure 1.6) [139, 140]. These vital processes are regulated by
interactions of the matrix proteins with cytokines and growth factors, as well as the
binding to cell surface integrins and mediating downstream intracellular signalling [141,
142]. The ECM provides a biological scaffold and homeostatic maintenance in a variety
of organs within the human body [139, 143]. Furthermore, ECM proteins in both their
native and non-native state are vital in instigating inflammation, and subsequent wound
healing [144–146].
During the progression of atherosclerosis, extensive vascular remodelling, regeneration,
and repair occur in the arterial wall [147, 148]. The ECM can be triggered by nearby cells
to initiate extensive turnover, especially when ECM proteins are detected to be damaged
by cells [18, 149]. Cells, such as EC and SMC, can up-regulate matrix degrading enzymes
such as matrix metalloproteinases (MMPs) and in conjunction with tissue inhibitor of
metalloproteinases (TIMPs), works to regulate the degradation of ECM [150]. Moreover,
cells can up-regulate gene expressions to activate production of new ECM proteins into
the milieu [151]. Modifications to ECM proteins can lead to improper binding to other
proteins and/or cells, and can trigger an inflammatory response [131, 152]; these responses
have been associated with a variety of inflammatory diseases including those observed
in the lungs [153], bones [154], different types of cancers [150], and the cardiovascular
system, such as in atherosclerosis [148].
Vascular ECM found in in arterial basement membrane includes: proteoglycans (proteins
decorated with GAGs), structural proteins and specialised proteins. The composition is
highly dependent on the location within the body, as each protein possess differentiated
and specialised structures and properties.
21
Figure 1.6: Schematic diagram demonstrating the structure of an artery wall. This includes the EC
layer with the sub-endothelial basement membrane located underneath the EC layer. SMCs are located
in the arterial media layer with corresponding basement membrane located beneath the SMC layer. The
necrotic core in the arterial wall is characterized by fatty deposits and infiltration of inflammatory cells
and develops in the sub-endothelium space. Adapted from Yurdagul et al, 2016 [155].
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1.4.1 Proteoglycans and Glucosaminoglycans
Proteoglycans are proteins decorated with GAGs, which are long un-branched
polysaccharides containing disaccharide repeating regions composed of amino sugar, d-
galactosamine or d-glycosamine, and uronic acid, d-glucoronic acid or l-iduronic acid
[156, 157]. These GAGs have net negative charges due to the variable sulfated side chains
[21]. In addition, the rigidity of proteoglycans provides structural integrity and provides
passageways between cells allowing cell migration [158, 159]. GAGs include heparan,
chondroitin, dermatan, and keratan sulfates, as well as hyaluronic acid. Proteoglycans
are not confined to being decorated with one type of GAG, instead heterogeneity of sugars
can exist in the make-up of these proteoglycans. Proteoglycans can be post translationally
decorated with HS and CS GAGs within cells at the rough endoplasmic reticulum via
O-linked glycosylations by glycosyltransferases [156]. The sulfation of HS has been found
to have sites with variable high and low sulfated regions with transitional regions in
between [160]. Hyaluronic acid (or hyaluronan) is unique as it is the only GAG that is
not sulfated and is not covalently attached to proteins forming a proteoglycan and are
the largest polysaccharides produced by vertebrate cells [161].
Proteoglycans can be grouped according to their GAG characteristics, which also defines
their function in the ECM (Table 1.2).
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Table 1.2: Types of GAGs present on different proteoglycans and their role in the body.
Type of GAGs Proteoglycan Role References
Heparan Sulfate Perlecan - Pro-angiogenic [162, 163]
- Matrix maintenance
- Turnover and repair
- Cell signaling
Syndecan - Growth factor binding [164, 165]
- Matrix adhesion
- Cell-cell adhesion
Type XVIII Collagen - Regulator of angiogenesis [166]
- Vascular function
Chondroitin Sulfate Versican - Wound healing [154, 158]
- Angiogenesis
- Vascular disease
- Tumour growth
Aggrecan - Osmotic pressure in cartilage [157, 167]
- Provides compression resistance
Dermatan Sulfate - Interacts extensively with CS [168–170]
- Role in neuronal development
- Role in cancer progression
Keratan Sulfate - Hydration of cornea and cartilage [171]
- Structural stability in bone
Hyaluronan - Viscosity in cartilage [161, 172]
- Lubricates interstitial space
- Regulates inflammation
- Remodelling of ECM
24
1.4.2 Collagen, Elastin, and Laminin
Structural proteins, such as collagen and elastin, are important in providing the integrity
and strength to the overall extracellular environment to provide tensile support and to
its neighbouring cells [139]. This is particularly important in the basement membrane of
the arterial wall as these matrix proteins play a role in maintaining homeostasis and in
the progression of atherosclerosis [139, 140, 148].
1.4.2.1 Collagen
Collagen is the most abundant protein in mammals with several extensive studies on its
properties, functions and location. It has a large helical structure composed of three left
hand helices super coiled into a right hand helix, called collagen microfibrils. In terms of
its composition, there are high levels of glycine, proline and two uncommon amino acids,
hydroxyproline and hydroxylysine [173]. Furthermore, maturation of collagen fibrils has
been observed to be mediated by lysyl oxidase (LOX), which forms cross-links between
collagen fibrils [174]. This is vital in forming stable collagen fibrils in the basement
membrane [174]. ECs predominantly reside on type IV collagen rich basement membrane
in the intimal layer, while smooth muscle cells are surrounded by types I and II collagen
in the medial layer [175, 176]. Collagen fibres have been heavily studied with focus
on natural remodelling. Further research examines diseases such as atherosclerosis, and
collagen’s vulnerability to proteolytic degradation by endogenous enzymes (proteases such
as MMPs) [173].
1.4.2.2 Elastin
Elastin, another important matrix protein, similarly provides structural integrity, largely
in its role to regulate elasticity of the tissue through stress and strain [177]. It is
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composed of an assembly of soluble tropoelastin protein and when cross-linked together
by desmosine and isodesmosine, it makes a complex insoluble protein molecule [177, 178].
Elastin does not have a high turnover rate like some other matrix proteins [179]. Due
to this fact, the degradation of elastin has been suggested to be a contributory factor in
aging and many diseases such as atherosclerosis [180, 181].
In the vascular wall, elastin is localised within in the arterial intima, and is important in
regulating the mechanical stress and strain due to fluctuations in blood pressure [148]. It
is synthesized primarily by elastogenic cells, such as fibroblasts and SMC, and released
into the ECM milieu and it self-assembles into the functional monomeric fibrils [182, 183].
Cross-linking of elastin has been observed to be facilitated by LOX, similar to collagen
[184]. As atherosclerosis advances, a reduction or fragmentation of elastin was associated
with increased risk of plaque rupture [185].
1.4.2.3 Laminin
Laminin plays a key role in cell survivability and maintenance by providing a base for
cellular anchorage and mediating cellular proliferation, differentiation, migration and
adhesion [186]. It is a heterotrimeric protein composed of alpha (α-), beta (β-), and
gamma chains (γ-). Different combinations of αβγ chains give rise to the sixteen currently
identified laminin isoforms found in vivo [186]. A murine embryonic epithelium-derive
laminin-111 (α1, β1, γ1) is commonly used in studies and has been found to be present in
adult humans, specifically in cranial blood vessels [142]. The sub-endothelium and medial
layer of blood vessels in humans have been observed to have a prevalence of laminin α4
chain, such as found in laminin 8 (α4, β1, γ1) and laminin 9 (α4, β2, γ1) [187, 188]
In atherosclerotic lesions, it has been observed that there is an abundance of different
laminin chains detected in both mice and humans [189]. Early studies investigated
the attraction between laminin and neutrophils [190], and others emphasised on how
laminin/elastin receptors contributed to atherogenesis [191, 192]. Due to the abundance
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of laminin endothelial basement membranes, it has been suggested to be a likely target
for oxidation during atherosclerosis [131, 132]. However, there are limited studies
investigating this reaction between laminin and oxidants, with some recent studies
examining the effects of peroxynitrite on basement membrane and laminin [131, 132].
In a few recent studies, investigations observed that oxidised laminin was capable of
increasing the attachment of monocytes and ECs [193, 194]. These studies suggests the
importance of native and modified laminin in the arterial wall during atherosclerotic
lesion development.
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1.4.3 Fibronectin
1.4.3.1 Structure and function
FN is a dimeric glycoprotein of approximately 460 kDa in size, is composed of two nearly
identical monomer subunits ranging between 220-270 kDa and is bound by disulfide bonds
at the carboxy-termini [149, 195, 196]. There are two identified types of FN; soluble
plasma FN, produced mainly by hepatocytes and released into plasma, and cellular FN,
produced by various cells (such as EC, SMC, and fibroblasts) [149, 195, 196]. Plasma
and cellular FN share a number of functional regions, but there are regional differences
due to alternative splicing that give rise to their different activities [197].
FN contains three main modules: type I1-12, type II1-2 and type III1-17, and also a non-
homologous variable sequence [149, 196]. Specific functional domains are featured on
these larger subunits, and when FN is folded, these functional domains are exposed [198,
199]. Cellular FN possesses extra domain A (EDA) and extra domain B (EDB), which
are alternatively spliced type III modules that are absent on plasma FN [200]. The EDA
and EDB regions are proposed to be important cellular receptors that play a role in
matrix assembly, although there are limited studies and research into these domains are
ongoing [200].
There are several functional domains on FN including: two heparin binding sites, two
fibrin binding sites, collagen binding sites, as well as specific cellular integrin sites [149,
196]. The majority of the type I module is located at the amino-termini with a small
section located at the carboxy-termini; the two fibrin binding fragments, and the heparin
binding fragment (HBF) I are located in this module [196, 202]. The type II module is
the smallest of the three and possesses the collagen binding fragment [202]. The type III
module consists of the cell binding fragment (CBF) including the RGD motif (Arg-Gly-
Asp), where the α5β1 and αVβ3 integrin are also located [203]. A complex relationship
exists between type III9 and type III10, which provides a synergistic effect allowing ready
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Figure 1.7: Schematic diagram of a FN monomer chain. The diagram indicates Type I-III modules,
the location of important binding fragments and the alternatively spliced variant domains. Adapted
from Wang et al, 2008 [201].
access to integrins (e.g. α5β1) [204, 205]. The HBF II on the carboxy-termini has been
shown to bind to syndecan-2, and due to the high affinity of this fragment, it has been also
found to bind to GAGs on proteoglycan, such as HS and CS [206, 207]. This interaction
has been proposed to play a key role in matrix assembly and formation of insoluble fibrils
[208]. The alternatively spliced type IIICS (also called variable or V) has been found to
code for a further two integrin binding sites (α4β1 and α9β1) [200], and has been shown
to be involved in heparin binding [209].
The type II module possesses only sixty amino acids in length with several cysteine
residues involved in disulfide bonds [202]. This domain is found to play an extensive role
in collagen binding and assembly [202, 210]. The type I module at the amino-termini has
been observed to play a role in wound healing through fibrin and Factor XIIIa binding.
Moreover the absolute or partial deletion of the type I1-5 has been shown to impair FN
incorporation into the ECM [211, 212]
As can be derived, FN is a key matrix protein in mediating development and maintenance
in the vascular wall.
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1.4.3.2 Biological Properties
The complex structure of FN gives rise to its multifunctional properties and allows
important interactions with an array of ECM proteins, enzymes, and cells.
Studies have shown extensive interaction between FN and proteoglycans, such as
syndecan and versican [164, 213, 214]. Adhesion and spreading of particular cells on
syndecan is mediated by the HBF present on FN [206–208]. This process can be seen
with vinculin associated focal adhesions of fibroblast cells to FN, which was demonstrated
in the presence of heparan sulfated syndecan [164, 165]. This assistance of adhesion and
spreading was thought to be due to the active HBF on FN [164, 165]. It was suggested
that this particular pathway was due to the recruitment and activation of protein kinase
C, a protein that is heavily involved in cell signaling pathways [22]. An interaction with
FN, vascular endothelial growth factor (VEGF), and the G3 domain of versican promotes
angiogenesis, particularly in brain tumour growth [215, 216].
In addition, ECM assembly and cell adhesion are also regulated and dependent on the
important relationships that exists between FN and collagen [217, 218]. Collagen is
known to bind to the type II and adjacent type I module of FN, this interaction has
been examined extensively in literature. It is suggested that FN assists in mediating
binding of collagen to mannose receptors [210]. Mannose receptors are present primarily
on macrophages, which acts in both innate and adaptive immune systems, intracellular
signaling, and regulating responsive inflammatory molecules [219, 220]. This interaction
between FN and collagen also mediates cellular response, whereby studies have shown
this interaction can promote cellular migration, improve cell contractibility [221], increase
cell proliferation, and healthy cell morphology [222, 223]. The incorporation of collagen
into the matrix and proper collagen assembly is dependent on FN binding and assisting in
the process [221, 224, 225]. Furthermore, collagen I and FN complexes were also observed
to decreases MMP secretion when compared to FN in the absence of collagen, though
the mechanism is not completely elucidated [226].
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FN also interacts with EC, and SMC via the CBF, which is also known to bind
to particular groups of integrins [196, 227], mediating their function and morphology
[228–230]. FN in healthy vessels have been shown to assist in regulating vascularization
[231], via binding of the integrin to the CBF including the RGD site [232–234]. In vascular
tissue, FN anchors EC to the basement membrane providing structural integrity along
with also assisting with homeostatic cell functioning in adhesion, proliferation, migration
and capillary tube formation [231, 235, 236]; when FN is modified or damaged, such as
during inflammation, there is an impairment to FN’s ability to support cells [236]. This
was seen with the loss of healthy fibril assembly, by inhibition of FN polymerisation, which
resulted in inhibition of SMC growth and proliferation [147]. Furthermore, inhibition of
type III1, which is known to mediate FN-FN binding and matrix assembly, resulted in a
similar inhibition of vascular SMC growth and proliferation [237]. These studies support
the important of health FN in mediating cellular growth and proliferation.
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1.4.4 Modulation of ECM, particularly fibronectin, in atherosclerosis
The ECM plays an important role in various areas of the body by providing structural
support to overlying tissues and assisting in a multitude of cellular function. If ECM
proteins in the arteries are damaged through improper production or modified in diseases,
it can lead to detrimental effects causing morbidity or even mortality. Previously, it was
observed that perlecan-null mice were found to develop cardiovascular malformations and
ruptures of blood vessels [238]. This suggests that perlecan plays an important role in
cardiovascular development and likely maintains normal vascular architecture. Perlecan
expression was markedly increased in the fibrous caps and in the plaque core of advanced
lesion mice models when compared to healthy murine aorta [239]. Furthermore, exposure
of perlecan to HOCl and HOBr resulted in extensive modifications to the protein core,
which led to a reduction in cell adhesion [67]. Peroxynitrite was observed to alter both
the HS chain and protein core of perlecan, which resulted in concentration dependent
fragmentation and aggregation of proteoglycan [240].
Collagen has been known to play an important role in fibrous cap formation in
atherosclerosis [148]. Fragmentation of fibrillar types I and III collagen resulted in a
shift of SMC phenotype from contractile to synthetic [176]. Surrounding ECM was
found to be structurally affected in these atherosclerotic lesions and led to changes in
fibrous cap organisation, and subsequently plaque stability [176]. MMP-2 and MMP-9
have been detected in atherosclerotic lesions of mice [241], and these proteolytic enzymes
have been found to degrade collagen [242, 243]. While there is greater emphasis on the
action of MMP [241–244], collagen has been observed to undergo glycation [245, 246]
and glycoxidation [247], particularly in regards to complications arising from diabetes.
In contrast, there are limited studies examining the effects of MPO-derived oxidants
on collagen with one particular studying focusing on modifications to collagen II by
hypochlorite [248]. Exposure of collagen to hypochlorite was observed to oxidise and
fragment the protein but this was not examined extensively in detail [248].
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Laminin is a large basement membrane protein with several functional domains that
play a role in cell adhesion, migration, and regulates matrix mediated assembly and
signaling [186]. Laminin has been shown to be important in cell-matrix adhesion, via the
localisation of the α4 subunit with αvβ3 integrin-rich focal adhesion [249]. Furthermore,
interaction of laminin with collagen, nidogens and HSPGs were found to mediate laminin
deposition and matrix assembly [250, 251]. Nidogen is a sulphated glycoprotein and its
interaction with laminin is known to stabilise ECM [250, 251]. Nidogen-/- mice were
found to have a decreased expression of laminin-411 and abnormal and disorganised
basement membrane [252]. In more recent studies, diabetic monocyte-derived oxidant
was observed to carbonylate laminin-111, resulting in decreased monocyte attachment
and migration [193]. Furthermore, HUVEC exposed to laminin-111 oxidised by ferrous
ammonium sulphate resulted in up-regulated expression of ICAM-1 which subsequently
increased monocyte adhesion [194]. As can be derived, laminin is important to several
ECM functions, and modifications to this protein can further disrupt healthy vascular
function particularly in atherosclerosis.
In addition to these previous ECM proteins, FN has also been shown to be highly
important in maintaining homeostasis of a healthy vasculature, but in inflammatory
diseases, such as atherosclerosis, this property of FN can become impaired due to
modifications to the protein.
Early studies on FN have shown that inactivation of FN gene resulted in a cessation
of development during embryognesis [253]. These mice models were observed to lack
EC that could form healthy blood vessels, suggesting the importance of FN in blood
vessel development [253]. Furthermore, defects or deficits in important integrins (e.g.
α5 or β1) resulted in lethality during embryogenesis [253–256]. Formation of FN
during matrix assembly is important in atherosclerosis, whereby the reduction or absence
resulted in decreased collagen deposition, thinner arterial layers (intima and media), and
increased inflammatory cell infiltration [257]. Inhibition of the collagen/gelatin binding
fragment with an anti-60k Fab’ antibody (specific for the binding fragment) resulted in a
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reduction of both collagen and FN deposition [258]. This suggests the importance of FN-
collagen interaction for formation of fibrillar structures in the ECM [258]. Furthermore,
interactions between FN, cell surface receptors and integrins are important in initiating
matrix assembly [197].
FN plays a large role in matrix assembly by interacting with other ECM proteins, but
also interacts with cells (e.g. EC and SMC) to contribute to formation and function
of the endothelial intima layer and SMC media layer [14, 259]. Surface coated with
FN has been observed to enhance EC adhesion and was able to sustain adhered cells
for up to four days [235]. FN exposed to oxidants that are commonly associated with
atherosclerosis (such as HOCl and peroxynitrite) were observed to decreased EC adhesion
and impaired cell spreading [22, 130, 260, 261]. A certain mechanism of de-adhesion in
EC was found to be triggered by an external signal causing intracellular changes to Src
and phosphorylaton of Tyr-118 of paxillin [22]. This suggests that mitogenic processes for
vascular regeneration are dependent on FN binding growth factors, and the interaction of
FN with other ECM proteins. This is demonstrated by consecutively coating the surface
with collagen followed by FN and heparin, which resulted in greatly increasing binding
of mitogenic glycoprotein and heparin binding growth factor (HBGF) [262].
Collagen and thrombospondin-1 (THBS-1) deposition is highly dependent on the presence
of intact FN in the matrix [225]. THBS-1 has been observed to be important in mediating
cell-matrix and cell-cell adhesion [263]. Matrix structure and cellular function is highly
dependent on the structural integrity of the basement membrane. Deficiency in plasma
FN resulted in lower levels of SMC migration into the atherosclerotic plaque, reduction
in collagen deposition, and the formation of thinner fibrous caps [264]. Migration of SMC
into the atherosclerotic plaques have been reported to be important in generating stable
fibrous caps, however FN also promotes lipid retention, and increased inflammatory cell
infiltration [265]. Furthermore, it was reported that degraded FN resulted in increased
leukocyte migration/chemotaxis across the EC layer [266, 267], and increased neutrophil
degranulation [268]. In support of this, inhibition of FN assembly resulted in a reduction
34
in inflammatory response in atherosclerosis [147, 269]. FN plays an important role in
ECM stabilisation and together with other ECM proteins provides strong substrata for
EC and SMC. Thus, these studies demonstrate the importance of FN in regulating cell
function and ECM assembly within the basement membrane.
During inflammation, the production of MPO has been linked with the co-localisation and
binding to ECM proteins [21, 22, 270]. MPO has been shown to bind to GAGs [21, 270],
but recently shown to also bind to FN [22]. The co-localisation may suggest ECM FN to
be a possible target of MPO-derived oxidant due to their proximity [21, 22]. A number of
studies have examined the detrimental effects of hypochlorite on FN such as fragmentation
of the protein [22, 260], loss of cell adhesion, loss of specific antibody recognition [22, 261],
amino acid changes, and oxidative by-products [46, 64, 271]. Studies have also shown that
the reduction of plasma FN levels is associated with lower levels of SMC migrating into
atherosclerotic lesions, resulting in plaques that are more prone to rupture as they have
decreased collagen and thinner fibrous caps [264]. These studies support a major role for
FN in atherosclerotic lesion development [22, 260, 271], and support investigations as to
how structural alterations to FN, such as via oxidation, which may alter the function of
FN. Furthermore, the deletion of spliced EDA exons of cellular FN showed a reduction
in the size of atherosclerotic lesions in mice with atherosclerosis [272, 273]. These studies
indicate modifications or absence of either the whole protein or of particular regions can
affect the development of an atherosclerotic lesion.
As described, the ECM is important to both the structural integrity of the basement
membrane, providing binding sites and harbouring molecules for healthy cell function.
Thus, it can be seen how crucial it is to understand how modifications on these particular
proteins can have a downstream consequences to the stability of the overlying tissue,
particularly in the progression of inflammatory diseases such as atherosclerosis.
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1.5 Thesis hypothesis and aims
In light of the current data available, FN is present in vascular walls and mediates
remodeling both in healthy matrix turnover but also in inflammatory diseases such
as atherosclerosis [18, 148]. It is hypothesised that MPO-derived oxidants (HOCl
and HOSCN) will modify ECM-derived proteins particularly FN, which will result
in structural and functional changes to the vascular basement membrane. Moreover,
modifications induced by HOSCN would be less extensive compared to HOCl due to its
specificity. These ECM alterations affect EC behaviour and will result in endothelial
dysfunction leading to the subsequent development of atherosclerosis.
This hypothesis will be addressed by the following specific aims:
1. To investigate the structural changes (fragmentation and aggregation) induced by
HOCl, on human plasma FN and cellular FN in HCAEC-derived whole ECM
extract, and whether it leads to consequential biological dysfunction with regards
to cell adhesion, proliferation and gene expression.
2. To investigate the structural changes (fragmentation and aggregation) induced by
HOSCN (a more specific oxidant), on human plasma FN and cellular FN in HCAEC-
derived whole ECM extract and whether the modifications are as extensive as
observed with HOCl.
3. To investigate whether the changes induced by reagent HOCl and HOSCN are
observed with treatment utilizing MPO enzyme, H2O2, and halides (Cl- and SCN-).
4. To determine the extent of modifications on human plasma FN in a mixture of Cl-
and SCN- utilizing the enzymatic MPO/H2O2 system.
5. To determine the occurrence of modified matrix components in human
atherosclerotic lesions.
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Chapter 2
Materials and Method
2.1 Materials
All products were sourced from Sigma Aldrich (St. Louis, MO, USA) unless otherwise
noted. Water used in preparation of solution and use in experiments were filtered through
a four-stage Millipore MilliQ system (“MilliQ water”). Chelex was used to remove trace
metal ions from buffer solutions and was obtained from Bio-rad (Hercules, California,
USA). LPO (from bovine milk; 427489) was purchased from Merck (Darmstadt,
Germany). Phosphate buffer saline (20x PBS) was obtained from VWR (Solon, OH,
USA). Pierce BCA protein assay solution (23223) was obtained from Life Technologies
(Slangerup, Denmark) or Thermo Scientific (Rochford, IL, USA). For SDS-page and
Western blot experiments, Xcell Surelock Mini-cell sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) tank (EI0001), NuPAGE™ 3-8% Tris-Acetate Protein
Gels 1.0mm (10 wells, EA0375BOX; 12 wells, EA03952BOX; 15 wells, EA03755BOX),
NuPAGE™ Reducing buffer (NP0009), NuPAGE™ LDS sample buffer 4x (NP0007),
HiMark™ pre-stained High Molecular Mass standard (LC5699), HiMark™ Unstained
Protein standard (LC5688), NuPAGE™ Tris-Acetate SDS Running buffer 20x (LA0041),
iBlot 2 Gel Transfer Device (IB21001), and iBlot 2 polyvinylidene fluoride (PVDF)
Regular stacks (IB24001) were purchased from Life Technologies (Slangerup, Denmark).
Trypsin (R001100), Hoechst 33342 (H1399), ActinRed 555 Ready Probe (R37112)
Nuclease-Free water (AM9939) were also purchased from Life Technologies (Slangerup,
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Denmark). Western lighting PLUS ECL (NEL104001) solution for developing Western
blots was sourced from Perkin Elmier (Waltham, MA, USA). HCAEC, HCAEC Growth
Medium (095212), Endothelium Cell Basal media without phenol red (210PR-500; Endo-
Basal Media) was obtained from Tebu-bio (Roskilde, Denmark). CellTiter 96® Aqueous
One Solution Assay (G3580), was acquired from Promega (Nacka, Sweden). RNAse Zap
(79254), RNease Mini Kit (74104), RT2 First Strand Kit (330404), and RT2 SYBR Green
ROX qPCR Mastermix were obtained from Qiagen (Copenhagen, Denmark). ThioGlo 1
fluorescence thiol reagent (HC9080) was acquired from Berry and Associate (Michigan,
USA).
MPO enzyme was purchased from Planta (Vienna, Austria). Both bovine and human
plasma FN was sourced from Sigma Aldrich (St. Louis, MO, USA). Whole human ECM
was harvested from HCAEC.
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2.1.1 Primary antibodies
Mouse monoclonal antibody probing for FN CBF (clone A17; ab26245) and FN EDB
(clone C6; ab154211) were purchased from Abcam® (Cambridge, UK). Mouse monoclonal
antibody against FN HBF (clone A32) was obtained from Life Technologies/Thermo
Scientific (CSI0053202; Slangerup, Denmark). Mouse monoclonal antibody against FN
EDA (close 3E2; F6140) was sourced from Sigma Aldrich (Louise, MO, USA). Mouse
monoclonal antibody targeting a HOCl-generated epitope was appreciatively donated by
Prof. Ersnt Malle and Prof. Astrid Hammer from Medical University of Graz, Austria
[63] (Table Table 2.1).
Table 2.1: List of primary antibodies and dilutions used in experiments.
Epitopes Clone Dilutions
ELISA WB
FN; Cell Binding Fragment (CBF) A17 1:50 000 1:10 000
FN; Heparin Binding Fragment (HBF) A32 1:1000 1:2000
FN; Extra Domain A (EDA) 3E2 1:1000 1:2000
FN; Extra Domain B (EDB) C6 N/A 1:2000
HOCl-generated epitope 2D10G9 1:50 N/A
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2.2 Methods
2.2.1 Reagent and enzymatic oxidant synthesis
2.2.1.1 Hypochlorous Acid
HOCl stock solutions were commercially purchased and regularly checked by diluting
in NaOH and using UV-Vis spectrophotometry at 292 nm and a coefficient of 350 M-1
cm-1 . Stock solutions were generally made to the same molar concentration. HOCl was
prepared by diluting stock reagent HOCl in milliQ water to an initial concentration of
50 mM; this solution was then serially diluted accordingly to the required concentrations
to form the molar ratio required in each experiments (Table Table 2.2). For 1 µM of FN
in Western blotting experiments, a 1:5 dilution was performed to acquire the necessary
molar ratio (Table Table 2.2).
Table 2.2: Diluton of HOCl for required molar ratio in experiments. This example was prepared for
a 1:5 dilution in Western blotting experiments for 1 µM of FN.
Concentration Total Vol. (µL) Vol. of higher conc. (µL) Vol. NaPhosbuffer (µL) Molar Ratio
50000 100 100 0 10000x
25000 100 50 50 5000x
5000 100 20 80 1000x
2500 100 50 50 500x
1000 100 40 60 200x
500 100 50 50 100x
250 100 50 50 50x
125 100 50 50 25x
50 100 40 60 10x
25 100 50 50 5x
2.2.1.2 Hypothiocyanous acid
Aliquots containing 50 µL of 45 µM LPO were previously prepared. Exactly 850 µL of
10 mM pH 6.6 potassium phosphate buffer was added to dilute the LPO aliquot. To
this solution, 200 µL of 150 mM sodium thiocyanate (NaSCN) was utilised to produce
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HOSCN. H2O2 was added in 10 µL of 75 mM H2O2 every minute to a final total of 50
µL while the sample was kept on ice. Samples were quickly inverted to mix the solution,
followed by incubation for 15 mins on ice. After incubation, 0.1-0.2 mg of bovine liver
catalase was added and incubated for 5 min at 21°C to quench any remaining H2O2 in
solution. Catalase enzyme was removed by filtering through a 10k cutoff Nanosep Omega
filter system followed by centrifuging at 12,000rpm for 5 min 4°C.
To check the concentration of HOSCN, 5-thio-2-nitrobenzoic acid (TNB) assay was
utilised to spectrophotometrically determine the optical absorbance at 412 nm using the
extinction coefficient, ε412 14150 M-1 cm-1. 5,5′-Dithiobis(2-nitrobenzoic acid) (DTNB)
stock was prepared by diluting 2 mg of DTNB in 250 µL of 1 M solution of sodium
hydroxide (NaOH), and allowed to mix for 5 mins at 21°C. This was then mixed with
4,750 µL of milliQ water in a glass bottle. DTNB reagent was diluted by combining 200
µL of DTNB stock in 9800 µL (9.8 mL) of 0.1 M pH 7.4 sodium phosphate buffer to
give diluted DTNB (dilDTNB). The solution was checked using a UV-Vis spectrometer
or compatible plate reader against 0.1 M pH 7.4 sodium phosphate buffer as a reference.
For most efficient reading, absorbance should be between 0.4-0.6 absorbance.
When determining concentration of HOSCN, 5 µL of HOSCN was diluted in 995 µL
dilDTNB (1:200); this was calculated against a control of 5 µL of 10 mM pH 6.6 potassium
phosphate buffer also diluted in 995 µL dilDTNB (1:200). Samples were transferred to
spectrometric cuvettes (Grenier Bio One; Frickenhausen, Germany) and measured at 412
nm on a Shimadzu UV-vis (Kyoto, Japan), with 0.1 M pH 7.4 sodium phosphate buffer
as a reference. Alternatively, measurements can be made using a Greiner UV-Star 96 well
plates (M3812) and quantified using a plate reader at 412 nm. Samples were measured
in triplicates to obtain an average reading, and the concentration was calculated using
the formulae in Figure 2.1.
Once concentration of HOSCN was determined, HOSCN was diluted to an initial
concentration of 1 mM in milliQ water. This solution was then serially diluted down
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Figure 2.1: Formula for calculating the concentration of HOSCN. The ex. coefficient of TNB (412)
was taken as 14150 M-1 cm-1,
to the desired concentration and concurrent molar ratio (Table Table 2.3). Below is an
example prepared for 1 µM of FN in Western blotting experiments, where a further 1:5
dilution was made to acquire the desired final molar ratio.
Table 2.3: Diluton of HOSCN for required molar ratio in experiments. This example was prepared
for a 1:5 dilution in Western blotting experiments for 1 µM of FN.
Concentration Total Vol. (µL) Vol. of higher conc. (µL) Vol. milliQ (µL) Molar Ratio
1000 100 40 60 200x
500 100 50 50 100x
250 100 50 50 50x
125 100 50 50 25x
50 100 40 60 10x
25 100 50 50 5x
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2.2.1.3 Enzymatic synthesis of oxidants
To produce HOCl enzymatically, MPO enzyme was used in samples in accordance to the
known mechanism of MPO reacting with existing Cl- and H2O2. Samples had sodium
chloride (NaCl) added to obtain a final concentration of 100 mM followed by addition
of MPO enzyme to acquire the desired concentration (check the concentration used in
experiments). H2O2 was added in consecutive additions to prevent high concentration of
H2O2 from inactivating the MPO enzyme. Cl- can be substituted for SCN- to generate
HOSCN. For more precise concentration and details of MPO in reactions, please refer to
corresponding methodology.
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2.2.2 ELISA
A stock solution of 1 mg/ml of purified human plasma FN was diluted to a final
concentration of 10 µg/mL in 0.5 M pH 7.4 of sodium phosphate buffer, and milliQ
water for a final buffer concentration of 0.1 M pH 7.4 sodium phosphate buffer. In a
high protein-binding 96-well plates, 50 µL of the 10 µg/mL (concentration rounded to 2
decimal places; 0.02 µM) FN solution was coated onto each well, followed by an overnight
incubation at 4°C on a rocker. Maximum FN binding was previously determined using
a serial dilution of decreasing FN concentration and a micro-BCA was performed to
determine maximum concentrations of bound FN. It was found that there was minimal
loss at this concentration and therefore future experiments were based on these results.
On the next day, the 96-well plate was washed twice with 200 µL of 1x PBS. Each well was
treated with 50 µL of oxidant by taking the concentration from Table 2.2 or Table 2.3
and diluting to the appropriate molar ratio or concentration in 0.1 M pH 7.4 sodium
phosphate buffer (refer to Table 2.4). Plates were then incubated for 2 hr at 37°C before
being washed twice again with 1x PBS. Primary antibodies were prepared by diluting
the respective antibody (Table 2.1 in 0.1% (w/v) casein 0.1% (w/v) Tween-20 PBST.
Human plasma FN treated with HOCl, HOSCN, enzymatic reactions were probed for
CBF (1:50000), HBF (1:1000), and HOCl-generated epitope (1:50). Furthermore, whole
ECM extract which contains cellular FN was probed for CBF (1:50000), HBF (1:1000),
and EDA (1:1000). After an incubation overnight, plates were washed twice with 200
µL of PBST before being incubated with either horse peroxidase (HRP)- or alkaline
phosphatase (AP)- linked secondary antibody for 1 hr at 21°C. This was followed by four
times washes with PBST, prior to development. Working ABTS solution was prepared
fresh by addition of H2O2 (1:1000) into pre-made ABTS solution and 100 µL was added
into each well. The absorbance was immediately read at 405 nm, followed by another
reading at 5 min, 10 min, 30 min, and 60 min.
In the enzymatic experiments, surface-bound human plasma FN (0.02 µM) on 96-well
44
plates (prepared as above overnight at 4°C on a rocker) was washed twice with TBS and
exposed to 50 µL containing: 10 µL of 0.5 M pH 7.4 sodium phosphate buffer, 1 µL of
1 µM of MPO (0.02 µM), 5 µL of 1 M Cl- (100 mM), and increasing concentrations of
H2O2 (0, 4, 8, 16, 24, 32 µM) in batch additions (maximum of 0.2 µL of 2 mM H2O2 stock
solution) (Figure 2.5), and milliQ water for 2 hr at 37°C. Procedure followed as above post
treatment substituting the changes as follows: AP-linked antibodies were used in place
of HRP-linked antibodies, and 1x Tris-buffered saline (TBS) was used instead of PBS
in these experiments. Development of plates was with 100 µL of Alkaline phosphatase
Yellow (pNPP) Liquid Substrate (p7998; Sigma), with a stopping solution of 3 N NaOH
(25 µL per 100 µL). The absorbance was measured at 405 nm immediately, followed by
another measurement at 5 min, and 10 min. Stopping solution was added at 10 min and
measured once more immediately after addition.
Table 2.4: Concentration of oxidants as a molar ratio of human plasma FN for ELISA results.
FN (µM) Concentration of (µM)
0.02 0
5
10
25
50
100
200
Table 2.5: Concentration of H2O2 as a molar ratio of human plasma FN for ELISA results.
FN (µM) Concentration of H2O2 (µM) Molar Ratio
0.02 0 0x
4 200x
8 400x
16 800x
24 1200x
32 1600x
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2.2.3 Treatment of purified protein and whole ECM extract for
SDS-PAGE
Purified human plasma FN (stock 1 mg/ml) was prepared by diluting it in 0.5 M pH
7.4 sodium phosphate buffer and milliQ water following Table 2.6 to give the desire
concentration of human plasma FN in sample. For control samples, oxidants were replaced
with milliQ water (FN only control). Prepared samples were then incubated for 2 hr at
37°C, followed by samples being split in half prior to addition of SDS-PAGE reagents
so that samples can be ready for loading for protein separation. Samples were split in
half as to retain the same treatment conditions when preparing samples for reducing or
non-reducing conditions.
Whole ECM extracted from HCAEC was calculated for samples to supposedly contain 1
µM of FN (450 kDa) with the assumption that there’s a majority of FN in samples for a
final mass of 10 µg. FN concentration was not determined and thus a molar treatment
used. Oxidant dilution was appropriately adjusted for 1:10 dilution for sample treatments
(Refer to Table 2.2 and 2.3).
The concentrations (and molar ratio) of treatment of human plasma FN with enzymatic
MPO/Cl-/H2O2 experiments were based on a previous study by Vissers et al. (Table 2.8)
[260].
Table 2.6: Preparation of human plasma FN as 1 µM with treatment with HOCl or HOSCN.
Solution Example for six reactions (µL)
1 mg/ml FN 6
0.5 M pH 7.4 Phosphate buffer 2.66
MilliQ water 2
Oxidant (1:5 dilution) 2.66
Total Volume 13.32
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Table 2.7: Preparation of HCAEC-derived whole ECM extract as 1 µM with treatment with HOCl
or HOSCN.
Solution Example for eight reactions (µL)
Stock HCAEC-derived whole ECM X
0.5 M pH 7.4 Phosphate buffer 6.67
MilliQ water Total minus X
Oxidant (1:10 dilution) 3.33
Total Volume 33.33
Table 2.8: Preparation of human plasma FN as 0.2 µM with enzymatic treatment using MPO, Cl-,
and H2O2.
Solution Example for eight reactions (µL)
0.2 µM MPO 0.8 µM MPO
1 mg/ml FN 5 5
0.5 M pH 7.4 Phosphate buffer 10 10
MilliQ water Total to 50 Total to 50
MPO (5 µM stock) 1 4
NaCl (1 M stock) 5 5
H2O2 (10 mM stock) 0, 0.2, 0.4, 0.6, 0.8 0, 0.2, 0.4, 0.6, 0.8
Total Volume 50 50
Table 2.9: Preparation of human plasma FN as 0.2 µM with enzymatic treatment using MPO, SCN-,
and H2O2.
Solution Example for eight reactions (µL)
20 µM SCN- 500 µM SCN-
1 mg/ml FN 5 5
0.5 M pH 7.4 Phosphate buffer 10 10
MilliQ water Total to 50 Total to 50
MPO (5 µM stock) 1 1
NaSCN (5 mM stock) 0.2 5
H2O2 (10 mM stock) 0, 0.2, 0.4, 0.6, 0.8 0, 0.2, 0.4, 0.6, 0.8
Total Volume 50 50
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Table 2.10: Preparation of human plasma FN as 0.2 µM with competitive enzymatic treatment using
MPO, Cl-, SCN- and H2O2.
Solution Example for eight reactions (µL)
0.2 µM MPO 0.8 µM MPO
1 mg/ml FN 5 5
0.5 M pH 7.4 Phosphate buffer 10 10
MilliQ water Total to 50 Total to 50
MPO (5 µM stock) 1 4
NaCl (1 M stock) 5 5
NaSCN (5 mM stock) 0, 0.2, 1, 2, 3, 4, 5 0, 0.2, 1, 2, 3, 4, 5
H2O2 (10 mM stock) 0, 0.8 0, 0.8
Total Volume 50 50
2.2.4 SDS-PAGE
Samples were then prepared for separation using 1-dimensional SDS-PAGE under
reducing or non-reducing conditions. For reducing samples, 10x NuPAGE reducing
solution was added in a 1:10 dilution to the final volume depending on sample prep,
and in non-reducing samples, milliQ water was added in place of. All samples had 4x
NuPAGE sample buffer added in a 1:4 dilution of the final volume. All samples were then
heat denatured for 10 min at 70°C, then the appropriate volume of samples were loaded
onto 3-8% (w/v) 1 mm NuPAGE® Tri-acetate gels which were electrophoresed at 160 V
for 70 min in 1x Tris-Acetate SDS-Running buffer. HiMark™ Pre-stained high molecular
mass protein standard was used as a molecular mass marker with a reference range from
30-460 kDa. Once separation has occurred, gels were visualised using silver staining, or
were transferred onto a PVDF membrane by an iBlot 2 system for further Western blot
analysis.
Table 2.13 can be used for all enzymatic MPO experiments including the competitive
study (Table 2.9 and 2.10).
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Table 2.11: Preparation of treated human plasma FN for SDS-PAGE.
Solution (µL) Reducing
+ −
Protein sample from Table 2.6 6.67 6.67
10x NuPAGE reducing solution 2.4 0
4x NuPAGE sample buffer 6 6
MilliQ water 12.27 14.67
Total Volume 24 24
Volume loaded 4.8 (0.25 µg of protein per lane) 4.8 (0.25 µg of protein per lane)
Table 2.12: Preparation of treated HCAEC-derived FN for SDS-PAGE.
Solution (µL) Reducing
+ −
Protein sample from Table 2.7 16.67 16.67
10x NuPAGE reducing solution 6.4 0
4x NuPAGE sample buffer 16 16
MilliQ water 8.9 15.3
Total Volume 64 64
Volume loaded 16 (1.25 µg of FN per lane) 16 (0.25 µg of FN per lane)
Table 2.13: Preparation of enzymatically treated human plasma FN for SDS-PAGE which were used
with both concentration of MPO experiments.
Solution (µL) Reducing
+ −
Protein sample from Table 2.8 25 25
10x NuPAGE reducing solution 4 0
4x NuPAGE sample buffer 10 10
MilliQ water 1 1
Total Volume 40 40
Volume loaded 8 (0.5 µg of protein per lane) 8 (0.5 µg of protein per lane)
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2.2.4.1 Silver stain
Silver staining was used to visualise structural changes to protein samples such as
aggregation or fragmentation. Gels were first removed from casing, and were then
fixed in 50% (v/v) ethanol, 10% (v/v) acetic acid for a minimum of 30 min. Once
gels were fixed, they were rinsed in 5% (v/v) methanol for 15 min, followed by three 5
min consecutive washes in milliQ water. After the gels were washed, it was submerged in
freshly prepared 0.02% (w/v) sodium thiosulfate for 2 min, then washed in milliQ water
for 2 min. Gels were incubated in ice cold 0.2% (w/v) silver nitrate for 25 min, then
washed in milliQ water for 5 min. Gels were subsequently washed and silver containing
liquid discarded according to standard laboratory protocol. Developer solution of 3%
(w/v) sodium carbonate, 0.0004% (w/v) sodium thiosulfate (prepared from previously
made solution), and 0.05% (v/v) formaldehyde, was poured over the gel until submerged.
Developer solution was changed after 2 min, and once bands started appearing, gels were
immersed in a stopping solution of 1.4% (w/v) EDTA. Over development of bands were
prevented by adding a stop solution before the preferred band density formed.
2.2.4.2 Western blotting
Once separation was performed, gels were transferred onto PVDF membranes using an
iBlot 2 gel transfer device (Life Technologies) and ran at 160 V for 70 min. The PVDF
membranes were blocked in 1% (w/v) BSA in TBS with 0.1% (w/v) Tween 20 (TBST)
for 1 hr on a shaker at 21°C, followed by an incubation with the desired antibody 2.1 at
4°C overnight on a rocker. The next day, membranes were rinsed for 5 min with TBST
at 21°C on a shaker, prior to incubating with the respective secondary antibody diluted
in 1% (w/v) BSA in TBST for 1 hr at 21°C on a shaker. Membranes were then washed
in TBST for 1 hr with a change in washing solution every 15 min, then rinsed in TBS,
and left in TBS solution until development.
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Membranes were developed using Western lighting PLUS ECL reagents (1:1 ratio of
reagent A to reagent B). Membranes were covered in the reagents, and developed on a
Bio-rad® Chemidoc™ (California, U.S.A.) system or Syngene G:Box XR5 (Cambridge,
UK).
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2.2.5 High Performance Liquid Chromatography
Bovine plasma FN samples were treated with HOCl and prepared by following the
treatment described in 2.14. Samples were prepared in inscribed hydrolysis vials to a
total volume of 200 µL from a stock solution of 90 µL of stock 5 mg/ml bovine plasma
FN (final concentration of 5 µM) diluted in 40 µL of 0.5 M pH 7.4 Phosphate buffer, and
30 µL of milliQ water. Each vial was then treated with a 40 µL of oxidant, followed by
an incubation for 2 hr at 37°C. Sample vials were delipidated and precipitated by the
addition of 25 µL of 0.3% (w/v) deoxycholic acid and 25 µL of 50% (w/v) TCA, which
was incubated for 5 min on ice. The samples were spun down at 9000rpm for 2 min at 4°C
to form a protein pellet. The protein pellet was washed with ice cold acetone four times
with protein pellet being spun down again at 9000rpm for 2 min at 4°C between washes.
Remnant acetone was carefully dried off with nitrogen gas. Once samples were dry, the
protein pellets were re-suspended in 150 µL of MSA containing 0.2% (w/v) tryptamine,
then each samples were transferred to respective pico-tag hydrolysis vials. The pico-tag
vials were evacuated three times by alternating 10 secs of nitrogen, followed by 30 secs of
evacuation (VWR gas pump), then a final evacuation was performed for 1-2 min, before
being incubated overnight (16 hr, keeping each experimental time consistent) at 110°C
in an oven. The next day, the vacuum vials were released to check that pico-tag vials
were sealed properly before being allowed to cool to 21°C. Samples were neutralized by
addition of 150 µL freshly prepared 4 M of NaOH (16% (w/v) NaOH in milliQ water; 1:1
ratio to MSA). Samples were filtered by centrifuging at 10000rpm for 2 min, through 0.2
µm Nanosep filters (Pall). Samples were diluted 10-fold into milliQ water, before 40 µL
of the diluted samples were transferred to respective HPLC vials with 200 µL inserts.
Amino acid standard (A9781; Sigma-Aldrich), and 500 µM methionine sulfoxide for
analysis was obtained commercially and prepared to 12.5 µM in milliQ water. The
standard mixture was diluted further to create a linear standard from 0 to 50 pmol
in increments of 10 pmol in milliQ water per 6 µL injection. Standard mix was also
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Table 2.14: Preperation of bovine plasma FN as 5 µM and treated with HOCl for amino acid analysis
using HPLC.
Solution (µL) Example for one reaction vial
Stock protein (5 mg/ml) 90
0.5 M pH 7.4 Phosphate buffer 40
MilliQ water 30
Oxidant (1:5 dilution) 40
Total Volume 200
filtered through 0.2 µm Nanosep filters (Pall) at 10000 rpm for 2 min, then 40 µL of
each standard was transferred to their own HPLC vial with 200 µL inserts in duplicates.
Activated fluoraldehyde o-Phthaldialdehyde (OPA) reagent solution was prepared with
20:1 dilution to 2-Mercaptanol. The auto-injector was programmed to inject samples
with 20 µL of activated OPA.
Table 2.15: Preperation of amino acid standard derivatisation.
pmol per 6 µL injection 12.5 µM standard stock (µL) MilliQ water
0 0 120
10 24 96
20 48 72
30 72 48
40 96 24
50 120 0
The separation of amino acids was completed using a gradient buffer of low to high
percentage organic solvent. Buffer A was comprised of 20% (v/v) methanol, 2.5% (v/v)
Tetrahydrofuran (THF), 50 mM pH 5.3 sodium Acetate in milliQ water. Buffer B was
comprised of 80% (v/v) methanol, 2.5% (v/v) THF, 50 mM pH 5.3 sodium acetate in
milliQ water. Both buffers were prepared and filtered through a 0.2 µm Nanosep filters
(Pall) using a vacuum apparatus.
Shimadzu HPLC machine was set-up with an auto-sampler programmed to derivatise
each sample with 20 µL, followed by samples being mixed 3 times with incubation for
1 min. A Shimadzu Shim-pack xR-ODS, 4.6 mmid x 100 mm column was used, with a
gradient elution between buffer A and buffer B (Table 2.17). The flow rate was adjusted
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Table 2.16: Method to prepare HPLC buffer A and buffer B.
Solution Buffer A (ml) Buffer B (ml)
1M sodium acetate pH 5.3 200 200
THF 50 50
Methanol 400 1600
MilliQ water 1350 150
to 1.2 mL/min with the initial buffer A concentration starting at 100% and buffer B at
0%. The percentage of buffer B was increased to 25% slowly over 6 min and maintained
at 25% for 1 min, before a steep increase to 62% in 30 sec, and was maintained for 2.5
min. Buffer B was then ramped up to 100% over 2 min, and maintained for 1 min, before
buffer A was increased all the way back up to 100% for 3.5 min. The fluorescence of
the derivatised amino acid was measured at 340 nmex, and 440 nmem using a Shimadzu
RF-AXS20 fluorescence detector.
A chromatagram of observed amino acid elution was used as seen in figure 2.2.
Table 2.17: HPLC buffer ratios.
Time (min) Flow Buffer A (%) Buffer B (%)
0 1.2 100 0
6 1.2 75 25
7 1.2 75 25
7.5 1.2 38 62
10 1.2 38 62
12 1.2 0 100
13 1.2 0 100
13.5 1.2 100 0
17 1.2 100 0
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Figure 2.2: Chromatogram of amino acid elution for HPLC.
2.2.6 Thiol Assay
Bovine plasma FN sample solution was prepared at 5 µM according to table 2.18. Samples
were either untreated or treated with 1x, or 50x molar ratio of HOCl or HOSCN to a final
sample volume of 50 µL with a 96-well clear bottom plate. Samples were treated with 0,
5, and 250 µM of HOCl or HOSCN and was incubated for 2 hr at 37°C. An anhydrous 2.6
mM stock solution of ThioGlo (Berry and Associates; HC9080) was prepared following
the manufacturer’s instructions, which was stored in the dark at 4°C for use.
Table 2.18: Preperation of bovine plasma FN as 5 µM with treatment with HOCl for Thiol analysis.
Solution (µL) Example for one reaction vial
Stock protein (5 mg/ml) 22.50
0.5 M pH 7.4 Phosphate buffer 10
MilliQ water 7.5
Oxidant (1:5 dilution) 10
Total Volume 50
A 5 µM GSH standard stock was prepared in milliQ water by making a 0.5 mM GSH
solution in milliQ in a volumetric flask. This 0.5 mM GSH solution was diluted 1:100 to
form the final 5 µM GSH solution. A linear standard was made from 0 to 5 µM in an
integer of 1 µM according to table 2.19, and then 50 µL was transferred to the 96-well
plate in triplicates. Working solution of ThioGlo was prepared by diluting the stock
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solution 1:100 in 1x PBS and then 50 µL was transferred into each standard and sample
well. The plate was mixed briefly on a plate shaker and incubated for 10 min in the dark
at 21°C. The fluorescence was measured at 384 nmex, and 513 nmem.
Table 2.19: Method to prepare GSH standard for Thiol Assay.
Concentration of GSH (µM) 5 µM stock (µL) MilliQ water
5 400 0
4 320 80
3 240 160
2 160 240
1 80 320
0 0 400
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2.2.7 Cell Adhesion
Clear bottom 96-well plates were prepared the same way as an ELISA plate when
performing assay using crystal violet and calcein-AM; refer to section 2.2.2. Once plates
have been treated they were proceeded under the respective methodology.
2.2.7.1 Cell adhesion – Crystal Violet
Treated plates were rinsed twice with 200 µL of sterile PBS before being blocked with
100 µL of 3% (w/v) BSA in DPBS for 1 hr at 37°C in a cell culture incubator. While
plates were being blocked, HCAEC were prepared and re-suspended in 1% (w/v) BSA in
Endo-Basal media. Plates were rinsed again twice with 200 µL, followed by being seeded
with 50 µL of 2.5 x 105 cells/ml per well (12,500 cells), and incubated for 1.5 hr at 37°C in
a humidified atmosphere containing 5% carbon dioxide (CO2) . Any cells that were not
adhered were rinsed off twice with 200 µL of sterile DPBS, and remaining adhered cells
were fixed with 100 µL of 10% (v/v) formaldehyde in DPBS for 15 min at 21°C. Once
cells were fixed, plates were washed four times with 200 µL of deionized water, followed
by air drying the plate for 1 hr at 21°C. A 200 µL solution of 0.1% (w/v) crystal violet in
200 mM MES at pH 6.0 was used to stain each well and left for 20 min at 21°C. Excess
crystal violet was washed off the plate with four times washes with 200 µL of deionized
water before being allowed to air dry for 1 hr at 21°C. The crystal violet taken up by cells
were re-solubilised in 200 µL of 10% (v/v) acetic acid, and absorbance was measured at
590 nm.
2.2.7.2 Cell adhesion – Calcein-AM fluorescence
Plates were similarly washed, and blocked with 3% (w/v) BSA in PBS for 1.5 hr at 37°C.
HCAEC were trypsinised off the flask and re-suspended back in sterile 1% (w/v) BSA in
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Endo-Basal media in a small sterile tube, and incubated with 5 µM per 5 x 106 cells/ml
for 30 min at 37°C in a humidified atmosphere containing 5% CO2. Cells were washed
once with warm 1% (w/v) Endo-Basal Media, before being seeded onto twice washed
with DPBS plates with 50 µL of 2.5 x 105 cells/ml per well (12,500 cells), followed by
incubation at 1.5 hr at 37 °C in a humidified atmosphere containing 5% CO2. Plates
were carefully washed four times with 200 µL of 1% (w/v) BSA in Endo-Basal media by
swirling, and blotting excess media on paper towel. Once relatively blotted dry, add 200
µL of DPBS into each well and the fluorescence was measured at 492nmabs, and 517nmex.
2.2.7.3 Cell adhesion – Immunocytochemistry
Cultureslide Lab-Tek II Chamber 8 well (VWR) were coated with 250 µL of 10 µg/ml
(0.02 µM) of human plasma FN and BSA used as control at the same concentration,
and incubated overnight at 4°C. The next day, chambers were washed twice with 500
µL of sterile PBS before treatment with 250 µL of oxidant (refer to Table 2.4), followed
by incubation for 2 hr at 37°C. After incubation, chambers were washed with 500 µL of
sterile PBS, then blocked with 500 µL of 3% (w/v) BSA in PBS for 1 hr at 37°C. The
chambers were rinsed again with 500 µL of sterile PBS, then HCAEC was seeded with
250 µL of 2*105 cells/ml (50,000 cells) into each well, and incubated for 1.5 hr at 37°C
in a humidified atmosphere containing 5% CO2 to allow cells to adhere. Any un-adhered
cells were washed off twice with 500 µL of sterile PBS, and fixed with fixing solution
of 7.56% (v/v) of 38% formaldehyde, 0.72% (w/v) sucrose in PBS for 15 min at 37°.
Chambers were washed twice with PBS to remove excess fixing solution, then cells were
permeabilised with permeabilising solution, 10.30% (w/v) sucrose, 0.292% (w/v) NaCl,
0.476% (w/v) HEPES, 0.5% (v/v) Triton X-100 in milliQ water for 5 min at 4°C to
allow fluorescence probes to permeate into cells. Each well was rinsed with 500 µL of
0.5% (w/v) Tween-20 PBST before being blocked with 1% (w/v) BSA in PBS for 1 hr at
21°C. Chambers were twice washed with 500 µL PBST, and were incubated overnight at
4°C with 250 µL of 1x rhodamine-phalloidin diluted in 1% (w/v) BSA in PBS to stain
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F-actin fibres within cells.
The next day, chambers were washed with 500 µL of PBST, followed by incubation with
250 µL of Hoechst 33342 (H1399; 1:2000 dilution to get a final DMSO concentration
of 5 µg/ml) in PBS for 15 min in the dark at 21°C, whereby the stain can permeate
into the nuclei. Chambers were washed twice with 500 µL of PBS to remove any excess
stain, and left in PBS. When ready to image, remove the plastic chambers, apply one
drop of SlowFade Diamond Antifade (S36963; ThermoFisher Scientific) to help mount the
slide prolong the fluorescence, then clean the coverslip prior to imaging on a fluorescence
microscope.
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2.2.8 Cell Metabolic Activity
HCAEC metabolic activity plates were prepared the same way as HCAEC adhesion
experiment. After plates have been seeded and incubated with 12,500 HCAEC for 1.5
hr at 37°C in a humidified atmosphere containing 5% CO2, the plate were twice washed
with 200 µL sterile PBS. They were incubated with fresh HCAEC growth medium for
48 hr at 37°C in a humidified atmosphere containing 5% CO2. This method can also be
completed post cell adhesion using Calcein-AM protocol by leaving plates for 48 hr with
200 µL fresh HCAEC growth media. After 48 hr, 20 µL of CellTiter 96® Aqueous One
Solution Assay (G3580; Promega) was added into each sample well, and the absorbance
was measured at 490 nm, 0 hr, 1hr, 2hr, 3hr, and 4hr. Analysis of data was made on
data collected at 2 or 3 hr.
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2.2.9 RNA expression
Sterile 6-well culture plates were coated with 2 ml of 20 µg/ml (0.04 µM) of human
plasma FN overnight. On the next day, each well was either untreated (0.1 M sodium
phosphate pH 7.4 buffer) or treated with 1250x molar ratio (50 µM) of HOCl or HOSCN
diluted in 0.1 M sodium phosphate buffer pH 7.4, in triplicates for 2 hr at 37°C. HCAEC
were seeded into each well at a density of 5 x 106 and incubated for 72 hr at 37°C in
a humidified atmosphere containing 5% CO2. Medium was discarded and each well was
rinsed with sterile PBS to wash off any remaining serum and media. Using a Qiagen
RNeasy Mini Kit, the HCAEC was harvested by adding 350 µL of RLT buffer and a
scraper was used to remove all cells from well surface. The lysates were transferred to
sterile eppendorf tubes and the cell pellet was broken up using a 25 gauge syringe and
pipetting up and down. To the samples, 350 µL (1:1 ratio to RLT buffer) of 70% ethanol
was added to precipitate out DNA and RNA, and the total sample was spun through an
Rneasy Mini Spin column for 15 sec at 8000g. The flow-through was discarded before
DNA was digested by adding 350 µL of RW1 to the RNeasy column, followed by a
centrifuge for 15 sec at 8000g, with the flow-through being discarded. For each sample,
DNase 1 working solution was prepared by combining 10 µL of stock solution to 70 µL
buffer RDD (1:8 dilution) and gently inverting to mix, followed by a quick centrifuge. To
each sample, 80 µL of DNase 1 was added directly to the RNeasy column membrane and
incubated for 15 min at 21°C. The RNeasy column was washed with 350 µL of RW1, with
the flow-through being discarded, followed by another wash with 700 µL of RW1 with
centrifuge for 15 sec at 8000g. Each sample tube was spun down with 500 µL of RPE for
15 sec at 8000g, discarding flow-through, followed by another wash with 500 µL of RPE
and centrifuged for 2 min at 8000g. The flow-through was discarded, and the RNeasy spin
column was transferred to a new sterile 2 ml collection tube. The column was centrifuged
for 1 min at full speed to dry off the membrane. The collection tube was discarded, and
the RNeasy column was placed into a new sterile 1.5 ml collection tube. To each sample
tube, 30 µL of RNase-free water was directly added to the membrane of the RNeasy spin
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column, and centrifuged for 1 min at 8000g to elute out RNA. If concentration of RNA
was expected to be greater than 30 µg, another 30-50 µL of RNase-free water can be
spun through or the previous eluate can be spun through the column again.
RNA samples were then tested for purity by using a NanoDrop machine or a SpectraDrop
micro-volume 24-well microplate, and measuring the spectrum absorbance of samples.
When using a SpectraDrop micro-volume 24-well microplate, 2 µL of each sample was
pipette into each 0.5-mm spacers sample well, this was measured against RNase-free
water. Spectral absorbance measurements were made at 260 nm, 280 nm, 230 nm, and
320 nm. To analyse sample contamination, ratio between 260:230 (organic contamination)
and 260:280 (DNA contamination) were calculated 2.20. Nucleic concentration was
calculated as the optical density for absorbance at 260 nm (OD260) was 1, which was
equivalent to 40 ng/µL of nucleic acid.
Table 2.20: Absorbance for determining different components in RNA prepped samples.
Absorbance Ratio for high purity RNA
Abs 260 Abs260/Abs280
Nuclein Acid concentration - 1.8 for DNA purity
OD260 = 1 = 40ng/µL 1.8 - 2.1 for RNA purity
Abs 230 Abs260/Abs230
Detects organic contaminations <1.8
for example: phenol, trizol
Abs 280 Abs260/Abs320
Protein detection 1.8 - 2.2
Abs 320
Non-nucleic acid or protein contaminant
Nucleic acid concentration was calculated for each sample for total yield and volume
required for 400 ng of nucleic acid for cDNA synthesis using RT2 First Strand Kit
(330404: Qiagen). Reagents were thawed out from the kit and briefly centrifuged to
settle the solutions. For each sample, genomic DNA elimination (DNA-elim) mix was
prepared by combining RNA with Buffer GE, and Nuclease-Free water (Table 2.21). The
DNA-elim mix was incubated for 5 min at 42°C, then immediately put onto ice for a
minimum of 1 min. The Reverse-Transcriptase (RT) mix was prepared by combining 5x
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Buffer BC3 (2:5), Control P2 (1:10), RE3 RT-mix(1:5), and Nuclease-Free water (3:10)
to a total volume of 10 µL per reaction (Table 2.22).
Table 2.21: Preparation for elimination of DNA.
Component (µL) Volume (µL)
RNA sample X (equal to 400ng of RNA)
Buffer GE 2
Nuclease-free water 10 - X
Total Volume 10
Table 2.22: cDNA synthesis preparation method.
Component (µL) Volume (µL) per reaction
5x Buffer BC3 4
Control P2 1
RE3 RT-mix 2
Nuclease-free water 3
Total Volume 10
Into each sample tubes containing 10 µL of DNA-elim mix, 10 µL of RT-mix was added
and gently mixed. Samples were incubated in a thermal cycler for 15 min exactly at 42°C,
then the RT was inactivated with an immediate incubation for 5 min at 95°C. Samples
were centrifuged briefly to spin down any condensation, then 91 µL of RNase-free water
was gently mixed in. Samples were placed on ice to continue real-time PCR or stored in
-20°C until ready for use.
An RT2 Profiler PCR Human Extracellular Matrix and Adhesion molecules (330231;
QIAGEN) was used for analysing a multi-array of genes associated ECM and adhesion,
housekeeping genes, and controls for genomic DNA, RT-transcriptase controls, and
positive PCR control. First, RT2 SYBR Green Mastermix was centrifuged for 10-15
sec to settle the contents. Sample PCR mix was prepared in sterile 2 ml eppendorf tubes
by adding in 51 µL of 2x RT2 SYBR Green Mastermix, and 43 µL of RNase-free water
to the 8 µL of cDNA synthesis reaction for a total of 102 µL. This allows for an excess
of 6 µL for pipetting errors; samples can be prepared at higher volume for greater error
capacity. Pipette tips were changed for each well to avoid cross contamination, and 10 µL
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was added to each well. An adhesive plate cover was used to cover each plate, followed
by centrifuging for 1 min at 21°C at 1000g to minimise any bubbles present in samples.
RT2 Profiler PCR Array was kept on ice prior to performing PCR. PCR cycling was
programmed as per Table 2.23 using ViiA-7 instrument with ViiA-7 Software v1.2 (Life
Technologies).
Table 2.23: Setup for thermocycler for qPCR.
Stages Time Temperature (°C) Temp Change Cycles
Hold 10 min 95 1.6 1
PCR 15 sec 95 1.6 40
1 min 60 1.6
Melt Curve 15 sec 95 1.6 1
1 min 60
15 sec 95 0.05
The threshold was defined with the log view of the Y-axis of the amplification plots, and
set to 0.02, which should sit above the background signal but should sit in the lower third
when examining the amplification plot linear phase. Using the linear plot phase of the
Y-axis, the baseline should be set to where the first amplification was visible starting from
cycle 2 but no further than cycle 15; amplifications were usually visible around cycles
14 to 18. The threshold should remain the same between all RT2 Profiler PCR Array
to ensure consistent analysis. CT values were exported to a blank Excel sheet and data
analysis can be performed using SABiosciences PCR Array Data Analysis Template and
Web-based analysis software (www.SABiosciences.com/pcrarraydataanalysis.php).
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2.2.10 Immunohistochemistry of Human Atherosclerotic Lesions
Aortae or aortae abdominalis sections were obtained from subjects who have died from
cerebral haemorrhage. Lesions obtained this way were classified according to Stary’s
system to microscopically identify normal to thickened intima (lesion type II-III), to
prominent calcified atheroma (lesion type IV). Samples were obtained within 12 hr of
post mortem. Tissue were immediately frozen in cryostat (Microm HM500 OM; Microm,
Walldorf, Germany) using tissue freezing medium (Tissue Tec OCT-compound; Miles,
Elkhard, Ind., USA). Glass slides were used to collect 5 µm of serial cryosections which
were air dried for 2 hr at 21°C, followed by fixing with acetone for 5 min at 21°C. Samples
were stored at -80°C until required for further analysis.
Acetone fixed tissue sections were thawed for 5 min at 21°C, and PBS was used to
rehydrate sections, followed by blocking with Ultra V block for 10 min (Lab Vision,
Fremont, CA, USA). Once samples were blocked, they were incubated with primary
monoclonal anti-FN or polyclonal anti-FN antibody for 30 min which were diluted with
antibody diluent (Dako), followed by a wash with PBS. Sample slides were incubated in
appropriate secondary antibodies; Polyclonal anti-FN incubated sections were incubated
with HOCl-generated epitope antibody, and monoclonal anti-FN sections were firstly
blocked with normal mouse serum (1:25) for 15 min, followed by incubation with Cy-3
labelled anti-HOCl generated epitope antibody in dark moisture chambers at 21 °C.
Sections were mounted with Moviol (Calbiochem-Novabiochem, La Jolla, USA), and
analysed with a confocal laser-scanning microscope in sequential mode (Leica SP2, Leica
Lasertechnik GmbH, Heidelberg, Germany). Settings used in analysis for Cy-2 (green
staining) incubated samples were 488 nmex, and 500-540 nmem, and for Cy-3 (red staining)
were 543 nmex, and 560-620 nmem
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Chapter 3
Modifications to fibronectin by HOCl
3.1 Introduction
FN is a dimeric glycoprotein of approximately 460kDa in size and composed of two
monomer subunits (220-270kDa) bound by two disulfide bonds at the carboxyl termini
[149, 195, 196]. There are two defined types of FN; soluble plasma FN, which is produced
primarily by hepatocytes and released into blood plasma, and insoluble cellular FN, which
is produced by various cells, such as fibroblasts and EC, and is present in the basement
membrane of tissues [149, 195, 196]. Plasma FN plays a key role in wound healing by
interacting with fibrin and causing a coagulation cascade to form blood clots. Cellular FN
interacts with the surrounding extracellular matrix (ECM) to create a complex network
providing structure and assisting in cellular functions, such as adhesion, proliferation and
migration [140, 274]. Furthermore, FN has been found to initiate matrix assembly in
response to certain functional sequences (CBF or HBF) by interacting with cell surface
receptors and integrins [149, 197].
The integrity of atherosclerotic plaques is highly dependent on vascular remodelling,
ECM deposition, and vascular smooth muscle cells (SMC) migration. Changes to a
number of these factors can result in smaller, thinner plaque caps, which have been found
to be more unstable and have higher risk of rupturing [1]. Plaque ruptures causes a
coagulation cascade, forming luminal clots and subsequently myocardial infarction or
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strokes [1]. The importance of FN is notable in the development of atherosclerosis and in
several other diseases [1, 140, 253, 274]. In the progression of atherosclerosis, increased
expression of FN has been found localised within areas of injury and plaque development
[275–277]. Patients with coronary artery disease (CAD) were demonstrated to have
elevated plasma FN levels [278–280]. However, other studies have shown that circulating
plasma FN levels do not correlate with occurrence of CAD [281, 282]. Circulating FN is a
potential contributor to CAD development, but it is likely to act in conjunction with other
atherosclerosis promoting factors. For example, deficiency of plasma FN in apoE-/- mice
was found to result in a smaller number and sizes of atherosclerotic plaques, with reduced
levels of monocyte recruitment [264]. However, the plaques that formed were found to
have decreased matrix protein deposition, decreased vascular SMC infiltration into injury
area, and were thinner and more unstable, which would indicate higher susceptibility to
plaque rupture in humans [264]. Furthermore, FN is also known to stimulate EC growth,
whereby EC incubated on FN were found to have sustained adherence of up to four days
[235]. These important functions are accompanied with increased levels of inflammatory
cells, and lipoprotein retention [265]. These findings suggests the importance of FN in
plaque development and progression.
Atherosclerotic plaques have been reported to have high levels of inflammatory cells
with particularly large numbers of macrophages in the shoulder region of lesions [283].
This means that FN, and other ECM species, are in close proximity with inflammatory
oxidants released by activated leukocytes, which suggests that they would be likely targets
of these reactive oxygen or nitrogen species [21]. Myeloperoxidase (MPO), is a haem-
peroxidase that produces certain reactive oxygen species (ROS) [11]. Hypochlorous acid
(HOCl) is one of the major reactive oxygen species to be produced by MPO in response
to inflammation, and in high concentrations it has been found to target host proteins,
such as ECM molecules, and cells, such as ECs [50, 57, 152, 284]. HOCl is highly
reactive and oxidises a range of targets, including: iron-sulfur centres, sulfide (thioether)
groups, sulfhydryl groups and unsaturated fatty acids [8, 45–48]. Furthermore, it has
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been demonstrated that in vitro exposure of FN to HOCl, causes several structural
and functional modifications [22, 64, 65, 260, 261]. HOCl has previously been found to
fragment FN and cause protein aggregation [65, 260], whereby these structural changes
have been proposed to cause loss of FN epitopes important for function and survival [22,
261, 271]. Inhibition of the gelatin binding site with an anti-50k antigen binding fragment
(Fab’) resulted in a decreased deposition of collagen type I, pro-collagen type III and FN,
suggesting that the fibrillar structures formed between the two proteins are important
[258].
These data suggest that FN is important in vascular architecture in arterial remodelling
and in the initiation and progression of certain diseases. Taking these previous findings
into consideration, it was hypothesised that human plasma and cellular FN would be
targeted and modified by HOCl. These modifications would cause structural changes to
FN, leading to aggregation, fragmentation, and subsequent biological dysfunction of cells
incubated on HOCl-modified FN.
3.2 Aims
The experiments carried out during these studies were aimed at elucidating the effects
of HOCl on isolated human plasma FN and cellular-derived FN in whole ECM extracts.
The structural modifications of FN by HOCl and the subsequent effect on antibody
recognition of the FN epitopes important to its function were investigated. Amino acid
analysis was performed to examine changes to amino acids using HPLC and ThioGlo.
Furthermore, biological changes were examined using HCAEC exposed to HOCl-modified
FN, by measuring cellular adhesion, cell metabolism, and gene expression. Lastly, these
experiments investigated the occurrence of FN and an HOCl-generated epitope in human
atherosclerotic lesions.
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3.3 Results
3.3.1 Effect on human plasma fibronectin epitope with HOCl
modification
Modifications occur through oxidation by HOCl, leading to structural changes in FN, and
the subsequent loss of epitope recognition, and further biological dysfunction. Monoclonal
antibodies were utilised to detect sites of functional interests on plasma FN including the
CBF, HBF, and the presence of HOCl-generated epitopes. The CBF is very important
for cell adherence to the sub-endothelial basement membrane, whereby the loss of this
particular interaction could lead to a dysfunctional arterial matrix and wall, while the
HBF interacts with heparin and heparan sulfates, which functions to stabilise the matrix
and cell adhesion [149, 195, 196]. The 2D10G9 antibody used to detect HOCl-generated
damage was originally raised against HOCl-oxidised LDL and binds onto an unidentified
HOCl-generated epitope [63]. Measurements were made on plated FN exposed to oxidant,
before using an ELISA method to quantify antibody recognition. The types of chemical
modification and favoured region cannot be identified using this particular method.
In initial experiments, 50 µL of 10 µg/ml of FN (0.02 µM) in 0.1 M of pH 7.4 phosphate
buffer was coated on high-binding protein ELISA plates overnight at 4°C. The sample
wells were then washed with 1x PBS to remove any unbound FN, and were treated with
50 µL of corresponding concentrations of reagent HOCl (0, 5, 10, 25, 50, 100, 200 µM)
diluted in 0.1 M of pH 7.4 phosphate buffer (refer to Table 2.4). Plates were incubated
for 2 hr at 37°C, followed by a wash with 200 µL of 1x PBS to remove any excess
HOCl or secondary products to prevent artefacts or other by-products. Plates were then
blocked with 100 µL 0.1% (w/v) casein in PBS to prevent any non-specific binding,
subsequently washed and incubated with 50 µL primary anti-CBF, anti-HBF, and anti-
HOCl epitope antibodies. Sample plates were incubated overnight at 4°C on a rocker to
ensure even binding of primary antibody, followed by a wash with 200 µL 0.1% Tween 20
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in PBS (PBST) and incubation of respective secondary antibody for 1 hr at 21°C on a
rocker. Sample plates were washed four times with 200 µL PBST, and were subsequently
quantified with 100 µL of freshly prepared ABTS solution by adding H2O2 in a ratio of
1:1000 of stock ABTS. Quantifications were made at 405 nm at 30 min.
Exposure of surface-bound human plasma FN to HOCl was observed to have
modifications to the CBF epitope, showing a statistically significant loss of epitope at
500x molar ratio of HOCl (Figure 3.1A). There was approximately 60% loss of recognition
at 1250x molar ratio of HOCl and complete loss of the epitope at 2500x molar ratio
(Figure 3.1A). FN HBF also showed statistically significant loss at 500x molar ratio with
almost complete loss at 2500x molar excess (Figure 3.1B). This loss of recognition was
accompanied by the increasing presence of a HOCl-generated epitope detected using the
2D10G9 antibody reaching statistical significance at 2500x molar excess (Figure 3.1C). At
higher concentrations, there was a decrease in the presence of HOCl-generated epitopes,
likely due to further modifications leading to destruction or aggregation of the protein
resulting in regions where the antibodies cannot penetrate.
This result has shown that HOCl modifies FN, particularly at the CBF and HBF
functional epitopes, causing loss of antibody recognition. In light of this, further
experiments were carried out to investigate potential structural changes to FN using SDS-
PAGE, including examination by Western blotting to examine the structural damage of
those functional epitopes.
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Figure 3.1: ELISA of human plasma FN treated with increasing concentrations of HOCl. Each well
was coated with 0.5 µg (0.02 µM) of human plasma FN in 0.1 M phosphate buffer and either left
untreated (control) or treated with HOCl (0, 5, 10, 25, 50, 100, 200 µM), and incubated for 2 hr at 37°C.
FN epitope was detected by using a mouse monoclonal A) anti-FN CBF antibody (A17; 1:10000), B)
anti-FN HBF antibody (A32; 1:1000), C) anti-HOCl generated epitope (2D10G9; 1:50), and conjugated
with anti-mouse HRP secondary antibody (1:1000). The data are presented as a percentage of the
relative absorbance of control (no oxidant; 0 µM treatment). Error bars are ± SD from three technical
triplicates obtained from each of three independent experiments. Statistical analysis was performed using
one-way ANOVA with Tukey’s multiple comparison post hoc tests to determine significance. Statistical
significance was identified as follows: * = p < 0.05, ** = p < 0.01, and **** = p < 0.0001.
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3.3.2 Effect of HOCl on the structure of human plasma fibronectin
To further investigate HOCl-induced modifications of FN, structural changes were
examined using SDS-PAGE separation followed by silver staining and Western blotting
of treated proteins to probe for alterations to functional epitopes leading to modifications
unrecognised by antibodies. Smaller molar ratios of FN:HOCl were used as to identify
minor structural changes of FN (and corresponding functional epitopes) at concentrations
lower than the concentration where complete loss of antibody recognition was observed
(i.e. < 1250x molar ratio). Silver staining was used to detect protein bands, including
the parent dimer band (black arrow) at around 460 kDa (Figure 3.2) and the parent
monomer band (white arrow) at 230 kDa (Figure 3.2). SDS-PAGE was used to identify
whether there were changes to protein mass arising from HOCl-induced modifications or
whether oxidant exposure led to fragmentation or aggregation of FN protein. By having
non-reducing and reducing samples, information can be obtained on the possible presence
of higher aggregates based on whether they contain new inter-chain (reducible) disulfide
bonds or are aggregating by other chemical bonds.
Human plasma FN (2.5 µg at 1 µM) in 0.1 M pH 7.4 phosphate buffer was treated
with increasing molar ratios of reagent HOCl (0, 5, 10, 25, 50, 100, 200 µM) diluted
in 0.1 M pH 7.4 phosphate buffer, prior to separation on the basis of molecular
mass by SDS-PAGE. Gels were subsequently fixed with 10% (v/v) acetic acid and
50% (v/v) methanol solution, and protein bands were detected with silver staining.
The data obtained under non-reducing conditions showed increased detection of dimer
and decreased detection of monomer bands, with increased presence of both higher
aggregates and fragments in a HOCl dose-dependent manner (Figure 3.2A). The samples
electrophoresed under reducing conditions showed increasing detection of the monomer
band, with dimers/higher aggregates appearing following incubation with high (> 200x)
HOCl molar ratios (Figure 3.2B).
After SDS-PAGE separation, protein bands were transferred onto PVDF membranes
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Figure 3.2: Silver staining of SDS-PAGE gels showing structural changes to human plasma FN treated
with increasing molar ratios of HOCl. Human plasma FN (1 µM) in 0.1 M phosphate buffer was either
untreated (control; 0x oxidant treatment) or treated with increasing concentrations of HOCl (0, 5, 10,
25, 50, 100, 200 µM), and incubated for 2 hr at 37°C. Samples were separated using 3-8% Tris-acetate
SDS-PAGE gels under A) non-reducing or B) reducing conditions. Gels were then fixed, and visualised
with silver stain and referenced against HiMark™ pre-stained high molecular mass standards. Bands are
labelled as follows: black arrow = parent dimer, white arrow = parent monomer band, Aggs. = higher
aggregates, and Frags. = fragments.
using an iBlot 2 transfer system and probed for the presence of functional epitopes.
PVDF membranes were blocked with 1% (w/v) BSA in 1x TBS and 0.1% (v/v) Tween
20 (TBST), followed by incubation with primary antibody overnight at 4°C. Excess
primary antibody was removed by washing with TBST, then the samples were incubated
with a HRP-conjugated secondary antibody followed by four washes with TBST
before development with ECL reagent and acquisition of blot images with an imaging
machine. Western blots were performed and probed for FN CBF under non-reducing and
reducing conditions. HOCl-treated FN samples showed an increased detection of both
dimer/higher aggregate (black arrow) and monomer (white arrow) bands under non-
reducing conditions (Figure 3.3A). Higher mass aggregates and fragments that possessed
the CBF were also detected in a dose-dependent manner at higher HOCl molar ratios
(Figure 3.3A). Samples electrophoresed under reducing conditions were found to show
the presence of dimer/higher aggregate at high HOCl to FN molar ratios (Figure 3.3B).
Fragments of FN were also detected with increasing fragmentation occurring at high
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molar ratios of HOCl to FN (Figure 3.3B).
Figure 3.3: Western blotting showing structural changes to human plasma FN treated with increasing
molar ratio of HOCl. Samples were separated on SDS-PAGE under A) non-reducing or B) reducing
conditions and transferred onto PVDF membranes. PVDF membranes were probed with mouse
monoclonal anti-FN CBF antibody (A17; 1:10000), and conjugated with anti-mouse HRP secondary
(1:2000). Blots were developed with ECL-plus reagent. Bands are labelled as follows: black arrow =
parent dimer, white arrow = parent monomer band, Aggs. = higher aggregates, and Frags. = fragments.
Structural changes on the proteins are usually caused by modifications to the amino
acid side chains, leading to changes in interactions between each other, that can cause
aggregation, or modifications to the peptide backbone resulting in fragmentations. Thus,
amino acid analysis was utilised to assist in identifying what amino acids were targeted
on FN during exposure to HOCl.
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3.3.3 Amino acid analysis of HOCl treated bovine plasma fibronectin
HOCl is known to target and modify certain amino acids on protein, and by analysing
which amino acids are affected, sites of modifications can be identified. Amino acids that
are major targets of HOCl in decreasing kinetic order are Cys > Met > His > Cystine >
Trp> Lys> Tyr [51]. FN was treated with varying concentrations of HOCl and incubated
for 2 hr at 37°C which was then precipitation by adding 0.3% (w/v) deoxycholic acid and
50% (w/v) TCA and incubated for 5 min on ice (Figure 3.4). Samples were spun down
to form a protein pellet, which was washed four times with ice cold acetone, with any
remaining acetone being removed with N2 gas. The protein pellet was then hydrolysed
with the addition of 0.2% (w/v) tryptamine in MSA in pico-tag hydrolysis vials, under
vacuum, and incubated overnight at 110°C to release the free amino acids. Vials were left
to cool to 21°C the next day and neutralised with 4 M NaOH, and subsequently filtered
through 0.2 µm Nanosep filters (Pall). Quantifications were made with HPLC with
fluorescence detection after being tagged with OPA. This particular method is unable
to measure changes to Cys/cystine residues and other methods are needed to define
these residue modifications. Bovine plasma FN (P07589; Uniprot data), closely related
to human FN in structure (90% sequence similarity; Uniprot data), was used for these
experiments as this was easier to obtain in the amounts required needed for experiments.
Amino acids were separated using a gradient buffer and a Shimadzu Shim-pack xR-ODS
column, following method used previously [130].
Amino acid analysis of bovine plasma FN treated with HOCl showed that methionine was
heavily modified with a dose-dependent decrease of the parent amino acid. This decrease
was statistically significant with a 200x molar ratio and HOCl, and a complete loss of the
parent was detected at a 1000x molar ratio (Figure 3.5A). Methionine sulfoxide (MetSO)
is commonly regarded as the major product of methionine oxidation [50]. Analysis of FN
showed that there was some MetSO present in the untreated samples, and no statistically
significant increase was detected with increasing molar ratios of HOCl (Figure 3.5B).
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Figure 3.4: Methodology used to prepare bovine plasma FN for amino acid analysis using HPLC.
Bovine plasma FN was treated with increasing concentration of HOCl, prior to being precipitated and
hydrolysed to released free amino acids, which were tagged with OPA, and quantified using HPLC with
fluorescence detection.
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However, at 1000x molar ratio, there was a statistically significant decrease in MetSO,
which was likely due to secondary oxidation of the sulfoxide to the sulfone which cannot
be detected in this method.
Trp and Tyr residues are also reactive targets of HOCl [49]. It was demonstrated that
when FN was treated with HOCl, there was a decrease in Trp in a dose-dependent
manner, with statistically significant loss starting at 200x molar ratio (Figure 3.5C).
However, although Tyr is also known to be oxidised by HOCl, there was no changes to
the parent Tyr residues of FN when exposed to increasing concentrations of HOCl. This
may be due to its low reactivity and the abundance of alternate targets in FN. Other
amino acids (Asp, His, Ser, Glu, Arg, Gly, Thr, Ala, Val, Phe, Ile, Leu, Lys) were not
found to be targeted by HOCl in these studies and thus were omitted from these results.
Furthermore, a ThiolGlo assay was performed to analyse the modifications to thiol
residues on FN treated with HOCl. Treatment with 1x molar ratio of HOCl resulted
in no significant changes to the concentrations of thiols (Figure 3.6). Increasing the
treatment to HOCl 50x resulted in a loss of thiols of close to 50% (Figure 3.6).
Having identified that FN was structurally modified by exposure to HOCl, likely through
changes to certain amino acids or the structural peptide backbone, it was proposed that
loss of FN structural integrity would lead to a biological dysfunction. Thus, biological
assays were utilised to identify cellular function.
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Figure 3.5: Amino acid analysis of bovine plasma FN treated with increasing molar ratio of HOCl.
Bovine plasma FN (5 µM) was treated with the indicated molar ratio of HOCl (0, 5, 50, 1000, 5000
µM) then hydrolysed and derivatised for detection after separation using HPLC. Data analysis showed
changes in A) Met, B) MetSO, C) Try, and D) Tyr. The data are presented as a percentage relative to
control (no oxidant 0x treatment). Error bars are ± SD obtained from three independent experiments.
Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison post hoc
tests to determine significance. Error bars are ± SD from three independent experimental triplicates.
Statistical significance is identified as follows: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, and ****
= p < 0.0001. Other amino acids were not mentioned here as there was an were no changes detected.
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Figure 3.6: ThioGlo analysis of thiol levels on bovine plasma FN treated with HOCl. FN (5 µM)
was treated with increasing molar ratios of HOCl (0, 5, 250 µM) in a 96-well plate for 2 hr at 37°C
then ThioGlo reagent was added to each well. Concentration was measured against a GSH standard
to determine absolute concentrations. Statistical analysis was performed using one-way ANOVA with
Tukey’s multiple comparison post hoc tests to determine significance. Statistical difference is identified
as follows: * = p < 0.05.
3.3.4 Effect of cell adhesion on HOCl-modified human plasma
fibronectin
In light of the structural changes identified above, further investigations into the biological
effects that modified FN has on HCAEC activity were undertaken. The CBF is important
as it acts as a ligand to integrins on cells to mediate cell adhesion. Experiments were
prepared by coating 96-well plates with FN (0.02 µM), and treated with increasing
concentration of HOCl for 2 hr at 37°C, followed by a wash with sterile PBS to remove any
excess HOCl or by-products to prevent direct interactions with cells. Plates were blocked
with 3% (w/v) BSA in PBS, washed with sterile PBS, then HCAEC were incubated
onto each plate with 12,500 cells per well, for 1.5 hr at 37°C in a humidified atmosphere
containing 5% CO2. HCAEC were fixed with 10% (v/v) formaldehyde and stained with
crystal violet. Plates were then washed with subsequent air drying four times, and cell
stained with crystal violet were re-solubilised with acetic acid for the absorbance to be
read at 590 nm.
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Figure 3.7: Methodology used to prepare HCAECs incubated on HOCl-modified FN for quantification
with crystal violet. Human plasma FN was coated on a 96-well and exposed to increasing concentration
of HOCl. It was then blocked and incubated with HCAEC, which were fixed and stained with crystal
violet. Acetic acid was used to re-constitute crystal violet to measure absorbance at 590nm.
The experiment demonstrated a loss of cell adhesion, which was seen by a dose-dependent
decrease in cell adhesion with increasing concentrations of initial HOCl, with statistical
significance detected with a 500x or greater molar excess of HOCl (Figure 3.8). This loss
of cell adhesion corresponded with loss of recognition to the CBF of FN as demonstrated
by the ELISA experiment examining epitope antibody recognition (Figure 3.1A).
In light of these promising data indicating a loss of cell adhesion when HCAEC are left
to adhere to HOCl-modified FN, further experiments were carried out in which HCAEC
morphology were examined using immunocytochemistry (ICC) to identify cell integrity.
An 8-well glass chamber slide was coated with FN (0.02 µM) overnight in 0.1 M pH 7.4
phosphate buffer, then the slides were washed with PBS, treated with HOCl, prior to
blocking with sterile 3% BSA in PBS to reduce non-specific binding. The wells were
seeded with 50,000 cells and incubated for 1.5 hr at 37°C in a humidified atmosphere
containing 5% CO2, and any un-adhered cells were washed off with sterile PBS. Cells
were fixed (7.56% (v/v) of 38% formaldehyde, 0.72% (w/v) sucrose in PBS) for 15 min at
37°, then permeabilised by adding permeabilising solution (10.30% (w/v) sucrose, 0.292%
(w/v) NaCl, 0.476% (w/v) HEPES, 0.5% (v/v) Triton X-100 in milliQ water) for 5 min
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Figure 3.8: Crystal violet staining of HCAEC adhesion on HOCl-modified human plasma FN. Human
plasma FN (0.02 µM) was treated with increasing concentrations of HOCl (0, 5, 10, 25, 50, 100, 200 µM)
and incubated for 2 hr at 37°C before being fixed, stained with crystal violet, and re-solubilised with
acetic acid. The data are presented as a percentage relative to control (no oxidant; 0x treatment). Error
bars are ± SD from three technical replicates obtained from each of three independent experiments.
Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison post hoc
tests to determine significance. Statistical significance was identified as follows: **** = p < 0.0001.
on ice to allow fluorescent dye to penetrate cells, washed with PBST, then blocked with
1% BSA in PBS for 1 hr at 21°C. Each well was incubated with rhodamine-phalloidin
diluted in 1% BSA in PBS overnight at 4°C, which stains F-actin fibres red. Plates were
washed with PBST, then subsequently incubated with Hoechst 33342 for 15 min at 21°C,
which stained cell nuclei blue. Slides were mounted using SlowFade Diamond antifade,
and imaged using a fluorescence microscope.
The chosen concentrations for ICC were based on the concentration/molar ratio where
significant loss of recognition of the antibody or decrease in cell adhesion were observed
on ELISA and crystal violet results. FN treated with 500x, 1250x, 2500x molar ratio of
HOCl demonstrated decreased number of HCAEC attached onto the treated FN with less
nuclei (DAPI blue fluorescence) stained, when compared to untreated control (0x oxidant
treatment) (Figure 3.10). Loss in cell numbers were also accompanied by impaired cellular
spreading as seen with the reduction in F-actin filaments spreading (red fluorescence),
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Figure 3.9: Methodology used to prepare HCAECs incubated on HOCl-modified FN for quantification
with immunocytochemistry. FN was coated on at 8-well slide and exposed to HOCl. Each sample
wells were blocked, and incubated with HCAEC. Bound HCAEC were permeabilised and stained with
rhodamine-phalloidin, followed by staining with Hoechst. Slide was mounted with SlowFade Diamond
Antifade prior to imaging with fluorescence microscope.
82
whereby cells incubated on FN treated with higher concentrations of HOCl were unable
to spread into contact with adjacent HCAEC (Figure 3.10).
Figure 3.10: Immunocytochemistry of HCAEC adhesion on HOCl-modified human plasma FN. Human
plasma FN (0.02 µM) was coated on an 8-well glass chamber slide treated with increasing concentrations
of HOCl (0, 10, 25, 50 µM) for 2 hr at 37°C before being fixed then stained with rhodamine-phalloidin
for F-actin (red) and Hoechst 33342 for nuclei (blue) for fluorescence microscopic imaging.
Although cells may retain their ability to adhere to HOCl-treated FN, not all adhered
cells are metabolically active. Cell metabolism was therefore investigated to determine
whether these adhered cells are still metabolically active.
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3.3.5 Effect of cell metabolic activity on HOCl-modified human
plasma fibronectin
To further examine the biological effects that HOCl-modified FN has on ECs; cell
metabolism was measured using a live cell MTS assay which involves the reduction of MTS
tetrazolium to a coloured formazan. This reduction is thought to occur intracellularly
of metabolically active cells through the NAD(P)H-dependent dehydrogenase enzymes
[285]. Experiments were performed following the same method used for cell adhesion
(Figure 3.7). Instead of fixing cells, endothelial growth media was re-introduced into
the wells to allow the HCAEC to recover over 48 hr before cell metabolic activity was
quantified by addition of MTS reagent to each sample well. The absorbance of each
sample well was measured at 490 nm at 3 hr.
When compared to untreated control (0x), HOCl-modified FN showed a decrease in
cell metabolic activity in a dose-dependent manner. There was a statistically significant
decrease of almost 50% cellmetabolic activity at 2500x molar excess, with an even greater
decrease observed at 5000x and 10000x molar excess of HOCl compared to untreated
controls (0x) (Figure 3.11). This greatly reflects that a decreased in cells attached would
also caused a decrease in cell metabolic activity.
Both cell adhesion and metabolic activity were observed to be affected when HCAEC
were incubated on HOCl-treated FN. In light of this, real time qPCR was performed to
further investigate cellular responses to HOCl-treated FN by examining gene expression
in HCAEC.
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Figure 3.11: MTS assay of HCAEC metabolic activity on HOCl-modified human plasma FN. Human
plasma FN (0.02 µM) was treated with increasing concentrations of HOCl (0, 5, 10, 25, 50, 100, 200
µM) and incubated for 2 hr at 37°C before adding MTS reagent to each well. The data are presented
as a percentage relative to control (no oxidant; 0x treatment). Error bars are ± SD from three technical
replicates obtained from each of three independent experiments. Statistical analysis was performed using
one-way ANOVA with Tukey’s multiple comparison post hoc tests to determine significance. Statistical
significance was identified as follows: **** = p < 0.0001.
3.3.6 Effects of HOCl modified human plasma fibronectin on HCAEC
gene expression
Quantitative real-time PCR (qPCR) was performed to measure changes to gene
expression in HCAEC adherent on HOCl-treated human plasma FN. Surface bound FN
on 6-well plates were either left untreated (control; 0x oxidant treatment) or treated
with a 1250x molar ratio (50 µM) of HOCl, for 2 hr at 37°C. The wells were then
washed with sterile PBS to remove any excess HOCl or by-products to prevent their
interactions directly with HCAEC. HCAEC (500,000 cells) were seeded into each well and
incubated for 72 hr, prior to collection and extraction using a Qiagen RNeasy Mini Kit.
A Qiagen RT2 Profiler PCR Human Extracellular Matrix and Adhesion molecules Array
(330231; QIAGEN) was used to analyse a multi-array of genes associated with ECM and
adhesion, housekeeping genes, and controls for genomic DNA, RT-transcriptase controls,
and positive PCR control. Data analysis was performed using SABiosciences PCR Array
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Data Analysis Template and Web-based analysis software (www.SABiosciences.com/
pcrarraydataanalysis.php). Fold regulations were calculated using data compared to
control with normalisation within each sample set; significance was taken at p-value <
0.05. A table consisting of all genes examined are listed below (Table 3.1) with a following
table showing genes that showed significant changes in gene expression when compared
to untreated (0x oxidant treatment) control (Table 3.2).
Certain types of genes that were found to be up- or down-regulated were ADAMTS,
growth factors, integrin chains, adhesion molecules (CTNN and selectins), matrix
metalloproteinases (MMP), thrombospondin (THBS), ECM proteins such as collagen
chains, FN, laminin chain, versican, and ECM promoter. ADAMTS13, collagen chains
(5A1, 6A1), CTGF, CTNN (A1, B1, D1), integrin chains (A2, A7, B3, B4), MMP (11, 2),
SELL, SELP, SPG7, THBS (2, 3), TIMP (1, 2), ECM1, FN1, LAMA2 chain, and VCAN
genes were observed to be down-regulated with statistical significance (p < 0.05), when
HCAEC was incubated on HOCl-treated FN (Table 3.2). Certain genes were observed to
be significantly up-regulated under the same condition, such as integrin alpha 4 (ITGα4),
MMP1, and SELE (Table 3.2). The changes to integrin chains α4, β3 are important to
FN as they form the basis for cell binding.
The effects of HOCl on both the structure of plasma FN and the biological effects of
HOCl-modified FN on HCAEC were established, however cellular FN produced in the
subendothelial matrix may interact differently with HOCl. Cellular FN possesses variant
splice sequences on each chain, which are pertinent to matrix assembly and function. The
next experiments were designed to investigate the changes on the structure of cellular FN
exposed to HOCl in a whole ECM mixture harvested from HCAEC.
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Table 3.1: Gene expression investigated for ECM and adhesion molecules.
Genes Description
ADAMTS Type I, Type 13, Type 8 von Willebrand factor-cleaving protease
CD44 CD44 antigen; cell-cell interaction
CDH1 E-cadherin
CLEC3B Tetranectin
CNTN1 Contactin 1
[COL]1A1, 5-8A1, 11-12A1, 14-16A, 4A2, 6A2 Collagen chains
CTGF Connective Tissue Growth factor
[CTNN]A1, B1, D1, D2 Catenin α1, β1, δ1-2
ECM1 Extracellular matrix 1
FN1 Fibronectin
HAS1 Hyaluronan Synthase 1
ICAM1 Intercellular Adhesion Molecule 1
[ITG]A1-8, B1-5, AL, AM, AV Integrin chains
KAL1 Anosmin 1
[LAMA] A1-3, B1, B3, C1 Laminin Chains
[MMP]1-3, 7-16 Matrix Metalloproteinases 1-3, 7-16
NCAM1 Neural cell adhesion molecule 1
PECAM1 Platelet EC cell adhesion
SELE, SELL, SELP E-selectin, L-selectin, P-selectin
SGCE Sarcoglycan 
SPARC Secreted protein acidic and cysteine rich
SPP1 Secreted phosphoprotein 1
TGFB1 Transforming growth factor beta induced
[THBS]1-3 Thrombospondin 1-3
[TIMP]1-2 TIMP metallopeptidase inhibitor 1-2
TNC Tumor Necrosis Factor
VCAM1 Vascular cell adhesion protein 1
VCAN Versican
VTN Vitronectin
ACTB, B2M, GAPDH, HPRT1, RPLP0 House keeping genes
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Table 3.2: Gene expressions of HCAEC incubated on human plasma FN (0.04 µM) pre-treated with
a 1250x molar ratio (50 µM) of HOCl.
Genes Function Fold Regulation P-Value
ADAMTS13 von Willebrand factor-cleaving protease -2.00 0.008
COL12A1 Interaction between collagen I fibrils and matrix -5.09 0.011
COL5A1 Type V collagen pro-α1(V) chain chain -1.30 0.005
COL6A1 Type VI α1(VI) chain -1.86 0.022
CTGF Connective Tissue Growth Factor -1.12 0.009
CTNNA1 Plays a role in cell adhesion -1.24 0.020
CTNNB1 Adherens conunctions protein -1.39 0.018
CTNND1 Armadillo protein for signal transduction adhesion -1.21 0.048
ITGA2 Integrin α2 partial chain receptor to ECM proteins -1.24 0.026
ITGA4 Integrin α4 partial chain receptor for FN 1.69 0.008
ITGA7 Integrin α7 partial chain laminin -3.90 0.046
ITGB3 Integrin β3 partial chain for ECM & cell adhesion -1.81 0.003
ITGB4 Integrin β4 partial chain for laminin -3.10 <0.001
MMP1 Cleaves collagen 1.33 0.021
MMP11 Weakly degrades ECM; control of cell proliferation -1.89 <0.001
MMP2 Degrades ECM and signal transduction molecules -1.35 0.002
SELE CAM important in inflammation 1.91 0.004
SELL CAM between ECs and lymphocytes -5.39 <0.001
SELP CAM on ECs -5.37 <0.001
SPG7 Paraplegin; regulator of cell and proteins -1.17 0.002
THBS2 cell-cell & cell-matrix interactions -1.86 0.023
THBS3 cell-cell & cell-matrix interactions -1.76 0.016
TIMP1 MMP inhibitor -1.58 0.002
TIMP2 MMP & EC proliferation -1.52 0.004
ECM1 ECM formation & angiogenesis -1.88 0.026
FN1 Formation of plasma & cellular FN -1.26 0.007
LAMA2 Laminin α2 chain -1.56 0.045
VCAN Versican protein -1.47 0.021
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3.3.7 Effect of HOCl on cellular-derived fibronectin epitopes
Plasma and cellular FN are both shown to be present in atherosclerotic plaques [18,
148]. Cellular FN possesses spliced variants which gives rise to their specific vessel and
matrix assembly functions such as the detectable EDA and EDB. However, the EDA and
EDB region is proposed to be important in wound healing, thrombosis, and maintaining
vascular wall integrity [286–288]. Whole ECM consists of a mixture of proteins, which
are bound to each other by specific functional epitopes. By using whole ECM extract
in samples, we can examine whether FN is a target when present amongst a mixture of
proteins.
HCAECs were cultured over a week in 96-well plates to establish an ECM into each well.
HCAECs were removed with ammonium hydroxide and washed with PBS. The sample
wells now containing HCAEC-derived ECM was then treated with varying concentration
of HOCl (0, 5, 10, 25, 50, 100, 200 µM) diluted in 0.1 M pH 7.4 phosphate buffer for 2
hr at 37°C. Excess HOCl was washed off with PBS and blocked with 0.1% (w/v) casein
in PBS to prevent non-specific binding, before being incubated with primary antibody
overnight at 4°C. Unbound antibody was then washed off with PBST, and the sample
wells were subsequently incubated with secondary antibody, and developed using ABTS
solution. The absorbance was measured at 405nm.
It was observed that FN CBF epitope was targeted, which resulted in a statistically
significant loss of epitope recognition at 5 µM excess (Figure 3.12A). A greater loss
of epitope recognition was detected in a dose-dependent manner of increasing HOCl
concentrations to FN (Figure 3.12A). The HBF epitope was also detected to be modified
by HOCl, with a statistically significant loss of epitope recognition detected at 5 µM excess
of HOCl (Figure 3.12B). Increasing the concentration of HOCl resulted in a proportionate
loss of antibody recognition to HBF epitope (Figure 3.12B). The loss of recognition to the
CBF and HBF epitope, which are shared between cellular and plasma FN, were found to
be similarly modified by HOCl as observed on plasma FN (Figure 3.1). The EDA epitope
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found on cellular-derived FN was found to significantly lose antibody recognition upon
exposure to 10 µM excess of HOCl (Figure 3.12C). No further loss in epitope recognition
was observed when increasing concentration of HOCl.
Investigating the structural changes on cellular FN followed this experiment as
modifications to the functional epitope would suggest modification to the structural
integrity of the protein.
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Figure 3.12: ELISA of HOCl-modification of whole ECM-derived from HCAEC. HCAEC-derived
whole ECM on 96-well plates were treated with increasing concentrations of HOCl (0, 5, 10, 25, 50, 100,
200 µM). FN epitope was detected by using a mouse monoclonal A) anti-FN CBF antibody (A17;
1:10000), B) anti-FN HBF antibody (A32; 1:1000), C) anti-FN EDA antibody (3E2; 1:1000), and
conjugated with anti-mouse HRP secondary (1:1000). The data are presented as a percentage relative
to control (no oxidant; 0 µM treatment). Error bars are ± SD from three technical replicates obtained
from each of three independent experiments. Statistical analysis was performed using one-way ANOVA
with Tukey’s multiple comparison post hoc tests to determine significance. Statistical significance was
identified as follows: * = p < 0.05, and **** = p < 0.0001.
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3.3.8 Effect of HOCl modification on cellular-derived fibronectin
To investigate changes to the structure of cellular FN by HOCl, Western blotting was
performed and probed for the important CBF, HBF and EDA functional epitopes. Whole
ECM was extracted from HCAEC, and diluted to ”1 µM” (not actual concentration) FN
which was then treated with increasing concentration of HOCl. Samples were run on SDS-
PAGE under reducing conditions, and then was transferred onto a PVDF membrane prior
to Western blotting.
A loss of epitope recognition was detected on the CBF of FN when treated with increasing
concentration of HOCl. There was a notable loss of antibody recognition of the monomer
band (white arrow) beginning at 25x molar ratio excess of HOCl, and greater loss detected
at higher concentrations of HOCl (Figure 3.13A). Formation of aggregates or altered
species (black arrow) were detected at 100 µM and 200 µM excess of HOCl (Figure
3.13A). The changes to HBF were found to be similar with loss of antibody recognition
of the monomer band (white arrow) detected at 50 µM of HOCl, and aggregates (black
arrow) appearing at 100 µM and 200 µM excess of HOCl (Figure 3.13B).
The cellular-derived FN EDA region loss epitope recognition of the monomer band (white
arrow) with increasing molar excess of HOCl. This loss was detected upon exposure to
25x molar ratio or greater of HOCl (Figure 3.13C). When incubated with a 100 µM or
200 µM excess of HOCl, aggregates were detected with smearing of bands noted from
the monomer band (white band) up to 460 kDa (Figure 3.13C). Binding at 190 kDa was
also detected, which loss recognition when treated with higher concentration of HOCl,
and was not detectable at 200 µM excess of HOCl (Figure 3.13C).
Due to the effects of HOCl-induced modifications on both plasma and cellular FN,
investigations into the presence of FN within atherosclerotic lesions were investigated.
IHC analysis was performed to identify the presence and location of FN and HOCl-
generated damage.
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Figure 3.13: Western blot showing structural changes to whole ECM-derived from HCAEC treated
with increasing molar ratio of HOCl. Samples that were separated on SDS-PAGE under reducing
conditions and transferred onto PVDF blots and probed with mouse monoclonal A) anti-FN CBF
antibody (A17; 1:10000), B) anti-FN HBF antibody (A32; 1:2000), C) anti-FN EDA antibody (3E2;
1:2000) and conjugated with anti-mouse HRP secondary (1:2000). Blots were developed with ECL-plus
reagent and data is labelled as follows: black arrow = dimer/higher aggregates, and white arrow =
monomer band.
3.3.9 Presence of native and modified fibronectin in human
atherosclerotic lesions
IHC analysis was performed to elucidate whether FN exists in advanced atherosclerotic
lesions, whilst simultaneously examining the presence of a HOCl-generated epitope. By
identifying and examining where they are situated and whether they are co-localised,
it would further support the finding that FN is targeted by HOCl. FN plays several
keys roles in the healthy functioning of the arterial wall in blood vessels and has been
previously detected in atherosclerotic lesions. Human atherosclerotic lesions (Type II-III),
identified using the Stary’s system of classification, were cryosectioned onto glass slides
at 5 µm. Sections were incubated with either polyclonal anti-FN, or monoclonal anti-FN
CBF antibody with Cy-3 labelled anti-HOCl generated epitope. Sections were mounted
with Movial (Calbiochem-Novabiochem, La Jolla, USA), before analysis using a confocal
laser-scanning microscope in sequential mode (Leica SP2, Leica Lasertechnik GmbH,
Heidelberg, Germany). Data in this section include sample processing and imaging was
obtained in collaboration with Professor Ernst Malle from Institute of Molecular Biology
93
and Biochemistry, Centre of Molecular Medicine, at Medical University of Graz, Austria,
and Professor Astrid Hammer of the Institute of Cell Biology, Histology, and Embryology,
Centre of Molecular Medicine, at Medical University of Graz.
Examination using polyclonal anti-FN antibody provides an overall distribution of FN
located within lesion tissues, whereas FN CBF monoclonal antibody binds specifically
to the CBF of FN assists in identifying specific areas where FN-CBF may be critically
targeted, which may be modulated and damaged during the progression of atheroslcerosis.
Advanced type II-III atherosclerotic lesions were shown to contain high abundance of
FN, which was this found to be localised particularly in the basement membrane of ECs,
with some detected in the deep media layer of the arterial sections (green fluorescence,
Figure 3.14A and 3.14D). Polyclonal anti-FN antibody detected a large distribution of
FN throughout the arterial wall, with greater abundance at the intima layer, and in
certain areas in the medial layer (green fluorescence, Figure 3.14A). In polyclonal anti-FN
antibody lesion samples, Cy-3 labelled 2D10G9 antibody (which binds to HOCl-generated
epitopes) was found to be highly abundant within the intima layer of the arterial wall,
with lower abundance detected throughout the medial layer (red fluorescence, Figure
3.14B). Merging of polyclonal anti-FN antibody and HOCl-generated epitope showed co-
localisation of these two species localised at the intimal layer, but was also present within
the medial layer (yellow fluorescence, Figure 3.14C).
Detection of FN using anti-FN monoclonal antibody showed a high abundance of FN in
the intima, with some presence in the medial layer (green fluorescence, Figure 3.14C),
but at lower intensity of fluorescence compared to polyclonal anti-FN antibody samples
(green fluorescence, Figure 3.14A). HOCl-generated epitope was detected throughout the
whole lesion sample with higher abundance on the intimal layer, and with lighter presence
also detected through the medial layer similar to the polyclonal anti-FN antibody sample
(red fluorescence, Figure 3.14A and 3.14E). Merging monoclonal anti-FN and HOCl-
generated epitope showed co-localisation of these two epitopes with localised distribution
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within the intima, with some distinct areas of co-localisation in the medial layer (yellow
fluorescence, Figure 3.14F). Co-localisation in the medial layer was much less intense in
fluorescence signal in comparison to the samples which were incubated with polyclonal
anti-FN antibody (yellow fluorescence, Figure 3.14C).
Figure 3.14: IHC of advanced human atherosclerotic plaque showing localisation of FN and HOCl-
generated epitope. Advanced human atherosclerosis lesions sections were incubated with either A)
polyclonal anti-FN or D) monoclonal anti-CBF of FN (green), while a HOCl-generated epitope was
detected with B, E) 2D10G9 antibody (red). Images were merged to identify areas of C, F) colocalisation
(yellow).
Furthermore, protein extracted from human atherosclerotic lesions were investigated
by separation on SDS-PAGE under reducing conditions and transferred on PVDF
membranes by Western blotting. Membranes were probed for using anti-FN EDA and
anti-FN EDB antibodies to look for epitopes specific to cellular FN. Both epitopes were
found to be present with FN bands detected at around 460 kDa and around 230-240
kDa (Figure 3.15) similar to what has been found previously with HCAEC-derived ECM
(Figure 3.13). Moreover, fragments of FN were found to be present at lower molecular
mass with greater intensity particularly at 140 kDa (Figure 3.15).
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Figure 3.15: Western blots of advanced human atherosclerotic lesions from two donors. Advanced
human atherosclerosis lesions from two different donors were electrophoresed on SDS-PAGE under
reducing conditions and transferred onto PVDF membranes. Membranes were probed for A, C) anti-FN
EDA antibody (3E2; 1:2000) or B, D) anti-FN EDB antibody (C6; 1:2000) found on cellular FN, which
were conjugated with anti-mouse HRP secondary (1:2000). Blots were developed with ECL-plus reagent
and data is labelled as follows: black arrow = dimer/higher aggregates, and white arrow = monomer
band.
These results evidentially support the presence of FN and HOCl-generated epitope in
advanced human atherosclerotic lesions and that they are a likely target for modifications
by HOCl.
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3.4 Discussion
FN plays a pivotal role as an ECM protein in maintaining the integrity of the basement
membrane to provide a stable environment for cells, such as arterial ECs. FN possesses
a variety of functional sites, equivalent to those of other ECM proteins, such as the
collagen and heparin binding epitopes. More importantly, FN contains a CBF, which
contains a well known RGD cell binding site via α5β1 and αBβ3 integrin [196]. Changes
to ECM proteins can lead to a disruption in cellular activity and cause downstream
negative effects. HOCl is a known oxidant to be produced during inflammation, and
high concentrations in a localised area has been known to cause damage to host cells
and proteins. The proximity of FN in the arterial wall to areas of plaque formation
make it important for investigating the changes that can occur during the progression
of atherosclerosis. In the studies reported here, it was found that plasma and cellular-
derived FN were both targeted and modified by HOCl leading to structural changes and
loss of antibody recognition to biologically critical epitopes. These modifications were
also found to cause biological effects leading to loss of cell adhesion and metabolic activity,
and causing changes to gene expression of HCAEC.
The structure of FN was shown to be susceptible to oxidation and modification by HOCl.
These modifications result in the fragmentation and formation of larger aggregates on
FN, causing subsequent changes to functional epitopes. It was observed that structural
changes to FN occur at as low as 5x molar ratio as observed on silver staining (Figure
3.2), whereby both aggregation and fragmentation were observed with increasing molar
ratio of HOCl. Protein aggregation (or an altered species) (black arrow) were formed
and observed under non-reducing SDS-PAGE (Figure 3.2A), which are likely formed by
the oxidation of sulfhydryl groups, producing di-sulfide crosslinks or shuﬄing of existing
disulfide bonds leading to formation of tetramers. It may also be possible that changes to
protein charge due to oxidation may also lead to altered electrophoresis through the gels.
HOCl had been shown previously to target these reactive sulfhydryl groups, oxidising
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them to sulfenic acids (R-SOH), which readily react with other free sulfhydryl group to
form disulfide crosslinks causing protein aggregation [49, 289, 290]. When samples were
processed under reducing conditions (Figure 3.2B), a majority of these dimers/higher
aggregates were reduced, supporting the fact that those examined under non-reducing
conditions were formed by disulfide crosslinks. Although some crosslinks were reduced to
their disulfide forms to recover the native monomer, some dimers/higher aggregates were
still present, which could be formed by other stronger intermolecular covalent bonds, such
as di-Tyr and di-Trp [53, 54]. These non-reducible aggregates are likely produced by the
formation of di-Tyr crosslinks, a secondary species resulting from the dimerisation of two
Tyr phenoxyl radicals [64, 291]. These protein aggregation have been observed previously
with FN treated with HOCl [260], which coincided with the formation of di-Tyr [64]. Thiol
oxidation and consequential formation di-Tyr formation has been found to be associated
with inflammatory oxidation, and are co-localised in atherosclerotic plaques [130, 292,
293], along with the increasing presence of chlorinated Tyr residues (3-chloroTyr), di-
Tyr, o-Tyr, and DOPA [64]. Aggregation of FN can lead to certain functional epitopes
becoming buried and undetectable due to the nature of protein folding, and fragmentation
of FN, particularly within functional sequences, which can lead to a decreased or total
loss of recognition by cells or other ECM proteins.
Reducing samples were shown to present with decreased protein fragment intensity. The
reduction of samples were previously performed as to reduce the occurrence of re-oxidation
by alkylating the proteins [294]. Furthermore, the decreased in fragment intensity could
be explained by the alteration of Cys/Cystine residues in samples by the reducing agent,
such as DTT [295]. This alteration would change the way FN electrophoreses through the
gel leading to a decrease in the fragment bands observed under non-reducing conditions.
This would be the case for the silver stains and the Western blots in each of the following
chapters.
FN possesses 27 Met and 63 Cys residues, with only 3 of of the Cys residues not present
in the form of disulfides [296]. These amino acids are known to be targeted by HOCl, and
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have been found to be highly reactive and readily oxidised by this oxidant [50, 51]. FN
possesses only 2 free thiols (Cys residues), which have been found to be buried within the
protein [297]. Due to this knowledge, it was thought that HOCl would not be targeting
these free Cys residues prior to the other more readily available amino acids. Met on FN
were found to be oxidised by HOCl with increasing loss detected by amino acid analysis
with increasing HOCl treatment concentration (Figure 3.5A). MetSO is readily formed
by Met oxidation [50], which was shown to be present in non-treated samples of FN, and
increased a small amount with increasing molar ratios of HOCl (Figure 3.5B). MetSO is
a common oxidation product associated with inflammatory processes and is believed to
contribute to biological aging [298, 299]. Available Met on protein have been proposed
to be targeted by oxidants as an antioxidative mechanism to prevent modifications on
other species [300, 301]; although the slow reduction rate of MetSO to the native Met
may make it an ineffective antioxidant [302]. It was previously shown that the addition
of Met to samples treated with HOCl correlated with an inhibition of crosslinks [260].
The data obtained in the current study showed a decrease in MetSO concentration at the
highest molar ratio of HOCl (Figure 3.5B), which can be explained by further oxidation
of MetSO to the corresponding sulfone MetSO2 which was not analysed/quantified here.
MetSO formation has been suggested to precede the formation of carbonyls [303]; protein
carbonyls are common biomarkers for oxidative stress. In vivo, the body contains a family
of MetSO reductase enzymes which helps in reducing the MetSO formed; these reductase
enzymes have been reported to be at low levels in certain pathologies and thus enable
the accumulation of MetSO [304]. In certain cases, instead of the two-electron oxidation
which produces MetSO, a one-electron oxidation is also a possible mechanism that leads
to the formation of methionine radial cations [304]. Each species is produced by different
mechanisms and each induces specific secondary effects. The formation of MetSO at
certain active sites on protein can lead to an inactivation and a loss of functional binding
epitope; an example of enzyme inactivation due to MetSO formation is α1-proteinase
[305].
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Other amino acids that are also susceptible to HOCl are Tyr residues leading to formation
of chlorinated Tyr, and free amine groups or lysine residues leading to formation of
chloramines and secondary products [64, 65, 306]. Tyrosyl residues readily react with
HOCl forming 3-chloroTyr, and 3,5-chloroTyr, which are long-lived products and common
biomarkers of HOCl modification [48, 59]. These have been shown to be present in
atherosclerotic lesions, though only in small quantities but significantly elevated over
control samples [64]. Chloramine formation is also highly likely in these experiments, and
further modifications may be induced by chloramines over longer periods of incubation.
A common mechanism of chlorinated Tyr formation is the transfer of chlorine from
chloramines to Tyr residues [49], which have been shown to cause further reactions on
the parent, and the decay of chloramines has been correlated with increased levels of
carbonyls [49, 59].
Protein carbonyls are a non-specific biomarker associated with protein oxidation and
oxidative stress. Previous experiments with bovine FN treated with HOCl in the same
manner, have shown that carbonyl formation occurs readily with this oxidant as detected
with a protein carbonyl Western blotting technique (Siriluck Vanichkitrungruang,
Honours thesis, 2013). The overall increased levels of carbonyl content in HOCl-treated
ECM correlated with an increased occurrence of aggregation and fragmentation [260].
These results are consistent with previous studies which examined hypochlorite treatment
of P388D1 cells, which showed increased levels of carbonyls and a corresponding drop in
cell viability, thiol levels, and protein Met and Trp residues [46]. Amino acid analysis of
Tyr residues in bovine FN were found to be unchanged upon exposure to increasing molar
ratios of HOCl (Figure 3.5D); suggested that this detection method was not sensitive
enough to pick up small changes. Further experiments need to be performed to investigate
the formation of chlorinated Tyr in samples as possible by-products of FN oxidation by
HOCl.
Chloramines have been found to have a varible stability with this dependent on time and
temperature as shown in in vitro experiments [260, 307]. Chloramine decomposition
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has been shown to induce chlorination of Tyr [308, 309], and these species are also
known to be a major driver for protein fragmentation [310]. Chloramine decomposition
produces nitrogen-centred radicals, which along with hydrolytic reactions have been found
to lead to fragmentation of proteins [307, 311]. The actions of chloramines have been
previously observed by detection with EPR and SDS-PAGE, to cause fragmentation of
plasma proteins [307]. Furthermore, this was observed on ECM proteins using radio-
labelled amino acids [65]. In vivo, chloramines are susceptible to reduction by biologically
occurring reductants, particularly Met, ascorbate, and thiols such as glutathione [310].
Formation of chloramines may be reduced by Met residues on FN, supporting the loss
of Met in HOCl-treated plasma FN samples (Figure 3.5A). Elevated levels of chlorinated
Tyr, in particular 3-chloroTyr have been found to be present in LDL isolated from human
atherosclerotic lesions [312, 313]. Furthermore, modified Tyr residues were found in
atherosclerotic ECM samples derived from human atherosclerotic plaques, which was
not the case in healthy human and pig aorta [64], as well as in other inflammatory
diseases [314, 315]. High concentrations of 3-chloroTyr can be subsequently converted
to 3,5-chloroTyr, which has also been found to be a biomarker for atherosclerosis [48,
59]. Lastly, Trp residues which were found to be targeted by HOCl (Figure 3.5C), have
previously been found to be modified in FN during treatment with HOCl [260]. Trp have
also been found to form crosslinks as a by-product of oxidation, but there are limited
studies on the nature of such crosslinks and the relevance of specific species - this area is
worthy of further investigation [316]. The mechanism of fragmentation and amino acid
modifications on FN should be further investigated, along with elucidating the location
of these modifications. This would assist in defining areas of susceptibility and what
functional epitopes are targeted that lead to a loss of functionality with other ECM
proteins or cells.
FN possesses 100 Tyr and 39 Trp residues (Uniprot data; P02751); 56 of these Tyr
residues and all of the Trp residues are located in functional sites [130]. The CBF, which
contains the RGD site, is situated in the region 1267-1540 of the amino acid sequence and
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possesses 1 Met, 3 Trp, and 10 Tyr. The HBF II is situated between residues 1721-1991
of the amino acid sequence and possesses 3 Met, 3 Trp, and 11 Tyr residues (Uniprot
data; P02751). Two neighbouring Cys residues are positioned on 1232 and 2136, which
present as disulfide bonds (Uniport data; P02751). Based on the amino acid analysis of
FN, it was found that Met and Trp parent amino acids were modified by treatment with
HOCl (Figure 3.5). This suggests that the modifications on these residues may impact
on the integrity of these functional sites, and subsequently cause a loss of the antibody
recognition and changes to biological activity of HCAEC on HOCl-modified FN.
It was found that FN CBF was susceptible to modifications by HOCl, leading to loss of
epitope recognition (Figure 3.1A and 3.3) and loss in cell adhesion (Figure 3.8). These
results corresponded with previous findings that showed that the CBF and collagen
binding fragments were susceptible to modifications upon exposure of the sub-endothelial
matrix to HOCl [261]. Furthermore, it was shown that ECs derived from umbilical cord
vein were lower in number as viewed under contrast microscopy, and cell spreading was
impaired as noted by the rounding of cells, which indicated that these cells adhered less
well on matrix that was exposed to HOCl [261]. This was similarly observed in HCAECs
incubated on HOCl-modified FN (Figure 3.10).
The collagen-binding domain was also found to be modified by HOCl, which led to a
decrease in epitope recognition, albeit to a lesser extent compared to the CBF [261].
The HBF II that is recognised by the antibody used (clone A32) is positioned in the
third domain of FN; HBF interacts with heparin/heparan sulfate, and it has been found
that modifications to amino acids within this domain led to decreased heparin binding
to FN [317]. This supports the current data where it was found with that the HBF was
modified by HOCl which led to loss of epitope recognition (Figure 3.1B). Matrix assembly
is highly dependent on the interactions between ECM proteins; the loss of integrity of
this complex mixture can affect the production of ECM by cells, and lead to an unstable
plaque formation during the progression of atherosclerosis.
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These structural modifications causing aggregation and fragmentation have been
demonstrated to also cause HCAEC to behave differently. HCAEC incubated on FN
exposed to HOCl were shown to have decreased binding capacity to FN and an inability
to spread their F-actin to adjacent cells (Figure 3.10). This inability for cells to adhere
onto oxidatively modified FN is consistent with previous studies [22, 130, 261], which
supports the notion that changes to FN structure leads to decreased cell adhesion. It has
also been previously shown that low concentrations of HOCl can cause small changes
to protein folding leading to an increase affinity to certain antibodies, while higher
concentrations of HOCl caused a decrease in recognition [271]. Furthermore, knock-out
of the EDA exon of FN has been implicated in a reduction of atherosclerotic lesion size
in apoE-/- mice [272, 273]. EDA in conjunction with the Toll-Like Receptor 4 (TLR-4),
which is a signalling molecule for an inflammatory cytokine pathway, have been shown to
promote dose-dependent NFκB-mediated inflammation [318]. Therefore, these modified
FN in lesion sites may not only cause biological function changes, but also activate
an inflammatory response [225]. It has been observed previously that degraded FN
promotes leukocyte migration and chemotaxis to the injury site [266, 267], and increases
neutrophil degranulation [268]. Additionally, the inflammatory response was observed to
be lower when FN assembly was inhibited [147, 269], supporting the importance of FN
in mediating inflammation-induced leukocyte recruitment. This may suggest that FN is
modified by HOCl-mediated damage, causing vascular remodelling, cellular dysfunction
and promotion of leukocyte recruitment to the injury site. This positive feedback loop
may lead to further damage, and subsequently a detrimental cycle in the development of
atherosclerotic plaque.
HCAECs incubated on HOCl-modified FN were found to cause changes to HCAEC
gene expressions (Table 3.2). The genes examined were specific for ECM and adhesion
molecules, some of which are expressed exclusively by EC, while others are also expressed
by other cells, such as leukocytes. A complex and balanced homeostatic relationship is
required between MMP, ADAMTs, and TIMPs in normal turnover of basement membrane
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ECM. It was found that MMP-2, MMP-11, and MMP-14 had decreased gene expression
when HCAEC were incubated on HOCl-modified FN (Table 3.2). MMP-2 is normally
expressed during vascular formation and remodelling, and has been found to promote the
formation of atherosclerotic lesions, with MMP-2 deficient apoE-/- mice found to have
reduced atherogenesis [319]. Furthermore, up-regulation of MMP-2 has been associated
with aortic atherosclerotic lesion development [320], accompanied by a thin fibrous cap
which increases risk of plaque rupture and intra-plaque haemorrhage [321]. Down-
regulation of MMP-2 gene expression in HCAEC exposed to HOCl-modified FN could
suggest that in an acute injury, there are attempts at preservation of remaining intact
ECM and vasculature (Table 3.2).
Both MMP-11 and MMP-14 have been found to be elevated in atherosclerotic plaque;
particularly in areas with increased risk of rupture [322, 323]. MMP-11 weakly degrades
matrix protein, and preferentially targets serum proteinase inhibitors [324] and signal
transduction molecules [325]. The degradation of serum proteinase inhibitors have been
correlated with increased neointima formation, and fibrotic scarring on blood vessels
[324]. Furthermore, MMP-11-/- mice models showed extensive degradation of the internal
elastic lamina accompanied by abundant levels of intimal cells [324]. In addition, MMP-14
cDNA, expressed from adenovirus vector, is linked to focal adhesion kinase degradation,
and was examined to cause rounding of cells along with decreased cell adhesion of Baboon
aortic VSMC, which was not dependent on integrin levels [326]. In contradiction, there
have been mixed findings where previously MMP-14 expression has been suggested to
increase thickness of fibrous cap to promote plaque stability by its promotion of VSMC
migration and proliferation into the area [327].
It has been found that MMP-2 expression is due to presence of membrane type MMP
(such as MMP-14); the activation of MMP-2 is correlated to an up-regulation of MMP-14
[328, 329]. Down-regulation of MMP-14 could suggest the subsequent down-reglation of
MMP-2 in HCAECs incubated on HOCl-modified FN (Table 3.2. It was shown that FN-
derived synthetic peptides up-regulate the expression of MMP-9, MMP-2, and MMP-14 in
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human T lymphocyte cell lines [330]. This suggest that response of HCAECs incubated
on HOCl-modified FN are down-regulating MMP-2 and MMP-14 (Table 3.2). Down
regulation of MMP-14 was found to occur in HCAEC when they were incubated on
HOCl-modified FN, suggesting that loss of FN integrity was unable to upregulate MMP-
14 expression and subsequently activate MMP-2 (Table 3.2). In previous studies, it has
been shown that HOCl activates pro-MMP-7 due to oxidation of Cys residues [331]. In
atherosclerotic plaques, there was an up-regulated expression of MMP-7, MMP-13, and
MMP-3 genes [332]. These gene expressions were not observed to be upregulated in
HCAEC incubated on HOCl-modified FN, which is likely because the activators for these
genes are different or different cells are producing these MMPs in lesions.
TIMPs are inhibitors for MMP, and hence inhibit remodelling of the vasculature; each
TIMP possesses specificity for their respective MMP with possible weaker activity on
others. TIMP-1 effectively inhibits MMP-7, MMP-9, and MMP-14 and MMP-3, whereas
TIMP-2 is more effective at inhibiting and cleaving membrane type MMP-2 [333, 334].
Elevated expression of MMPs are observed in atherosclerotic plaques with corresponding
elevation of both TIMP-1 and TIMP-2 expressions, which is required to compensate for
the increased activity of MMPs [335]. Low to moderate levels of TIMP-2 are important
for the activation of MMP-2 [336], with TIMP-2-/- mice showing heavily impaired MMP-2
activation [336]. HOCl-modified FN was shown to cause a down-regulation of TIMP-2 in
HCAEC (Table 3.2); decreases in TIMP-2 have been observed in atherosclerotic lesions
when compared to healthy samples [337]. The presence of TIMP-2 has also been observed
to inhibit VSMC migration and proliferation [338]. Furthermore, over-expression of
TIMP-2 resulted in decreased migration of macrophages into the area, and reduced
atherosclerotic plaque size [339]. TIMP-1 has been observed to either be unchanged
[337], or elevated in atherosclerotic plaques [340]. TIMP-1-/- mice were observed to have
increased matrix accumulation in the neointimal area compared to mice that expressed
TIMP-1 [341]. TIMP-1 and TIMP-2 gene expression were both observed to be down-
regulated when HCAEC was incubated on HOCl-modified FN (Table 3.2), which is likely
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a response to the down-regulation of MMPs.
ADAMTS13 are primarily produced in the liver but vascular EC are found to have small
quantities of the mRNA for this enzyme which regulates thrombosis, angiogenesis, and
down regulates inflammation [342]. Past studies have identified von Willebrand factor
(vWF) as the only known substrate for ADAMTS13, which functions in both thrombosis
and inflammation [343–345]. It has been previously shown that ADAMTS13-/- and
vWF+/+ mice resulted in increased leukocyte rolling on unstimulated mesenteric veins
[346]. Furthermore, these knockout mice were also found to have increased leukocyte
adhesion with additional knockout of vWF showing markedly less changes compared to
WT [346]. A later study supported these findings and further showed that mice with both
apoE-/- and ADAMTS13-/- were more prone to developing early atherosclerotic lesions in
the aorta [347]. Moreover, lesions from apoE-/-/ADAMTS13-/- knockout mice were found
to have increased macrophage numbers, and were also found to have a lower content
of collagen [347]. Low levels of ADAMTS13 have been associated with increased risk
of CVD, particularly with increased risk of myocardial infarction in younger patients
that presented with high levels of vWF levels [348, 349]. Although the risk of CVD are
dependent on both ADAMTS13 and vWF levels in individuals, it has also been reported
that there is no direct correlation between ADAMTS13 and vWF levels [349]. The down-
regulation of ADAMTS13 expression in HCAEC incubated on HOCl-modified FN may
suggest an inflammatory response by HCAEC to increase recruitment of both leukocyte
and macrophages to the area of injury.
Cell surface integrins are important in cellular interactions with the surrounding ECM,
and thus modifications to ECM proteins can lead to consequential effects on cell activity.
A wide variety of cells express integrins and within the qPCR array performed, some
were either not expressed by EC or were not identified to adhere to FN [350] and hence
will not be discussed here. The RGD sequence in the CBF of FN is the site of cell
adhesion via integrins α5β1 and αVβ3; the variable region on FN also possesses a site for
binding to α4β1 integrin presented by cells [149, 196, 351, 352]. The down-regulation of
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ITGB3 is likely a response to HOCl-modified FN presenting without an adhesion ligand
for β3 integrin to bind to (Table 3.2). The αVβ3 region plays a role in cell survival,
proliferation and migration [353]. In the early stages of atherosclerosis, elevated levels
of αVβ3 adhesion molecules were found, and might be a response by the EC attempting
to promote cell proliferation and migration [350, 354]. The αVβ3 integrin is found to be
present in arteries, regardless of the presence of an atherosclerotic plaque, colocalised to
both ECs and SMCs within tissues [355]. The α4 integrin chain is expressed on EC for FN,
for initiation of ECM remodelling [356], and is a mechanism for recruiting macrophages
to atherosclerotic plaques [357]. There were no statistically significant changes to αV, α5,
and β1 expression from HCAEC incubated on HOCl-modified FN (Table 3.2). Down-
regulation of β3 was likely a response to the modified CBF on FN, as cells detected loss
of the ligand, thus in response up-regulated α4 attempting to increase HCAEC binding
capabilities to the variable region on FN, and recruit more macrophages to the site of
injury.
Selectins are part of a family of cell adhesion molecules (CAM), and are located as
transmembrane single chain glycoproteins. E-selectin and P-selectin are expressed by
ECs, whereas L-selectin is solely expressed by leukocytes and will not be discussed here
[350]. E-selectin on inactive resting EC is expressed at very low levels, with an up-
regulation occurring in response to inflammatory cytokines/stimuli [358, 359]. It has
been shown that up-regulation of E-selectin occurs in EC from atherosclerotic intima,
but not in non-atherosclerotic control samples [360]. Furthermore, it was also found that
the expression of E-selectin in individuals was exclusively on ECs, and expressed along
with ICAM-1 and VCAM-1 in the neovasculature of atherosclerotic plaques [360]. As
inflammation occurs, inflammatory cytokines IL-1 and TNF-α are released and have been
shown to up-regulate E-selectin expression [361, 362]. The up-regulation of the SELE
gene by HCAEC incubated on HOCl-modified FN is likely an inflammatory response to
promote the migration of leukocytes to the area of injury.
P-selectins (SELP) are expressed on ECs but predominantly on platelets, and plays an
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important role in leukocyte adhesion and recruitment in apoE-/- mice; this functions
to promote inflammation and consequentially atherosclerosis [363]. In the presence of
P-selectin in apoE-/- mice, plaques were found to be bigger with more calcification
and fibrosis [363]. Elevated levels of P-selectin were also found to be correlated with
coronary heart disease risk factors [364], and are found to be associated with thickening
of the intima-media layer, supporting its role in preclinical atherosclerosis [365]. The
expression of P-selectin is associated with an acute inflammatory response, as they are
stored internally in ECs and are able to be released immediately [358, 364, 366]. Down-
regulation of the SELP gene in HCAEC incubated on HOCl-modified FN may be due
to a chronic response to recruit leukocytes to the area by up-regulating SELE instead.
Furthermore, due to the action of P-selectin in recruiting platelets to sites of injury, the
down-regulation of SELP may be a response to decrease platelet binding thus preventing
clotting at the site of injury.
This was a preliminary study looking at gene expression, and further investigations clearly
need to be undertaken to further elucidate these changes, particularly in correlation with
protein expression and whether this reflects their respective gene expression. The changes
of gene expression in HCAEC as a result of acute or chronic injury might be a mechanism
that prevents instability of the ECM of which cells are bound to.
The importance of FN in maintaining vascular integrity is believed to be due to its
interactions with other ECM proteins, and cells, such as ECs, to provide a strong
and tensile ECM. The modifications and degradation of FN can lead to a reduction
in ECM integrity, negatively impacting cellular activity, preventing proper cell adhesion
or proliferation. The loss in healthy cell function and an intact ECM can increase the
likelihood of a thinner and more unstable fibrous cap. These unstable caps are more
susceptible to rupture, consequentially causing thrombosis in the affected area, which
can lead to myocardial infarction or stroke in individuals. These experiments have shown
that FN is susceptible to HOCl modifications, but there are other oxidants known to be
formed by the MPO system, such as HOSCN. HOSCN is highly specific and their effects
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on FN will be explored in the next chapter.
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Chapter 4
Modifications to fibronectin by HOSCN
4.1 Introduction
FN is an ECM protein that exists in the basement membrane of arterial EC. In
combination with other proteins, FN provides a healthy environment and network for cells
[149, 195, 196]. It is important for vascular remodelling during inflammation amongst
other important functions as discussed in Section 1.4.3 and Section 3.1.
Leukocyte migration into the arterial wall occurs as part of an inflammatory response to
the deposition of LDL [5]. MPO is released from leukocytes, which are known to generate
HOCl from H2O2 and physiological concentrations of Cl- [50, 51, 57]. However, it is known
that MPO has a higher specificity for SCN- when compared to Cl- (by almost 730 fold),
and elevated levels of this pseudohalide is found to produce elevated concentrations of
HOSCN [94, 99, 110, 367]. MPO compound I has a rate constant for SCN- of 9.6 ± 0.5 x
106 M-1, with a lower rate constant for Cl-, which is 2.5 ± 0.3 x 104 M-1 s-1 [27]. Elevated
plasma levels of SCN- (80-400 µM [96–99]) have been found to occur in smokers, where
CN- is detoxified to SCN- [98], as a result of ingestion of certain plants, fruits, and nuts
[368], and exposure to drugs such as nitroprusside [369].
HOCl is less specific and has been seen to react widely with several oxidisable groups
[49, 50]. However, HOSCN has previously been shown to specifically target thiols and
cysteine residues leading to reversible products such as RS-SCN adducts, sulfenic acids,
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and disulfides [106, 370]. These products can be reversed via GSH or by enzymes such as
glutaredoxin or thioredoxin reductase [106, 370]. Further oxidation of reversible products
can generate irreversible products such as cysteic acid [106]. The presence of HOSCN
is dependent on MPO and SCN- concentrations, and has been reported to have either a
detrimental or a protective effect [99, 106, 367, 371].
FN has been shown previously to be modified by HOCl (see Chapter 3 and references
therein) leading to structural changes and causing biological dysfunction, however there is
very limited information of the effects of HOSCN on ECM proteins with most studies on
this oxidant having investigated the cellular effects of this species. In light of the current
studies available about HOSCN, it was hypothesised that human plasma and cellular FN
might be targeted and modified by HOSCN but to a lesser extent in comparison to HOCl.
4.2 Aim
The experiments performed in this chapter aimed to elucidate the effects HOSCN has on
human plasma FN and cellular-derived FN in whole ECM extracts. Protein structural
changes and antibody recognition to specific functional epitopes were examined using
SDS-PAGE, Western blotting and ELISA assays. To determine thiol oxidation on FN by
HOSCN, ThioGlo assay was utilised against a GSH standard. Lastly, investigations were
carried out on the biological effects that HOSCN-treated FN has on HCAEC by utilising
cell adhesion and cell metabolic activity assays, and real time qPCR to determine changes
in gene expression.
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4.3 Results
4.3.1 Potential effects of HOSCN on human plasma fibronectin
epitopes
The concentration of SCN- in plasma is generally lower than Cl- but elevated levels
of plasma SCN- have been detected in smokers [99]. By identifying the changes made
by HOSCN on FN, we can elucidate how extensive these modifications are and detect
changes that may occur in these individuals that have elevated SCN- (80-400 µM) levels.
Preparation and treatment of FN using HOSCN followed the method used in Section
3.3.1. HOSCN was prepared by incubation of LPO in the presence of SCN- and H2O2,
prior to being diluted in 0.1 M pH 7.4 phosphate buffer and added to FN samples.
Human plasma FN (0.02 µM) was treated with HOSCN (0, 5, 10, 25, 50, 100, 200
µM) (Table 2.4), and changes to the CBF epitope were measured using ELISA. Human
plasma FN treated with HOSCN showed only minor changes to the recognition of the CBF
epitope with increasing HOSCN concentration (Figure 4.1). Treatment with HOSCN led
to a small loss of CBF epitope recognition with no marked loss with increasing molar
excess (Figure 4.1A). However, a statistically significant loss of epitope recognition was
detected at 2500x and 10000x molar excess (Figure 4.1A).
As these data suggests, there are some modifications caused by HOSCN to the FN CBF,
further investigations were conducted to examine the structural integrity of FN when
treated with HOSCN.
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Figure 4.1: ELISA of human plasma FN treated with increasing concentrations of HOSCN. Each well
was coated with 0.5 µg FN (0.02 µM) in 0.1 M phosphate buffer and either left untreated (control; 0x
oxidant treatment) or treated with HOSCN (0, 5, 10, 25, 50, 100, 200 µM), and incubated for 2 hr at
37°C. FN epitope was detected by using a mouse monoclonal anti-FN CBF antibody (A17; 1:10000), and
conjugated with anti-mouse HRP secondary (1:1000). The data are presented as a percentage relative to
control (no oxidant; 0x oxidant treatment). Error bars are ± SD from three technical replicates obtained
from each of three independent experiments. Statistical analysis was performed using one-way ANOVA
with Tukey’s multiple comparison post hoc tests to determine significance. Statistical significance is
identified as follows: * = p < 0.05.
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4.3.2 Effect of HOSCN on the structure of human plasma fibronectin
FN possesses two disulfide bonds at the carboxyl termini with 2-3 free thiols present on
the protein (Uniprot data; P02751) [296]. Due to the specificity of HOSCN for thiol
residues, it was therefore of interest to investigate whether this oxidant modifies FN
protein structure by using SDS-PAGE. Purified human plasma FN was left untreated (0x
oxidant control) or treated with increasing concentrations (0, 5, 10, 25, 50, 100, 200 µM)
of HOSCN. A lower molar ratio was used to examine the minor structural changes induced
by HOSCN on FN. Samples were then separated by SDS-PAGE under non-reducing or
reducing conditions with added high molecular mass marker, and then silver staining
was performed. Experiments were carried out as described in Section 3.3.2, to examine
potential changes such as aggregation or fragmentation.
Silver staining of human plasma FN samples exposed to HOSCN separated under non-
reducing conditions showed fragmentation of the protein with increasing molar excess
of HOSCN (Figure 4.2A). These fragments can be seen just below the dimer/higher
aggregate band (black arrow), and with the darker silver staining intensity just above
and below the monomer band (white arrow) (Figure 4.2A). Aggregation or formation of
an altered species are particularly evident at higher concentrations of HOSCN just above
the dimer band (black arrow), and evident by the smearing of the samples (Figure 4.2A).
Samples electrophoresed under reducing conditions did not show these fragments or higher
aggregates (or altered species) to such a notable extent (Figure 4.2B). No changes were
detected in the monomer band (white arrow), but there was a slight increase in the dimer
parent band (black arrow) with this being dependent on the molar ratio of HOSCN to
FN (Figure 4.2B).
To further investigate possible damage to FN, Western blotting was performed to detect
structural changes to the CBF epitope (clone A17). Treated samples were separated on
SDS-PAGE and transferred to PVDF membranes using an iBlot2 machine following the
method outlined in Section 3.3.2. Under non-reducing conditions, treatment of FN with
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Figure 4.2: SDS-PAGE with silver staining shows structural changes to human plasma FN treated
with increasing molar ratios of HOSCN. Purified human pFN (in 0.1 M pH 7.4 phosphate buffer) was
either left untreated (control) or treated with increasing concentrations of HOSCN (0, 5, 10, 25, 50, 100,
200 µM), and incubated for 2 hr at 37°C. Samples were separated using 3-8% Tris-acetate SDS-PAGE
gels under A) non-reducing or B) reducing conditions. Gels were then fixed, and visualised with silver
stain and referenced against HiMark™ pre-stained High Molecular Mass standard. Data are labelled as
follows: black arrow = dimer/higher aggregates, and white arrow = monomer band.
115
increasing molar excesses of HOSCN resulted in a small loss of epitope recognition of the
monomer band (white arrow) (Figure 4.3A). HOSCN treated FN also showed increasing
evidence of fragmentation, as observed both above and below the monomer bands (white
arrow) (Figure 4.3A). Samples electrophoresed under reducing conditions showed that the
monomer parent band (white arrow) decreased in intensity with increasing molar excesses
of HOSCN compared to control (0x oxidant treatment). Furthermore, there seems to be
a very slight decrease in the intensity level of dimer bands (black arrow) with increasing
concentrations of HOSCN (Figure 4.3B).
Figure 4.3: SDS-PAGE followed by Western blotting shows structural changes to human plasma FN
treated with increasing molar ratios of HOSCN. Samples that were separated on SDS-PAGE under A)
non-reducing or B) reducing conditions and transferred onto PVDF blots and probed with a mouse
monoclonal anti-FN CBF antibody (A17; 1:10000), and conjugated with anti-mouse HRP secondary
(1:2000). Blots were developed with ECL-plus reagent and data is labelled as follows: black arrow =
dimer/higher aggregates, and white arrow = monomer band.
In light of the data found and knowledge known about HOSCN, changes to thiol residues
were next investigated to determine whether these are targeted by HOSCN.
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4.3.3 Thiol assay analysis of HOSCN treated bovine plasma
fibronectin
FN possesses a low number of free thiol groups with 2-3 free thiols on the protein, which
may be targeted by HOSCN during oxidation [296]. Modifications to free thiols can lead
to protein structural changes (possibly via formation of intra-protein disulfide bonds) and
affect biological function. By examining whether free thiols are targeted by HOSCN, a
picture can be formed about HOSCN and its interaction with FN. Bovine plasma FN was
used for these experiments as it was easier to obtain the amounts required, however the
structure of human and bovine FN are closely related (90% sequence similarity; Uniprot
data). Bovine plasma FN (5 µM) bound on 96-well plates in 0.1 M pH 7.4 phosphate
buffer was exposed to increasing concentrations of HOSCN for 2 hr at 37°C. ThiolGlo
solution was prepared as a working solution following manufacturers instructions, and
transferred in a 1:1 ratio to samples and GSH standard. Samples were incubated for
10 min at 21°C on a shaker in the dark. Fluorescence was measured at 384nmex and
513nmem.
Non-treated (control) samples were found to have approximately 80 nM of detectable
thiol concentration. With FN samples exposed to 1x molar of HOSCN, thiol levels were
found to have decreased to 50% of control samples (Figure 4.4). Increasing the HOSCN
concentration to a 50x molar ratio relative to FN, it was observed the thiol concentration
was eventually zero with a statistically-significant loss compared to the control samples
(Figure 4.4).
These data suggests that HOSCN targets thiol residues on FN and causes small structural
changes leading to epitope modifications. As a consequence, further studies were carried
out to examine the biological effects of modifications induced by HOSCN on FN.
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Figure 4.4: ThioGlo analysis of thiol levels on bovine plasma FN treated with HOSCN. FN (5 µM)
was treated with increasing molar ratios of HOSCN (0, 5, 250 µM) in a 96-well plate for 2 hr at 37°C
then ThioGlo reagent was added to each well. Concentration was measured against a GSH standard
to determine absolute concentration. Statistical analysis was performed using one-way ANOVA with
Tukey’s multiple comparison post hoc tests to determine significance. Statistical difference is identified
as follows: ** = p < 0.01.
4.3.4 Effect of cell adhesion HOSCN-modified human plasma
fibronectin
The biological effects of HOSCN-treated FN on HCAEC was further elucidated by
performing a cell adhesion assay. These experiments were performed as described in
Section 3.3.4. Surface-bound FN (0.02 µM) was treated with increasing concentrations
of HOSCN (0, 5, 10, 25, 50, 100, 200 µM) diluted in 0.1 M pH 7.4 phosphate buffer,
followed by washing with PBS to remove excess oxidant to prevent direct interaction of the
oxidant with HCAEC. HCAEC were added to each sample well at a density of 12,500 cells
per well, followed by rinsing with 1% casein in PBS to remove any unadhered HCAEC.
Adhered HCAEC were fixed then stained with crystal violet, which was resolubilised in
acetic acid and absorbance was measured at 590 nm.
Exposure of human plasma FN to HOSCN resulted in minor changes in the ability of
cells to bind when compared to untreated (0x oxidant treatment) FN. However, increasing
HOSCN concentrations showed variable results, with no statistical significance detected
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with increasing concentrations of HOSCN (Figure 4.5).
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Figure 4.5: Cell adhesion of HCAEC on HOSCN-modified human plasma FN. Surface-bound human
plasma FN (0.02 µM) was treated with HOSCN (0, 5, 10, 25, 50, 100, 200 µM) and incubated for 2
hr at 37°C before being fixed, stained with crystal violet and absorbance was measured. The data are
presented as a percentage relative to control (no oxidant; 0x oxidant treatment). Error bars are ± SD
from three technical replicates obtained from each of three independent experiments. Statistical analysis
was performed using one-way ANOVA with Tukey’s multiple comparison post hoc tests to determine
significance. Statistical significance was not found.
To examine changes to the cellular structure, ICC was performed using a Hoechst
nuclei blue fluorescence stain and a rhodamine-phalloidin F-actin red fluorescence stain.
Experiments were carried out as described in Section 3.3.4 (Figure 3.9). Both cell number
and cell spreading can be examined with this method. Surface-bound human plasma FN
on an 8-well slide was treated with HOSCN, washed with PBS, and incubated with
50,000 cells for 1.5 hr at 37°C in a humidified atmosphere containing 5% CO2 before
being stained with Hoechst and rhodamine-phalloidin. The samples were imaged using
fluorescence microscopy.
The changes to the extent and nature of HCAEC adhesion and spreading on HOSCN-
treated FN (compared to controls) were less extensive compared to that induced by
HOCl (Figure 3.8). The number of cells did not fluctuate but appeared to be constant
with increasing concentrations of HOSCN (Hoechst blue fluorescence) (Figure 4.5B).
119
The ability of cells to spread and interact with other ECs was observed to be similar to
untreated control (0x oxidant treatment) samples (Phalloidin red fluorescence) (Figure
4.5B).
Figure 4.6: Immunocytochemistry of HCAEC adhesion on HOSCN-modified human plasma FN.
Human plasma FN (0.02 µM) was coated on an 8-well plate treated with increasing concentrations of
HOSCN (0, 10, 25, 50 µM) for 2 hr at 37°C before being exposed to HCAEC, which were subsequently
fixed and stained with rhodamine-phalloidin (red) and Hoechst 33342 (blue) for fluorescence microscopic
imaging.
These data suggests that HOSCN-modified FN may not alter the adhesion of HCAEC,
however the oxidant treatment may still generate other long term changes, which were
subsequently investigated by investigating cellular metabolic activity.
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4.3.5 Effect of cell metabolic activity HOSCN-modified human plasma
fibronectin
Cellular metabolic activity can be affected independently of cell adhesion, and impairment
of this process can be identified using an assay to examine whether cells maintain their
activity. Surface-bound FN was either untreated (0x oxidant control) or treated with
increasing concentrations of HOSCN, then washed to remove excess oxidant following
methods describe in Section 3.3.5. Each well was incubated with 12,500 cells per well,
and any unbound cells were washed away with 1% casein in PBS. Fresh growth media
was then added to each well, and HCAEC were incubated under normal tissue culture
conditions for 48 hr to recover, prior to addition of MTS reagent to measure absorbance
at 490 nm at 3 hr.
HCAEC adhesion on HOSCN-modified FN showed variable changes (Figure 4.5).
However, HCAEC incubated on HOSCN-modified FN showed a constant level of cell
metabolic activity with increasing concentration of HOSCN treatment of the FN (Figure
4.7). No statistically-significant changes were detected and HOSCN-modified FN,
therefore did not significantly affect the ability of the HCAEC to proliferate (Figure
4.7). Decreased cell metabolic activity would be heavily influenced by a decreased in
cells attached to the plate.
Due to the specificity of HOSCN oxidation, certain biological effects may not be severely
effected, but HCAEC may react by expressing different genes to deal with environmental
changes. Real time qPCR therefore was performed in light of the previous data to identify
possible changes in HCAEC gene expression when incubated on HOSCN-treated FN.
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Figure 4.7: MTS assay of HCAEC metabolic activity on HOSCN-modified human plasma FN. Human
plasma FN (0.02 µM) was treated with increasing concentrations of HOSCN (0, 5, 10, 25, 50, 100, 200
µM) and incubated for 2 hr at 37°C before adding MTS reagent to each well. The data are presented as
a percentage relative to control (no oxidant; 0 µM treatment). Error bars are ± SD from three technical
replicates obtained from each of three independent experiments. Statistical analysis was performed using
one-way ANOVA with Tukey’s multiple comparison post hoc tests to determine significance. Statistical
significance was not found.
4.3.6 Effects of HOSCN modified fibronectin on HCAEC gene
expression
Gene expression can be up- or down-regulated as a cellular response to change.
Experiments were carried out as described in Section 3.3.6. Surface-bound FN on
6 well plates were treated with 1250x molar excess (50 µM) of HOSCN for 2 hr at
37°C, prior to incubation with 500,000 HCAEC for 72 hr, followed by sample extraction
using a Qiagen RNeasy Mini Kit. A Qiagen RT2 Profiler PCR Human Extracellular
Matrix and Adhesion molecules (330231; QIAGEN) kit was utilised to investigate
multiple gene expression including ECM and adhesion molecules, housekeeping genes,
and experimental controls (Table 4.1). Data were analysed using SABiosciences PCR
Array Data Analysis Template in conjunction with a Web-based analysis software
from SABiosciences (www.SABiosciences.com/pcrarraydataanalysis.php). Treated
samples were compared against untreated (0x oxidant control) samples (Table 4.2).
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Table 4.1: Gene expression investigated for ECM and adhesion molecules.
Gene Description
ADAMTS Type I, Type 13, Type 8 von Willebrand factor-cleaving protease
CD44 CD44 antigen; cell-cell interaction
CDH1 E-cadherin
CLEC3B Tetranectin
CNTN1 Contactin 1
[COL]1A1, 5-8A1, 11-12A1, 14-16A, 4A2, 6A2 Collagen chains
CTGF Connective Tissue Growth factor
[CTNN]A1, B1, D1, D2 Catenin α1, β1, δ1-2
ECM1 Extracellular matrix 1
FN1 Fibronectin
HAS1 Hyaluronan Synthase 1
ICAM1 Intercellular Adhesion Molecule 1
[ITG]A1-8, B1-5, AL, AM, AV Integrin chains
KAL1 Anosmin 1
[LAMA] A1-3, B1, B3, C1 Laminin Chains
[MMP]1-3, 7-16 Matrix Metalloproteinases 1-3, 7-16
NCAM1 Neural cell adhesion molecule 1
PECAM1 Platelet EC cell adhesion
SELE, SELL, SELP E-selectin, L-selectin, P-selectin
SGCE Sarcoglycan 
SPARC Secreted protein acidic and cysteine rich
SPP1 Secreted phosphoprotein 1
TGFB1 Transforming growth factor beta induced
[THBS]1-3 Thrombospondin 1-3
[TIMP]1-2 TIMP metallopeptidase inhibitor 1-2
TNC Tumor Necrosis Factor
VCAM1 Vascular cell adhesion protein 1
VCAN Versican
VTN Vitronectin
ACTB, B2M, GAPDH, HPRT1, RPLP0 House keeping genes
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A down-regulation of ADAMTS13, COL5A1, CTNNA1, FN1, MMP8, SELL, SELP was
shown to occur when HCAEC were incubated on FN treated with HOSCN (Table 4.2).
SPARC was shown to be up-regulated in HCAEC incubated on HOSCN-treated FN
(Table 4.2) when compared to native FN.
Table 4.2: Gene analysis of HCAECs incubated on human plasma FN treated with 1250x (50 µM) of
HOSCN.
Gene Fold Regulation P-Value
ADAMTS13 -1.52 0.009
COL5A1 -1.23 0.009
CTNNA1 -1.17 0.019
FN1 -1.25 0.002
MMP8 -9.58 0.050
SELL -1.56 0.009
SELP -1.44 0.039
SPARC +1.18 0.045
In light of these data showing modifications on plasma FN, cellular FN was next
examined as it is a significant component of the basement membrane of the arterial
wall. Furthermore, studies on a mixture of ECM extracted from HCAEC culture was
also examined to assist in establishing whether cellular FN reacts in the same way when
it is present amongst the complex mixture of other proteins similar to what would be
found in vivo.
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4.3.7 Effect of HOSCN on cellular-derived fibronectin epitopes
Cellular FN possesses extra protein domains arising from splice variants with these
extra domain being important in vascular maintenance and matrix assembly; these extra
domain are known as EDA and EDB. Examining the effects HOSCN has on cellular FN
in a mixed ECM sample can give information on whether HOSCN targets FN amongst
other matrix proteins, and whether the important functional sites CBF, HBF and the
cellular EDA are modified. HCAEC were cultured over a week in 96 well plates, before
bound cells were removed and ECM in each well was exposed to HOSCN as described in
Section 3.3.7. Samples were probed for functional CBF, HBF and EDA epitopes using
specific antibodies, with absorbance measured using ELISA.
Whole HCAEC-derived ECM treated with HOSCN samples probed for the CBF (clone
A17) were found to not be targeted by HOSCN and showed no changes with increasing
treatment concentration of HOSCN (Figure 4.8A). Examination of the HBF on FN
showed no statistically significant changes with increasing concentrations of HOSCN
(Figure 4.8B). Probing for FN EDA when treated with increasing concentrations of
HOSCN showed that epitope recognition did not change with increasing concentrations
of the oxidant (Figure 4.8C).
These data establish that there were no changes to these specific FN epitopes when
exposed to HOSCN. However, as changes may also occur at other sites on FN, further
investigations were made to examine changes to FN protein structure within the complex
HCAEC-derived ECM.
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Figure 4.8: ELISA of whole ECM-derived from HCAEC exposed to HOSCN. HCAEC produced
ECM on 96-well plates were treated with increasing concentrations of HOSCN (0, 5, 10, 25, 50, 100,
200 µM). Specific FN epitopes were detected by using a mouse monoclonal A) anti-FN CBF antibody
(A17; 1:10000), B) anti-FN HBF antibody (A32; 1:1000), C) anti-FN EDA antibody (3E2; 1:1000), and
conjugated with anti-mouse HRP secondary (1:1000 dilution). The data are presented as a percentage
relative to control (no oxidant; 0 µM oxidant treatment). Error bars are ± SD from three technical
replicates obtained from each of three independent experiments. Statistical analysis was performed
using one-way ANOVA with Tukey’s multiple comparison post hoc tests to determine significance. No
statistical significance was detected.
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4.3.8 Effect of HOSCN modification on cell-derived fibronectin
The CBF, HBF, and EDA sites on FN are important in maintaining cell and vascular
health and integrity. Whole ECM extracted from HCAEC cultures were treated with
increasing molar excesses of HOSCN, and separated under reducing conditions on SDS-
PAGE. Proteins were then transferred onto PVDF membranes and probed for these three
functional epitopes.
Whole ECM-extracts exposed to HOSCN showed changes to ECM structure with
increasing molar excess of oxidant. The CBF of FN was shown to have slightly decreased
antibody recognition particularly of the monomer band (white arrow) at the higher molar
ratios of HOSCN, such as at 150 µM (Figure 4.8A). This loss of epitope recognition
correlated closely with what was measured in the ELISA examining loss of CBF epitope
recognition of human plasma FN treated with HOSCN (Figure 4.1A), although this loss
was not detected with whole ECM ELISA samples (Figure 4.9A). Examining the HBF of
FN, it was shown that HOSCN induced loss of epitope recognition to the monomer band
(white arrow) with 10 µM to 50 µM of HOSCN with the recognition returning at higher
molar excesses of HOSCN (Figure 4.9B).
The EDA, which is specific to cellular-derived FN, did not seem to be modified by
HOSCN; epitope recognition of the monomer band (white arrow) was not observed to
change with increasing doses of HOSCN (Figure 4.9C). A similar result was found when
an ELISA was performed on whole ECM exposed to HOSCN (Figure 4.9C). Thus, there
does not seem to be any major fragmentation or aggregation changes occurring for these
domains, which could be determined under these reducing gel conditions (Figure 4.9).
However structural changes may have occurred which may not be detected under reducing
gel conditions.
These data suggests that HOSCN acts on FN in lieu of other proteins present, but with
the severity of modifications being less extensive compared to FN exposed to HOCl. The
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Figure 4.9: Western blots showing structural changes to whole ECM-derived from HCAEC treated
with increasing molar ratios of HOSCN. Samples were separated by SDS-PAGE under reducing
conditions and transferred onto PVDF blots and probed with mouse monoclonal A) anti-FN CBF
antibody (A17; 1:10000 dilution), B) anti-FN HBF antibody (A32; 1:2000), C) anti-FN EDA antibody
(3E2; 1:2000), and conjugated with anti-mouse HRP secondary (1:2000 dilution). Blots were developed
with ECL-plus reagent and data is labelled as follows: black arrow = dimer/higher aggregates, and white
arrow = monomer band.
effects that HOSCN has on FN are discussed further below.
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4.4 Discussion
FN is known to play an important role in maintaining vascular integrity and health. It
exists in the basement membrane of ECs and acts as a scaffold by binding to other ECM
proteins and cells [148, 196]. During the development of atherosclerosis, inflammation
takes place and releases oxidants, such as HOCl and HOSCN [33]. The reaction of HOCl
have been extensively studied in previous research [49, 50]. In contrast, the chemistry
and biology of HOSCN, a much more specific oxidant that produces reversible oxidative
products by targeting thiols (RSH, Cysteine), has been studied to a much more limited
extent [94]. This study aimed to examine the effects that HOSCN has on FN, and how
these modifications might affect the biological functions of this protein.
FN exposed to HOSCN was observed to have distinctively less modifications under non-
reducing conditions when compared at the same molar ratio of HOCl. Starting at 5x
molar ratio, FN was found to form specific fragments, which can be seen above 290 kDa,
and above and below the monomer band (white arrow) (Figure 4.3). These fragments are
observed to increase with increasing molar ratios of HOSCN. Furthermore, treatment of
FN with HOSCN was observed to form aggregates under both non-reducing and reducing
conditions (Figure 4.3). This phenomenon is consistent with previous studies that showed
treatment of LDL with HOSCN, which led to a loss of parent protein with subsequent
formation of aggregates and fragments [371]. In previous studies, protein unfolding
and aggregation has been linked to HOSCN treatment, particularly under non-reducing
conditions via formation of disulfide bonds but there are limited studies investigating
protein fragmentation with this oxidant [102, 103].
HOSCN is known to reversibly oxidise Cys residues and GSH, although with a lower
kinetic rate constant compared to HOCl [50, 51]. Reduced:oxidised thiol ratios have
been used as an oxidative stress indicator, whereby changes to this ratio can indicate
high oxidative stress [372]; this particular ratio has been used as a predictor of early
atherosclerosis [373]. As previously stated, HOSCN has been found to react more
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specifically with thiol-containing protein in cells than HOCl using the thiol-specfic
fluorescent probe IAF [374]. High concentrations of HOSCN has been correlated with
depletion of thiol levels, as observed in the plasma of smokers [99]. In support of this,
a decrease in plasma thiol levels were shown to be correlated with increased risk of the
early stages of atherosclerosis [372, 373].
HOSCN treatment of protein thiols are found to form unstable transitory RS-SCN
derivatives, which are found to further react with water to generate sulfenic acid
intermediates (RS-OH) [94, 103]. Further reactions of this species with another thiol can
lead to the formation of disulfide bonds [94, 104–107]. FN possesses 2-3 free thiols, which
are likely to be the first targets for HOSCN depending on their accessibility (Uniprot
data; P02751). The oxidation of these free thiols would be expected to lead to the
formation of new disulfides between protein chains. This would explain the occurrences
of higher aggregates detected as seen a smear above the dimer band (black arrow)
(Figure 4.3). Another potential mechanism for the formation of such species is that
thiol oxidation can lead to thiol-disulfide exchange, whereby disulfide links are broken
and reformed with another Cys residue [105, 107, 375, 376]. Thiol-disulfide exchange can
cause conformational changes to FN which may lead to a shift in the observed molecular
mass on SDS-PAGE due to alterations in the rate of which the protein runs through the
gel. The mechanism leading to fragmentation is not fully understood and requires further
investigation to elucidate this process.
Although Cys residues are likely to be the first targets of HOSCN, this oxidant has also
been found to target Trp and Lys residues, especially if there is a lack of Cys residues
[26, 102]. Treatment of LDL with HOSCN has shown that Cys and Lys residues are
modified [371]. Degradation of HOSCN leads to formation of cyanate (OCN-) which has
been found to act on Lys residues (as well as other residues) to generate homocitrulline
[112, 113]. This process is called carbamylation and has been found to be correlated with
increased risk of CAD, with higher levels of homocitrulline found to be present in human
lesions [112, 113]. Protein carbamylation has been shown to cause HDL dysfunction,
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which would lead to a reduction in efficacy of lipid and partially reverse cholesterol
transport [113]. Furthermore, lipoprotein carbamylation was found to transform LDL
into a macrophage-targeted ligand which is taken up via scavenger receptors, and leads
to increased accumulation of cholesterol and foam-cell formation [112].
The FN CBF domain which involves residues 1267-1540 of the protein sequence possesses
5 Lys and 3 Trp residues, and the HBF domain (residues 1727-1991) possesses 15 Lys and
3 Trp residues (Uniprot data; P02751). There are also two free Cys residues located at
positions 1232 and 2136 (Uniprot data). In light of HOSCN reactivity with these amino
acids, the low levels of free thiols that can be targeted by HOSCN means these Lys or Trp
residues could be modified. The ThioGlo assay identified that free thiols were targeted
by HOSCN leading to a decrease in the levels of thiols detected (Figure 4.4). As certain
thiols may not be accessible to the oxidant and may not be detected, there are limitations
to the current experimental data with regards to the detection of total concentration of
Cys residues. However, it can be seen that there are likely minor modifications induced
by HOSCN to these domains, causing loss of antibody recognition (Figure 4.2, 4.8, and
4.9), with structural changes seen as the formation of aggregates and fragments (Figure
4.3). These effects may also be limited by the conformation of FN where certain areas
are inaccessible to the effects of HOSCN.
Gene expressions in HCAEC incubated on HOSCN-treated FN (Table 4.2) differed
to HOCl-treated FN (Table 3.2) with fewer number of genes altered in their level of
expression compared to control (0x treatment). Unlike the down-regulation of multiple
MMPs in HCAECs exposed to HOCl-treated FN, HCAEC incubated on HOSCN-treated
FN were found to only down-regulate MMP-8 by almost 10 fold (Table 4.2). MMP-8
is an important collagenase alongside MMP-13, which functions to breakdown type I-
III collagens [377, 378]. It has been shown previously that EC treated with condensate
from cigarette smoke had increased expression of MMP-1, MMP-9, and MMP-8 [379].
Furthermore, elevated levels of MMP-8 and MMP-13 have been associated with formation
of unstable plaques due to effects of these enzymes and macrophages on collagen within
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plaque [380–382]. MMP-8-/- and MMP-13-/- in apoE-/- mice were found to have decreased
lesion sizes, with lower macrophage population, and increased collagen content giving rise
to a more stable plaque phenotype [380–382]. MMP-8 has been linked to not only increase
in VCAM-1 expression in EC, but also decreased Ang II levels associated with high
blood pressure, a risk factor for atherosclerosis [380]. The reason that HCAEC exposed
to HOSCN-treated FN down-regulates MMP-8 may be to retain collagen binding and
prevent further collagen degradation along with decreased leukocyte migration to the
site of injury. This may help maintain arterial wall integrity, by forming a more stable
fibrotic plaque with a reduced risk of plaque rupture.
FN with HOSCN-induced modifications have also shown to modulate HCAEC selectin
gene expression (Table 4.2) but less so in comparison to HOCl-modified FN (Table
3.2). SELE was found not to be changed in response to HOSCN treated FN unlike
HOCl-treated FN; however SELP was down-regulated by both treatment. Both of these
selectins are expressed on EC, whereas SELL is solely expressed on leukocytes and hence
will not be discussed further here [350]. Elevated levels of SCN- (80-400 µM), such as in
smokers, have been found to elevate both SELE and SELP, with a corresponding increased
expression of other inflammatory markers such as interleukin-6 (IL-6), and C-reactive
protein [383–385]. Furthermore, HOSCN has been shown to induce up-regulation of
SELE and ICAM-1 expression in HUVECs via the NFκB pathway; this led to an increased
neutrophil adhesion on EC and recruitment of leukocytes [385]. This altered regulation
of SELE shown by HCAEC incubated on HOSCN-treated FN may be a primary reaction
to HOSCN-treated FN, with later responses occurring downstream.
SELP is expressed on both EC and (to a greater extent) on platelets and is found to
assist in leukocyte adhesion and recruitment as seen in apoE-/- mice [363]. As discussed
in Section 3.1, elevated levels of SELP were associated with CVD risk fators [364],
development of fibrotic atherosclerotic plaques [363], and intima-media thickening of
the arterial wall [365]. It may be that HCAEC down-regulates SELP expression in an
attempt to decrease leukocyte migration and reduce inflammation within the affected
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area. Furthermore, it may be an attempt to also reduce platelet binding, which would
lead to clot formation and possible downstream blockage of the artery.
One gene that was found to up-regulated by HCAEC incubated on HOSCN-treated FN
and not HOCl-treated FN was Secreted Protein Acidic And Cysteine Rich (SPARC).
SPARC has been shown to play a role in ECM synthesis during remodelling, in wound
healing, and functions in cell repair by promoting changes to cell shape [386, 387]. SPARC
interacts with ECM and cytokines, and regulates growth factors to affect cell growth; cell
proliferation can be regulated by SPARC through the G1 phase of the cell cycle [386,
387]. Furthermore, SPARC has been found to cause bovine aortic EC (BAEC) to secrete
less FN, but increase type-1 plasminogen activator inhibitor levels, which is important
for matrix remodelling [388]. High concentrations of SPARC have also been shown to
cause rounding of BAEC [388]. Knockout of SPARC (SPARC-/-) in mice was found to
reduce concanavalin A (Con A)-induced necroinflammation coinciding with a reduction
in TNF-α and IL-6 levels [389]. SPARC-/- mice were also found to have a reduction
in collagen fibers, and necroinflammation with decreased infiltration and proliferation of
CD4+ T cells and subsequently decreased fibrosis in liver [390]. The effects of SPARC is
further supported in previous studies where inhibition of SPARC through knockout using
lentivirus was found to reduce numbers of apoptic cells and increased binding capacity
of human microvascular EC to FN [389]. Inhibition of SPARC also led to decreased
adhesion and migration of lymphocytes across the EC monolayer [389].
This up-regulation in SPARC appears to be linked with the other alterations in gene
expression in HCAEC incubated on HOSCN-treated FN, whereby the cells appear to be
attempting to create collagen fibers within the injury area. Although SPARC has been
found to promote inflammation and migration of leukocytes, its extent of promotion
compared with other inflammatory-based genes may be less and thus minimize the final
total amount of inflammation. Some of the other down-regulated genes are involved in
the prevention of collagen degradation and with the up-regulation of SPARC, these data
could be interpreted as HCAEC are attempting to remodel the basement membrane to
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form a more fibrotic environment.
Curiously, the sequence on FN involved collagen binding which lies between amino acids
308-608, with the critical binding site being residues 464-477, possesses 23 Cys residues
(Uniprot. data; P02751). These Cys are all involved in disulfide bonds (Uniprot. data;
P02751). This region is the foundation for the binding between FN and collagen, giving
structural integrity to the basement membrane and is vital to the linkage between collagen
and cells [202, 222, 391]. Further investigation is needed to elucidate the modifications
induced by HOSCN in the collagen binding epitope on FN. It may be that HOSCN is
modifying this collagen binding fragment, decreasing overall efficacy of collagen binding
between cells and FN. Although, cells were able to maintain binding to FN via the CBF
and corresponding RGD site, it has been found that collagen and FN in combination
helps to in initiate and enhance cell spreading and migration [222]. The importance of
collagen extends to the formation of stable fibrous caps in atherosclerotic lesions, and
reduced plaque rupture.
The differences in expression and regulation fold between HOCl-treated FN (Table 3.2)
and HOSCN-treated FN (Table 4.2) appears to be associated with the severity of the
modifications induced to FN by each oxidant. The extensive modifications caused by
HOCl appears to lead to a greater response, which may be involved with the possible
recruitment of leukocytes and ECM remodelling, and attempts to lay down healthy ECM
and generate new binding ligands for HCAEC. However, the HCAEC plated on HOSCN-
treated FN seem to retain their binding capacity, and appear to induce gene changes that
may be designed to maintain collagen integrity and a ”healthy” basement membrane.
This chapter examined modifications induced by HOSCN on FN in terms of protein
structure and functional epitopes, and how this might affect cellular function. Further
investigations would help to elucidate in greater detail the effects that HOSCN has on FN,
for example through amino acid analysis to identify changes to specific functional side
chains, and examination of other functional epitopes which may harbour more cysteine
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residues that could be targeted, such as the collagen binding fragment. Furthermore,
in vivo conditions may result in less extensive modifications due to the presence of
antioxidants in cells and surrounding ECM [392, 393], such as vitamins C and E, and
GSH, which helps to convert vitamin C and E back into their active form [393, 394].
Further research into the reaction between HOSCN and antioxidants may be of use.
The complex interrelationships between MPO, HOCl, and HOSCN can be seen over these
two chapters. Exposure to HOCl resulted in heavily modified peptides and subsequently
biological dysfunction. HOSCN has been shown to be a much milder oxidant causing
reversible oxidation at lower concentrations, giving rise to lower levels of oxidation than
that found with HOCl, but has been shown to also be somewhat damaging to both
proteins and cells at higher concentrations. The extent of HOCl and HOSCN generation
at sites of inflammation in the body has been shown to be closely correlated with MPO
levels, and thus the experiments reported in the next chapter used the enzymatic MPO
system to examine FN modifications and its downstream biological effects.
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Chapter 5
Effects of modifications to fibronectin by
Myeloperoxidase, Chloride or
Thiocyanate, and Hydrogen Peroxide
5.1 Introduction
MPO generates HOCl and HOSCN during inflammation in atherosclerosis, which are
known to react with lipids, DNA, peptides, and proteins [49, 50]. MPO has been found to
co-localise with ECM proteins mediating MPO-derived damage [21, 22, 395]. Replication
of this mechanism was performed with MPO, in the presence of Cl- or SCN-, and H2O2
to better understand the relationship between FN and MPO-derived oxidants. Exposure
of sub-endothelial matrix or FN to reagent HOCl or MPO/Cl-/H2O2 has previously
been shown to result in structural changes to the protein, chloramine formation, and
a reduction in cell adhesion to these modified matrix proteins [22, 260, 261]. The studies
in this chapter were based on these previous results.
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5.2 Aim
This Chapter aims to elucidate the effects of MPO, in the presence of Cl- or SCN-), and
H2O2, on human plasma FN. Two concentrations of MPO were used to reflect a normal
and diseased state. The modifications were examined with treatments using a lower (0.02
µM) and a higher (0.1 µM) concentration of MPO, physiological concentrations of Cl-, and
a lower (20 µM) or higher (500 µM) concentration of SCN-. Structural modifications were
examined using silver staining and Western blotting, whereby modification to epitopes
were examined using Western blotting and ELISA. Biological functions were investigated
using Calcein-AM assay for HCAEC adhesion and MTS assay for HCAEC metabolic
activity.
137
5.3 Results
5.3.1 Effects of myeloperoxidase, chloride, and hydrogen peroxide on
human plasma fibronectin epitopes detected by ELISA
HOCl is enzymatically formed by MPO, Cl-, and H2O2. In these studies the overall extent
of HOCl formation was varied by increasing the H2O2 concentrations. As previously
mentioned, the CBF and HBF epitopes of FN play a key role in maintaining matrix
integrity and cell adhesion. ELISA experiments were carried out following the methods
outlined in Section 3.3.1 while replacing reagent HOCl with MPO enzyme, Cl-, and batch
additions of H2O2. An AP antibody was used instead of HRP secondary to prevent non-
specific interactions between HRP and samples. Samples were developed using a pNPP
solution (p7998; Sigma) and absorbance was measured at 405 nm at 10 min.
Incubation of human plasma FN by the MPO/Cl-/H2O2 system resulted in a statistically
significant loss of recognition of the CBF epitope starting at 800x molar excess of H2O2
in a dose-dependent manner (Figure 5.1A). There was approximately 35% loss of epitope
recognition at 1600x molar excess of H2O2 (Figure 5.1A). Investigation of the FN HBF
showed similar dose-dependent loss of epitope recognition with a statistically significant
loss observed at 800x molar excess of H2O2 and even greater loss of recognition of almost
50% compared to CBF at 1600x molar excess of H2O2 (Figure 5.1B). Modifications to
these functional epitopes were accompanied by a dose-dependent increase in a HOCl-
generated epitope as detected by the monoclonal 2D10G9 antibody (Figure 5.1C).
Statistically significant detection of the HOCl-generated epitope was detected with 800x
molar excess of H2O2 and increasing levels were detected with increasing concentrations
of H2O2 (Figure 5.1C).
Establishing that physiological levels of Cl- (100 mM) along with MPO and H2O2
generates damage to the functional epitopes on FN as well as a HOCl-generated epitope
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Figure 5.1: ELISA of human plasma FN modified using enzymatic treatment with MPO/Cl-/H2O2.
Each well was coated with 0.5 µg (0.02 µM of FN in 0.1 M phosphate buffer) and either left untreated
(0 µM H2O2) or treated with MPO/Cl- and increasing concentrations of H2O2 (0, 4, 8, 16, 24, 32 µM),
and incubated for 2 hr at 37°C. FN epitopes were detected using a mouse monoclonal A) anti-FN CBF
antibody (A17; 1:10000), B) anti-FN HBF antibody (A32; 1:1000), C) anti-HOCl generated epitope
(2D10G9; 1:50), and conjugated with anti-mouse AP secondary (1:1000). The data are presented as a
percentage relative to control (0 µM H2O2). Error bars are ± SD from three technical replicates obtained
from each of three independent experiments. Statistical analysis was performed using one-way ANOVA
with Tukey’s multiple comparison post hoc tests to determine significance. Statistical significance is
identified as follows: ** = p < 0.01, *** = p < 0.001, and **** = p < 0.0001.
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indicates a similar mechanism observed with reagent HOCl (Figure 3.1). Experiments
were subsequently carried out to investigate the structural changes on FN under these
treatment conditions.
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5.3.2 Effects of myeloperoxidase, chloride, and hydrogen peroxide on
the structure of human plasma fibronectin
Structural modifications were investigated using SDS-PAGE with silver staining (Figure
5.2), and epitope structure was examined using Western blotting (Figure 5.3 and 5.4).
Samples were treated with MPO enzymatic system with either 0.02 µM or 0.1 µM of
MPO (Figure 5.2), 100 mM of Cl-, and increasing concentrations of H2O2 (0, 20, 40, 80,
120, 160 µM), prior to performing separation by mass using gel electrophoresis and silver
staining following the methods previously described in Section 3.3.2.
Silver staining of FN treated with MPO/Cl-/H2O2 showed a range of modifications.
Under non-reducing conditions, at 100x molar excess of H2O2, formation of dimers/higher
aggregates (black arrow) were observed when treated with both 0.02 µM and 0.1 µM of
MPO (Figure 5.2A and 5.2B). Increasing presence of higher aggregates were detected as
smearing on the gels with increasing concentrations of H2O2. Samples treated with 0.1
µM of MPO showed similar increasing presence of higher aggregates but also a detectable
loss in both dimers (black arrow) and monomer bands (white arrow) (Figure 5.2A).
Formations of species with higher aggregates or altered structures were also detected
with both 0.02 µM and 0.1 µM of MPO both above and below the monomer bands
(white arrow) (Figure 5.2A and 5.2B). Furthermore, a shift in protein molecular mass
was observed of the dimer bands (black arrow) with the addition of H2O2 compared to
control (no H2O2 treatment) (Figure 5.2A).
SDS-PAGE under reducing condition showed an increasing presence of aggregates with
higher concentrations of H2O2 in a dose-dependent manner (Figure 5.2B). Greater
detection of aggregates were detected when FN was treated with 0.02 µM of MPO and
20 µM of H2O2, which increased with higher intensity of aggregates detected at 600-800x
molar excess of H2O2 (Figure 5.2B). Protein smearing was detected at high concentrations
of H2O2 (600-800x molar ratio) (Figure 5.2B). This formation of aggregates seemed to
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be less with 0.1 µM of MPO treatment but higher aggregate smearing was observed
at 400-800x molar excess of H2O2 (Figure 5.2B). An increasing amount of species with
altered structure was detected with greater intensity at 0.02 µM treatment of MPO just
above the monomer bands (white arrow) (Figure 5.2B). No changes were detected on the
monomer bands when compared to their untreated counterparts.
Western blots of treated samples were used to examine the functional CBF and HBF
epitopes on FN, to obtain complementary data to that found in the silver staining
experiments. Probing for the CBF (clone A17), showed loss of antibody recognition in
a dose dependent manner, with greater loss observed to occur with 0.1 µM treatment of
MPO and 100-800x molar excess of H2O2 where there is a detectable loss in intensity
of both the monomer (white arrow) and dimer (black arrow) bands (Figure 5.3A).
Furthermore, formation of higher aggregates was observed with 0.02 µM of MPO
treatment, and there appeared to be lower levels of aggregates detected with 0.1 µM
of MPO treatment at the same H2O2 concentrations (Figure 5.3A). Under reducing
conditions, there were notable formation of aggregates and smearing of bands with masses
greater than 460 kDa, which can be seen with both 0.02 µM and 0.1 µM MPO treatment,
particularly at 800x molar excess of H2O2 (Figure 5.3B). This was more marked with 0.02
µM of MPO compared to 0.1 µM of MPO.
Repeating this method and examining the FN HBF showed similar modifications as seen
with the CBF antibody (Figure 5.4). Under non-reducing conditions, a loss of antibody
recognition was detected for the dimer bands (black arrow) with increasing concentrations
of H2O2, where greater loss was detected with 0.1 µM of MPO and 800x molar excess
of H2O2 (Figure 5.4A). There were modifications leading to a molecular mass shift of
the dimer/higher aggregates (black arrow) of FN when treated with MPO/Cl-/H2O2.
Under reducing conditions, there was more notable loss of HBF-antibody recognition
of the monomer bands (white arrow) with a greater extent of loss observed with 0.1
µM of MPO (Figure 5.4B). As seen with the CBF results (Figure 5.3B), dimers/higher
aggregates were also detected particularly with 0.02 µM of MPO treatment and at high
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Figure 5.2: Silver staining showing structural changes to human plasma FN treated with
MPO/Cl-/H2O2. Purified human plasma FN (0.2 µM in 0.1 M phosphate buffer) was either left untreated
(control 0x H2O2) or treated with MPO/Cl- and increasing concentrations of H2O2 (0, 20, 40, 80, 120,
160 µM), and incubated for 2 hr at 37°C. Samples were electrophoresed on 3-8% Tris-acetate SDS-PAGE
gels under A) non-reducing or B) reducing conditions. Gels were then fixed, and visualised with silver
staining and referenced against HiMark™ pre-stained High Molecular Mass standards. Data is labelled
as follows: black arrow = dimer/higher aggregates, and white arrow = monomer bands.
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concentrations of H2O2 (black arrow) (Figure 5.4B).
In light of these data showing modifications to FN epitopes, particularly to the biologically
important CBF, further assays were performed to investigate the effects of this oxidant
system on HCAEC adhesion and HCAEC metabolic activity.
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Figure 5.3: Western blotting of structural changes to human plasma FN treated with MPO/Cl-/H2O2.
Samples were separated on SDS-PAGE under A) non-reducing or B) reducing conditions and transferred
onto PVDF membranes and probed with mouse monoclonal anti-FN CBF antibody (A17; 1:10000),
followed by anti-mouse HRP-conjugated secondary antibody (1:2000). Blots were developed with ECL-
plus reagent and data were labelled as follows: black arrow = dimer/higher aggregates, and white arrow
= monomer bands.
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Figure 5.4: Western blotting of structural changes to human plasma FN treated with MPO/Cl-/H2O2.
Samples were electrophoresed on SDS-PAGE under A) non-reducing or B) reducing conditions and
transferred onto PVDF membranes and probed with mouse monoclonal anti-FN HBF antibody (A32;
1:2000), followed by anti-mouse HRP-conjugated secondary antibody (1:2000). Blots were developed
with ECL-plus reagent and data were labelled as follows: black arrow = dimer/higher aggregates, and
white arrow = monomer bands.
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5.3.3 Effects of myeloperoxidase, chloride, and hydrogen peroxide on
human plasma fibronectin cell adhesion
Modifications on human plasma FN with MPO-derived HOCl also led to biological
dysfunction leading to decreased cell adhesion. Surface-bound human plasma FN (0.02
µM) was left untreated (control) or treated with MPO enzyme, Cl- and increasing
concentration of H2O2, followed by two washes with sterile PBS to remove excess MPO
enzyme and H2O2. This prevents any direct interaction of the oxidant system with
HCAEC. HCAEC were pre-incubated with Calcein-AM live cell stain, prior to seeding
12,500 cells into each well. HCAEC were to adhere for 1.5 hr at 37°C in a humidified
atmosphere containing 5% CO2. Calcein-AM becomes fluorescent after hydrolysis by
intracellular esterases and is used as a live cell assay. Fluorescence was measured at λex
492nm, and λem 517nm to determine the number of adherent cells.
Exposure of human plasma FN to 0.02 µM MPO, 100 mM of Cl- and increasing
concentrations of H2O2 resulted in a dose-dependent decrease in HCAEC adhesion (Figure
5.5). A statistically significant loss of cell adherence was detected at 1600x molar excess
of H2O2 with approximately 30% loss in cell numbers when compared to untreated control
samples (0x H2O2 molar excess) (Figure 5.5).
Having established that HCAEC adherence to FN are affected when incubated with an
enzymatic MPO system, further investigations were conducted to examine cell metabolic
activity under the same conditions.
147
0x 400x 1600x
0
25
50
75
100
125
celladheMPOCl
H2O2 (molar ratio)
re
la
ti
ve
fl
u
o
re
sc
e
n
c
e
(%
)
*
A)
Figure 5.5: Calcein-AM fluorescence of HCAEC incubated on human plasma FN treated with
MPO/Cl-/H2O2. Surface-bound human plasma FN (0.02 µM) was left untreated (0x H2O2) or treated
with MPO/Cl- and increasing concentration of H2O2 (0, 8, 32 µM) and incubated for 2 hr at 37°C before
incubation with HCAEC pre-stained with Calcein-AM and subsequent detection of fluorescence. The
data are presented as a percentage relative to control (no oxidant 0 µM treatment). Error bars are ± SD
from three technical replicates obtained from each of three independent experiments. Statistical analysis
was performed using one-way ANOVA with Tukey’s multiple comparison post hoc tests to determine
significance. Statistical significance is identified as follow: * = p < 0.05.
5.3.4 Effects of myeloperoxidase, chloride, and hydrogen peroxide on
human plasma fibronectin on cell metabolic activity
It has been shown that human plasma FN exposed to MPO enzyme and H2O2 leads to a
reduction in HCAEC adhesion (Figure 5.5). Certain HCAEC may retain their adhesive
ability but unable to proliferate. By measuring HCAEC metabolic activity, it is possible
to examine whether modified FN further impairs HCAEC functions leading to a reduction
in growth rate of HCAEC. FN was exposed to MPO, Cl-, and increasing concentrations
of H2O2 (0, 8, 32 µM). Excess treatment was washed off with sterile PBS to prevent
interaction of the oxidant system directly with HCAEC. HCAEC were seeded at 12,500
cells per well and left to adhere for 1.5 hr at 37°C in a humidified atmosphere containing
5% CO2, before being washed with sterile PBS to remove any unadhered HCAEC. Growth
media was added back to each samples and these were left to recover for a further 48 hr
period, prior to addition of MTS reagent, and quantification of absorbance at 490 nm
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after a 3 hr incubation.
HCAEC that were incubated on human plasma FN treated with MPO/Cl-/H2O2 resulted
in a decrease in cell metabolic activity with significance detected at 400x and 1600x molar
excess of H2O2 compared to no treatment (0x molar ratio) control (Figure 5.6). A greater
loss of cell metabolic activity was not observed at higher concentrations of H2O2 (Figure
5.6).
Treatment of FN with MPO/Cl-/H2O2 resulted in structural modifications including a
loss of antibody recognition to functional epitopes. This loss of functional epitopes was
found to be reflected in a decrease in HCAEC adhesion and metabolic activity. Further
investigations were therefore conducted with the SCN- system to determine whether
similar modifications and changes would be detected as seen with the MPO/Cl-/H2O2
systems.
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Figure 5.6: MTS assay of HCAEC metabolic activity on human plasma FN treated with
MPO/Cl-/H2O2. Surface-bound human plasma FN (0.02 µM) was treated with MPO/Cl- and increasing
concentrations of H2O2 (0, 8, 32 µM), which was incubated for 2 hr at 37°C. Plates were washed prior
to addition of growth media and HCAEC were left to recover over 48 hr. MTS reagent was added into
each well and absorbance was measured at 490 nm after 3 hr. The data are presented as a percentage
relative to control (0x H2O2). Error bars are ± SD from three technical replicates obtained from each of
three independent experiments. Statistical analysis was performed using one-way ANOVA with Tukey’s
multiple comparison post hoc tests to determine significance. Statistical significance is identified as
follows: * = p < 0.05.
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5.3.5 Effects of myeloperoxidase, thiocyanate, and hydrogen peroxide
on human plasma fibronectin epitopes detected by ELISA
To further elucidate the effects that oxidants have on FN, an MPO enzymatic system
was used to generate HOSCN, using MPO, a low and a high concentration of SCN-,
and increasing concentrations of H2O2 (0, 4, 8, 16, 24, 32 µM). ELISA experiments were
carried out following Section 3.3.1 and Section 5.3.1, with either 20 µM or 500 µM of
SCN-. Samples were then probed for functional CBF, and HBF epitopes, which are
important in cellular functions, matrix assembly, and vascular integrity.
Human plasma FN exposed to 0.02 µM of MPO with 20 µM of SCN-, and 1600x molar
excess of H2O2 showed no changes to the CBF epitope (Figure 5.7A). When SCN-
was increased to 500 µM and exposed to increasing concentrations of H2O2, it was
shown that at 400x molar excess of H2O2 there was a statistically significant increase in
epitope recognition which remained with increasing H2O2 concentrations (Figure 5.7B).
Examination of the FN HBF epitope at 20 µM of SCN- with increasing concentrations
of H2O2, showed no modifications to this functional epitope (Figure 5.7C). At 500 µM of
SCN-, with increasing molar excess of H2O2, it was shown that there was an increased
recognition of HBF epitope at 400x molar excess of H2O2 (Figure 5.7D). Increasing
the H2O2 concentration to 800x molar excess showed a statistically significant loss of
recognition to the HBF epitope which remained constant up to 1600x molar ratio (Figure
5.7D).
Further investigations were then made to examine possible structural changes to these
functional epitopes using SDS-PAGE, silver staining and Western blotting.
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Figure 5.7: ELISA of human plasma FN modified using enzymatic treatment with MPO/SCN-/H2O2.
Each well was coated with human plasma FN (0.02 µM in 0.1 M pH 7.4 phosphate buffer) and was
either left untreated (control) or treated with 0.02 µM of MPO, A, C) 20 µM or B, D) 500 µM of
SCN-, with increasing concentrations of H2O2 (0, 4, 8, 16, 24, 32 µM) and incubated for 2 hr at 37°C.
FN epitopes were detected using mouse monoclonal A-B) anti-FN CBF antibody (A17; 1:10000), C-D)
anti-FN HBF antibody (A32; 1:1000), and AP conjugated secondary antibody (1:1000). The data are
presented as a percentage relative to control (0x H2O2 control). Error bars are ± SD from three technical
replicates obtained from each of three independent experiments. Statistical analysis was performed using
one-way ANOVA with Tukey’s multiple comparison post hoc tests to determine significance. Statistical
significance was identified as follows: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, and **** = p <
0.0001.
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5.3.6 Effects of myeloperoxidase, thiocyanate, and hydrogen peroxide
on the structure of human plasma fibronectin
SDS-PAGE protein separation was performed to further investigate the changes that
MPO-derived HOSCN has on the structure of FN. Human plasma FN (0.02 µM) was
incubated with 0.02 µM of MPO, either 20 µM or 500 µM of SCN-, and increasing
concentrations of H2O2. Samples were separated on SDS-PAGE under non-reducing or
reducing conditions followed by silver staining following the methodology described in
Section 3.3.2.
Exposure of FN to 0.02 µM of MPO, 20 µM of SCN-, and increasing concentrations of
H2O2 resulted in changes to the protein structure (Figure 5.8). At 200x molar excess
of H2O2, there were species of altered structures detected below the dimer band (black
arrow) (Figure 5.8A). Higher mass aggregates or another altered species (> 460 kDa) was
detected above the dimer parent bands (black arrow) and a fragment band was detected
at around 130 kDa (Figure 5.8A). These structural changes became more marked with
increasing concentrations of H2O2. In the presence of 500 µM of SCN-, these species of
altered structure of FN was observed with a smearing of protein bands below the dimer
bands (black arrow) (Figure 5.8A). Increasing intensity of higher mass protein aggregates
or altered species were also formed when treated with 500 µM of SCN-, and were detected
above the dimer bands (black arrow) as well as at the top of the gels in each wells at
200-800x molar excess of H2O2 (Figure 5.8A).
Under reducing conditions, exposure of human plasma FN to 20 µM of SCN- and
increasing concentration of H2O2 did not result in fragments and aggregates that were
previously noted under non-reducing conditions (Figure 5.8B). At 400x molar excess of
H2O2, it was observed that there were dimer/higher aggregates present (black arrow)
(Figure 5.8B). In the system with 500 µM SCN- and 400x molar excess of H2O2, there
was an increasing presence of dimers/higher aggregates (black arrow) compared to the 20
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µM of SCN- condition (Figure 5.8A). At higher concentrations of H2O2, a greater intensity
of aggregates or altered species were detected above the dimer band (black arrow) and
at the top of each well (Figure 5.8B).
SDS-PAGE gels were transferred onto PVDF membranes to be probed for FN CBF and
HBF functional epitopes, to further elucidate the effects of MPO/SCN-/H2O2 on the FN
structure. Examining the changes to FN CBF under non-reducing conditions showed
similar structural changes to these seen with silver staining (Figure 5.9A). Treatments
with 20 µM of SCN-, and starting at 200x molar excess of H2O2 resulted in loss of antibody
recognition to both the parent dimer (black arrow) and the parent monomer band (white
arrow) with a dose-dependent manner with H2O2 concentrations (Figure 5.9A). Exposure
with 20 µM of SCN- resulted in fragments possessing the CBF site below the parent dimer
bands (black arrow), and above and below the parent monomer bands (Figure 5.9A).
Increasing the SCN- concentration to 500 µM, showed loss of recognition to the parent
dimer (black arrow) and the parent monomer bands (white arrow) (Figure 5.9A), but
to a lesser extent compared to 20 µM of SCN- (Figure 5.9A). Fragmentation of FN was
also observed, but more smearing (as opposed to defined bands) was detected with 500
µM of SCN- compared to 20 µM of SCN- (Figure 5.9A). Under reducing conditions, a
minor loss of antibody recognition to the CBF was detected with both concentrations of
SCN- for the parent monomer band (white arrow) (Figure 5.9B). Fragmentation was not
observed, but a decreased recognition of both dimers around 460 kDa and higher mass
aggregates (black arrow and above) were detected with increasing H2O2 concentrations
(Figure 5.9B).
Probing for the FN HBF gave similar results to those seen for the FN CBF. Under non-
reducing conditions, with both 20 µM and 500 µM of SCN-, it was found that there
was a dose dependent loss of recognition to both the parent dimer (black arrow) and the
parent monomer bands (white arrow) at 200-800x molar excess of H2O2 (Figure 5.10A).
Starting at 200x molar excess of H2O2 for both concentration of SCN-, species of altered
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Figure 5.8: Silver staining showing structural changes to human plasma FN treated with
MPO/SCN-/H2O2. Purified human plasma FN (0.2 µM in 0.1 M phosphate buffer) was either left
untreated (0x H2O2) or treated with MPO/SCN- and increasing concentrations of H2O2 (0, 20, 40, 80,
120, 160 µM), and incubated for 2 hr at 37°C. Samples were separated using 3-8% Tris-acetate SDS-
PAGE gels under A) non-reducing or B) reducing conditions. Gels were then fixed, and visualised with
silver staining and referenced against HiMark™ pre-stained High Molecular Mass standard. Data is
labelled as follows: black arrow = dimer/higher aggregates, and white arrow = monomer band.
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structures were observed under the parent dimer bands (black arrow) (Figure 5.10A);
these bands were more notable with 20 µM of SCN-. Samples electrophoresed under
reducing conditions showed variable antibody recognition with increasing concentrations
of H2O2; it appeared that at 20 µM of SCN-, HBF epitope recognition increased with
increasing concentrations of H2O2 (Figure 5.10B). At 500 µM of SCN-, the intensity of
the monomer band (white arrow) did not change with increasing concentrations of H2O2
(Figure 5.10B). Neither fragmentations nor crosslinks were observed for either low or high
concentrations of SCN- under reducing conditions (Figure 5.10B).
These data showed that the overall FN structure is modified by treatment with
MPO/SCN-/H2O2. This result was similarly reflected in the Western blots, though
no distinguishable differences could be determined. Cellular function was further
investigated to determine whether HCAEC incubated on MPO/SCN-/H2O2 treated FN
would modulate HCAEC adhesion and metabolic activity.
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Figure 5.9: Western blotting of structural changes to human plasma FN treated with
MPO/SCN-/H2O2. Human plasma FN was separated using SDS-PAGE under A) non-reducing or B)
reducing conditions and transferred onto PVDF membranes and probed with mouse monoclonal anti-
FN CBF antibody (A17; 1:10000), followed by HRP conjugated anti-mouse HRP secondary antibody
(1:2000). Blots were developed with ECL-plus reagent and data is labelled as follows: black arrow =
dimer/higher aggregates, and white arrow = monomer band.
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Figure 5.10: Western blotting of structural changes to human plasma FN treated with
MPO/SCN-/H2O2. Human plasma FN was separated using SDS-PAGE under A) non-reducing or B)
reducing conditions and transferred onto PVDF membranes and probed with mouse monoclonal anti-FN
HBF antibody (A32; 1:2000), followed by HRP conjugated anti-mouse HRP secondary antibody (1:2000).
Blots were developed with ECL-plus reagent and data is labelled as follows: black arrow = dimer/higher
aggregates, and white arrow = monomer band.
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5.3.7 Effects of myeloperoxidase, thiocyanate, and hydrogen peroxide
on human plasma fibronectin on cell adhesion
As reported in the previous Sections, HOSCN generated by the MPO system can modify
FN structure. It was therefore important to identify whether modifications to FN CBF
and HBF epitopes would affect HCAEC functions. Surface-bound FN (0.02 µM) was
incubated with MPO, SCN-, and increasing concentrations of H2O2 (0, 8, 32 µM), as
described in Section 5.3.3. After treatment, the wells were washed with sterile PBS to
remove any excess oxidant and prevent direct interaction with HCAEC. HCAEC were pre-
stained with Calcein-AM live cell stain prior to seeding into each sample well at a density
of 12,500 cells per well, and left to adhere for 1.5 hr at 37°C in a humidified atmosphere
containing 5% CO2. Fluorescence was subsequently measured using λex 492nm and λem
517nm to quantify the number of cells adhered to the control and modified FN.
Human plasma FN treated with 20 µM of SCN-, and either 400x or 800x molar excess
of H2O2 showed no statistically significant changes in HCAEC adhesion when compared
to the no oxidant (0x H2O2) treatment control (Figure 5.11A). Experiments using 500
µM SCN-, and either 400x or 800x molar excess of H2O2 also showed no statistically
significant changes in cell adhesion (Figure 5.11B). In light of this data, cell metabolic
activity was further investigated to complement these findings.
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Figure 5.11: Calcein-AM fluorescence was employed to determine the extent of HCAEC adhesion to
control human plasma FN, or FN exposed to MPO/SCN-/H2O2. Surface-bound human plasma FN (0.02
µM) was treated with 0.02 µM of MPO, A) 20 µM or B) 500 µM of SCN-, and increasing concentrations
of H2O2 (0, 8, 32 µM), which was incubated for 2 hr at 37°C. HCAEC were pre-stained with Calcein-
AM and fluorescence was subsequently quantified. The data are presented as a percentage relative to
control (0x H2O2 treatment). Error bars are ± SD from three technical replicates obtained from each of
three independent experiments. Statistical analysis was performed using one-way ANOVA with Tukey’s
multiple comparison post hoc tests to determine significance. No statistical significance was observed.
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5.3.8 Effects of myeloperoxidase, thiocyanate, and hydrogen peroxide
on human plasma fibronectin on cell metabolic activity
HCAEC may adhere to modified FN but nay not retain healthy metabolic activity levels.
To test this hypothesis, surface-bound FN was left untreated or was exposed to 0.02 µM
of MPO, 20 µM or 500 µM of SCN-, and increasing concentrations of H2O2 (0, 8, 32
µM) for 2 hr at 37°C. The treatment was washed off with sterile PBS to prevent direct
interactions with HCAEC, followed by seeding 12,500 cells into each well, which were
left to adhere for 1.5 hr at 37°C in a humidified atmosphere containing 5% CO2. Fresh
endothelial growth media was added back to each sample well, and HCAEC were allowed
to recover over a 48 hr period prior to quantification of MTS absorbance at 490 nm after
a 3 hr incubation.
Treatment with 20 µM of SCN-, and both 400x and 800x molar excess of H2O2 showed
no statistically significant changes to cell metabolic activity compared to untreated (0x
H2O2) controls (Figure 5.12A). Treatment with 500 µM of SCN-, and either 400x or 800x
molar excess of H2O2 also showed no statistical significance in HCAEC metabolic activity
compared to controls (Figure 5.12B).
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Figure 5.12: MTS assay for cell metabolic activity of HCAEC incubated on native human plasma FN,
or FN treated with MPO/SCN-/H2O2. Surface-bound human plasma FN (0.02 µM) was treated with
0.02 µM of MPO, A) 20 µM or B) 500 µM of SCN-, and increasing concentrations of H2O2 (0, 8, 32
µM), which was incubated for 2 hr at 37°C. MTS reagent was added to each sample, and absorbance was
measured after a 3 hr incubation. The data are presented as a percentage relative to control (0x H2O2).
Error bars are ± SD from three technical replicates obtained from each of three independent experiments.
Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison post hoc
tests to determine significance. No statistical significance was observed.
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5.4 Discussion
MPO released into the ECM milieu has been known to interact with certain proteins
and proceeds to generate reactive oxidant, which can be damaging to the surrounding
ECM proteins. This chapter aims to elucidate the interaction between MPO and FN,
and simulate the in vivo enzymatic reaction (MPO system) to examine the modifications
on human plasma FN.
High levels of plasma MPO has previously been associated with prevalence of CAD [11,
396], and found to to bind to the sub-endothelial matrix [21, 22, 395]. MPO can be
released into the matrix from leukocytes present in the sub-endothelium, but has also been
found to transcytose through EC from plasma [21, 270, 397]. MPO, as a highly cationic
enzyme, interacts strongly with negatively charged GAGs via electrostatic interactions
[270]. Moreover, MPO has previously been found to co-localise with sub-endothelial FN,
which has been suggested to potentiate MPO activity [21, 22]. This localisation of MPO
to vascular ECM proteins has been linked to increased modifications induced by reactive
species produced by MPO including radicals, chlorinating and nitrating species [21, 22,
395]. Early studies have linked the transcytosis of MPO into the sub-endothelium with
increased levels of nitration on ECM proteins, as indicated by the presence of NO2-Tyr
formation in wild type mice models (vs MPO-/-) and human atherosclerotic lesions [21,
395]. Moreover, co-localisation of MPO- and HOCl-modified proteins with macrophages
has been observed in lesions associated with intracoronary thrombi [398]. The co-
localistion of MPO with sub-endothelial FN has been found to potentiate formation of
di-Tyr [35, 399] and carbonyl compounds [260], damage to FN and subsequent biological
dysfunction [22, 261]. Higher concentrations of FN were found to increase the extent of
MPO binding, with binding of MPO to FN resulting in a reduction in MPO mobility
on gel electrophoresis [270]. The reported close proximity of MPO and FN suggests that
oxidative species produced by MPO are likely targeting FN at specific sequences, however
there are limited studies investigating the binding relationship between MPO and FN.
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Analysis of the effects of MPO/Cl-/H2O2 human plasma FN using SDS-PAGE and silver
staining have shown that formation of aggregates occurs with low (100x molar ratio)
concentrations of H2O2 (Figure 5.2). Aggregates were observed under both reducing and
non-reducing conditions with higher levels detected in the latter case, consistent with
the formation of both reducible and non-reducible crosslinks. This pattern of aggregate
formation is similar to that which was observed previously when FN was treated with
reagent HOCl (Refer to Section 3). These aggregates are therefore likely to be formed
as a result of the generation of HOCl by the MPO system, with this causing structural
modifications on human plasma FN. MPO-derived HOCl is known to react with the
sulfhydryl groups of Cys, leading to the generation of R-SOH, which can subsequently
react with another free sulfhydryl group to form disulfide crosslinks [49, 289, 290]. This
can either be within a single protein structure (intramolecular cross-links) or between
different proteins (intermolecular cross-links); the latter may be the cause of (some of)
observed reducible aggregates [49, 289, 290]. When samples were electrophoresed under
reducing conditions, a considerable proportion of the dimers/aggregates were reduced to
monomers but a certain amount of aggregates were found to be non-reducible (Figure
5.2). These aggregates may arise from the generation of intermolecular di-Tyr or di-Trp
linkages, which contain stronger (non-reducible) intermolecular covalent bonds [53, 54].
As previously discussed in Section 3, di-Tyr crosslinks result from the dimerisation of
two Tyr phenoxyl radicals [64, 291]. These di-Tyr have been shown to form in FN on
treatment with an MPO system, and at greater quantities compared to treatment with
reagent HOCl [260]. Moreover, di-Trp may result from similar reactions of two Trp indolyl
radicals [316].
Fragmentation of FN was found to be similar when treated using the MPO/Cl-/H2O2
system (Figure 5.2) and with reagent HOCl (Figure 3.2). Fragments were more notable at
higher concentrations of reagent HOCl, and it is probably that increased concentrations
of H2O2 would also result in greater fragmentations. Protein fragmentation can arise
as a result of both carbonyl and chloramine/chloramide formation [260, 310]. Nitrogen-
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centred radicals are formed by decomposition of chloramines and chloramides, which are
known mediators of protein fragmentation as is the hydrolysis of the backbone carbonyl
[307, 311] (c.f. discussion on structural modifications induced by HOCl in Section 3.4).
An interesting structural modification of FN that was observed upon treatment with
the MPO/Cl-/H2O2 system was the apparent shift in the molecular mass of FN (Figure
5.2). This was observed only after addition of H2O2 (i.e. not a result of binding of
MPO to FN above), thus it may arise from the interaction of MPO-oxidant and FN, in
combination with a structural change caused by MPO-derived HOCl [22]. MPO-derived
HOCl is known to oxidise certain side chains causing an unfolding of FN protein, which
may result in greater access for MPO or its oxidants to certain sequences on FN, thus
increasing the molecular mass of FN [270, 271]. The shift in molecular mass may also
be due to binding of FN fragments through disulfide bonds or di-Tyr/di-Trp formations,
or increased binding of SDS to the protein as a result of the charge alteration or protein
unfolding [400–402]. Further investigation is needed to define the exact mechanism of
this molecular mass shift.
HOSCN is assumed to be the major oxidative species generated by the MPO system
when SCN- is substituted for Cl-. Treatment of human plasma FN with MPO/SCN- and
increasing amounts of H2O2 (Figure 5.8) resulted in structural modifications that reflect
those observed when FN was treated with LPO-derived reagent HOSCN (see Figure 4.2
and Section 4). As discussed in Section 4.4, HOSCN has a marked specificity for thiol
residues, thus aggregates are likely formed from thiol oxidation leading to formation of
new disulfides [94, 104–107] or as a result of oxidant catalysed thiol-disulfide exchange
[105, 107, 375, 376]. The observed alterations in FN mass on the gels could be a result
of conformational changes or protein fragmentation although there are limited studies
investigating HOSCN-induced mechanisms of protein fragmentation [102, 103].
These structural modifications may explain the epitope changes on FN protein observed
when the protein was treated with the MPO/H2O2 system using either Cl- or SCN-. If
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MPO is binding to FN at a particular location, this may result in a localised damage, and
identification of these sites could assist in identifying the sequence at which FN binding
occurs. Previous studies have shown that treatment of FN with MPO/Cl-/H2O2 system
was associated with decreased adhesion of ECs, along with ECs retracting and rounding
up [22, 261]. This was suggested to occur due to the inability of cells to bind to modified
ECM via an F-actin mediated adhesion pathway [22]. Cell adhesion was similarly found to
be impaired when FN was first treated with MPO/Cl-/H2O2 system prior to the addition
of HCAEC. Treatment of FN using this MPO system has been shown to cause a reduction
in antibody recognition to the CBF, which is important in mediating cell binding (Figure
5.1), and this is consistent with the observed decrease in cell adhesion (Figure 5.5). Thus
MPO appears to be converting H2O2 and Cl- to HOCl, which subsequently modifies FN
at the CBF epitope in a similar manner to what was found with reagent HOCl treatment
(Figure 3.1, 3.8, and 3.10). Treatment of FN with MPO/SCN-/H2O2 system also showed
some limited modifications on the CBF epitope but this was much less than detected
with LPO-derived reagent HOSCN and MPO-derived HOCl. Both LPO-derived and
MPO-derived HOSCN were found to have little effects on FN HBF epitope (Figure 5.7).
Consistent with these data, the results of experiments carried out to examine HCAEC
cell adhesion and proliferation on MPO/SCN-/H2O2-treated FN showed no significant
changes.
The ability for HCAEC to proliferate was also decreased when incubated on FN treated
with the MPO/Cl-/H2O2 system, but not with the MPO/SCN-/H2O2 system. FN has
been found to be a promoter of cell proliferation with cells other than ECs [403–405],
and this reduction is therefore likely to be due to modifications induced on FN by the
oxidants. However, there is little data on the mechanism by which this may occur, but
it may be contributed to by the role that FN plays in cell growth through cell shape
modulation [406], and interaction with certain cell-surface integrins [259, 404].
In addition to the evidence for alterations to the CBF and HBF functional epitopes
induced by MPO/Cl-/H2O2 system, evidence has also been obtained for the formation
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of a HOCl-generated epitope. This epitope was found to be present on HOCl-modified
LDL, which this antibody (clone 2D10G9) was originally raised against [63, 407]. The
presence of this epitope supports the conclusion that HOCl is being produced by this
MPO/Cl-/H2O2 system and is modifying FN. Other HOCl-induced modifications are
also highly likely to be present in these samples (e.g. 3-chloroTyr and di-Tyr), thus it
would be sensible to further investigate and quantify the formation of chlorinated species
and crosslinks [50, 57].
This chapter has provided preliminary evidence to support that MPO, in the presence of
Cl- or SCN- and H2O2, generates the oxidative species, HOCl and HOSCN, respectively,
and that these oxidants modify FN. These enzymatic systems may simulate more closely
to situations that is occurring in vivo than with the reagent oxidant, as there may be
interactions between MPO enzyme and FN protein which could dictate the severity and
location of modifications. The MPO/Cl-/H2O2 system has been found to modify FN
structure, causing alterations to the CBF and HBF epitopes, with subsequent formation
of a HOCl-derived epitope. A loss of cellular adhesion and proliferation were found to
occur with HCAEC when they were incubated on FN pre-treated with MPO/Cl-/H2O2.
Treating FN with MPO/SCN-/H2O2 caused minor structural changes similar to those
observed with HOSCN, but these effects were more limited and this system did not appear
to target the CBF or HBF epitopes, causing no significant changes to cell adhesion or
proliferation.
In light of these interesting findings, further investigations were conducted whereby Cl-
and SCN- were present simultaneously in the reaction system, to determine whether
there is competitive formation of the two oxidants, HOCl and HOSCN, and hence whether
certain oxidative modifications preside over the other. The next Chapter therefore reports
on investigations into the competition between Cl- and SCN- as the substrate for MPO,
to further elucidate the effects of the MPO/Cl-/SCN-/H2O2 system on FN.
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Chapter 6
Analysis of competitive oxidation of
chloride and thiocyanate by
myeloperoxidase
6.1 Introduction
As described in the earlier chapter of this thesis, MPO plays a key role in the generation
of oxidants, such as HOCl and HOSCN, from physiological concentrations of halides (Cl-)
and pseudohalides (SCN-) in the presence of H2O2 [50, 396]. Higher concentrations of
SCN- can divert MPO to produce more HOSCN, and mitigate HOCl-induced damage to
proteins, cells, and other targets.
Past studies have reported that the presence of SCN- have both a detrimental and
protective effect when investigated in in vitro and in vivo experiments [50, 94]. It has
been found that addition of SCN- to MPO/Cl-/H2O2 system attenuated HOCl-induced
damage on LDL [371] and FN [22, 408]. Moreover, SCN- has been found to protect against
cellular injury mediated by MPO, reducing apoptosis in HL-60 cells [409]. The damaging
effects versus the protective nature of SCN- is an important aspect in the development of
atherosclerosis, whereby smokers for example are usually found to have elevated plasma
SCN- levels [98, 99, 410]. This particular dichotomy will be explored more thoroughly.
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6.2 Aim
The studies in this Chapter investigated the effects of adding increasing concentrations of
SCN- to MPO/Cl-/H2O2 treatment of human plasma FN in order to determine whether
this modulates the extent of damage to FN. Epitope recognition was examined using
ELISA which probed for the FN CBF and HBF epitopes as well as a HOCl-generated
epitope. Structural modifications were investigated using both silver staining and Western
blotting for FN CBF and HBF epitopes.
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6.3 Results
6.3.1 Effects of enzymatic treatment with myeloperoxidase, hydrogen
peroxide, chloride, and increasing concentrations of thiocyanate
on functional epitopes of human plasma fibronectin
SCN- has a higher kinetic rate than Cl- for reaction with Compound I of MPO with
these reactions resulting in the formation of the hypohalous acids, HOSCN and HOCl,
respectively [51]. Oxidation caused by HOSCN is highly specific to thiols but is also
more readily reversible than the modifications caused by HOCl. The presence of SCN-
in samples causes the reaction to produce HOSCN over HOCl until either the SCN- or
H2O2 is depleted.
Surface-bound human plasma FN (0.02 µM) on 96-well plates were incubated with 0.02
µM of MPO, 100 mM of Cl-, increasing concentrations of SCN- from 0 µM to 500 µM,
and 32 µM of H2O2 for 2 hr at 37°C. Sample were washed twice with PBS to remove any
excess oxidants or enzymes prior to probing for the FN functional CBF, HBF epitopes,
and a HOCl-generated epitope. An AP bound secondary antibody was used to detect
the epitopes using pNPP solution as described in Section 5.3.1.
The CBF epitope plays an important role in cell binding, and when modified, can lead
to cellular dysfunction and a decrease in cell adhesion (see Section 3). Human plasma
FN (0.02 µM) treated with 0.02 µM of MPO, 100 mM of Cl-, and 1600x molar excess
of H2O2 reduced antibody recognition to FN CBF epitope (Figure 6.1A), replicating
what was found previously (see Figure 5.1A). When 20 µM of SCN- was added into
samples prior to addition of H2O2, this led to a retrieval of epitope recognition of the FN
CBF epitope back to almost the same level as control (Figure 6.1A). Furthermore, an
increase in the concentration of SCN- resulted in no further changes to the CBF epitope
recognition (Figure 6.1A).
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In further experiments, exposure of human plasma FN to 0.02 µM of MPO, 100 mM of
Cl-, and 1600x molar excess of H2O2, resulted in a statistically significant loss of HBF
antibody recognition (Figure 6.1B), similar to what was observed previous (Figure 5.1B).
With the addition of 20 µM of SCN- to similar reaction systems, antibody recognition
of the HBF site returned approximately to the same level as controls (Figure 6.1B).
With further increases in SCN- concentration, no increase or decrease of HBF epitope
recognition was observed (Figure 6.1B).
The HOCl-generated epitope recognised by the antibody 2D10G9 was found to be
present in samples treated with MPO, 100 mM of Cl-, and 1600x molar excess of
H2O2, at levels almost 18-fold higher than present in controls (Figure 6.1C); this is
similar to what was observed previously (Figure 5.1C). With the addition of 20 µM
of SCN- to the treatment system, the HOCl-generated epitope was not detected, with
the absorbance values decreased to control levels (Figure 6.1C). No further changes were
seen with increased SCN- concentrations in the samples. These studies also showed that
HOSCN does not produce any epitope recognised by this antibody clone (Figure 6.1C).
Furthermore, maximal inhibition was found to occur at 20 µM of SCN- as reported for
all epitopes examined.
These data together show that treatment of human plasma FN with MPO/Cl-/H2O2
can lead to modifications that can be reversed with the addition of relatively modest
concentrations of SCN-. Further investigations were therefore conducted to examine
structural changes to FN and the CBF and HBF epitopes using silver staining and
Western blotting.
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Figure 6.1: ELISA of human plasma FN modified following enzymatic treatment with MPO/Cl-/H2O2
and increasing concentrations of SCN-. Each well was coated with 0.25 µg FN (0.02 µM in 0.1 M
phosphate buffer) was either left untreated (control) or treated with 0.02 µM MPO, 100 mM of Cl-,
increasing concentrations of SCN- and 32 µM of H2O2. Samples were incubated for 2 hr at 37°C. FN
epitopes were detected using a mouse monoclonal A) anti-FN CBF antibody (A17; 1:10000), B) anti-FN
HBF antibody (A32; 1:1000), C) anti-HOCl generated epitope (2D10G9; 1:50), and conjugated with
anti-mouse AP secondary antibody (1:1000). The data are presented as a percentage relative to control
(no oxidant treatment). Error bars are ± SD from three technical replicates obtained from each of
three independent experiments. Statistical analysis was performed using one-way ANOVA with Tukey’s
multiple comparison post hoc tests to determine significance. Statistical significance is identified as
follows: **** = p < 0.0001.
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6.3.2 Effects of enzymatic treatment with myeloperoxidase, hydrogen
peroxide, chloride and increasing concentrations of thiocyanate
on the structure of human plasma fibronectin
Having shown that SCN- can retrieve epitope recognition for these particular functional
sites and also decrease the presence of a HOCl-generated epitope, the effects of increasing
SCN- on the structural changes induced by HOCl on FN was examined. Purified human
plasma FN (0.02 µM) was either left unoxidised (MPO only control) or treated with
either 0.02 µM or 0.1 µM of MPO, 100 mM of Cl-, with 160 µM of H2O2, and increasing
concentrations of SCN- from 0 to 500 µM. Samples were then separated on SDS-PAGE
under non-reducing or reducing conditions prior to silver staining to examine possible
structural changes.
Human plasma FN (0.02 µM) was treated with 0.02 µM of MPO, 100 mM of Cl-, with 800x
molar excess (160 µM) of H2O2 and in the absence of SCN-, reflects the modifications
previously found (Figure 5.2A). Under non-reducing conditions, FN parent monomer
bands (white arrow) were found to have decreased in staining intensity when treated
with MPO/Cl-/H2O2 in the absence of SCN- (Figure 6.2A). This treatment was also
found to cause fragmentation of the protein with the formation of additional bands,
particularly those below the monomer bands (white arrow) (Figure 6.2A). Aggregates or
other higher molecular mass species were also detected. With the addition of 20 µM of
SCN-, there are less higher aggregate bands formed but more protein bands were found
to be present with masses between 268-460 kDa (Figure 6.2A). Furthermore, fragments
with a mass of approximately 190 kDa appeared to be more prominent with increasing
concentrations of SCN- (Figure 6.2A). At 400 and 500 µM of SCN-, which is greater than
the concentration of H2O2 added (160 µM), fewer protein bands between 268-460 kDa
were observed (Figure 6.2A).
Treatment with 0.1 µM of MPO under non-reducing conditions, gave similar modifications
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to those seen with the lower concentration of MPO, together with greater loss of the parent
dimer (black arrow) and monomer bands (white arrow) (Figure 6.2A). At 100 and 400
µM of SCN-, aggregates caused by the treatment can be seen as a smear of the protein
bands and at the top of each well (Figure 6.2A). At 500 µM of SCN-, the modifications
detected were found to be similar to those generated by pre-formed HOSCN, particularly
the bands that are found to form above and below both the parent dimer and monomer
(Figure 4.2A).
FN samples treated with 0.02 µM of MPO, 100 mM of Cl-, with 800x molar excess
(160 µM) of H2O2 in the absence of SCN- and electrophoresed under reducing conditions,
resulted in fragmentation of FN with a band detected at approximately 180 kDa. This FN
fragment was observed with concentrations of SCN- between 0 to 100 µM (Figure 6.2B).
However, when the concentration of SCN- was in excess over the H2O2 concentration (i.e
400 to 500 µM of SCN-), the fragment around 180 kDa was not detected (Figure 6.2B).
At 400 µM of SCN-, formation of dimers/higher aggregates were detected (black arrow)
(Figure 6.2B).
Under reducing conditions, treatment with the 0.1 µM MPO system showed modifications
to the monomer bands (white arrow), which were more extensive in the absence of or at
low concentrations of SCN-, and particularly at 20 to 50 µM of SCN- (Figure 6.2B). At 100
µM of SCN-, the modification seems to be minimised, and increasing SCN- concentration
to 400 µM (i.e greater than the concentration of H2O2) did not result in the fragment
at around 180 kDa (Figure 6.2B). Furthermore, there was also an increased presence of
dimers/larger aggregates caused by this treatment, which was observed at 400 µM and
500 µM SCN- (Figure 6.2B).
To further elucidate the structural changes on FN, Western blotting for the FN CBF and
HBF epitopes was utilised. Proteins separated by SDS-PAGE were transferred to PVDF
membranes and were probed for either the CBF (clone A17) or HBF (close A32) of FN.
Under non-reducing conditions, examination of the CBF epitope showed that incubation
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Figure 6.2: Silver staining showing structural changes to human plasma FN treated with
MPO/Cl-/H2O2 and increasing concentrations of SCN-. Purified human plasma FN (0.2 µM in 0.1
M phosphate buffer) was either left untreated (MPO only control) or treated with MPO/Cl-/H2O2 and
increasing concentrations of SCN- and incubated for 2 hr at 37°C. Samples were electrophoresed using
3-8% Tris-acetate SDS-PAGE gels under A) non-reducing or B) reducing conditions. Gels were then
fixed, and visualised with silver stain and referenced against HiMark™ pre-stained High Molecular Mass
standard. Data are labelled as follows: black arrow = dimer/higher aggregates, and white arrow =
monomer bands.
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of FN with only 0.02 µM of MPO (in the absence of SCN- and H2O2) did not show any
changes to the CBF epitope (Figure 6.3A). In the presence of 100 mM of Cl and 800x
molar excess (160 µM) of H2O2 (absence of SCN-) resulted in extensive aggregate and
fragment formation (Figure 6.3A), which were similar to those observed in the previous
Chapter (Figure 5.2A). Moreover, it can be seen that treatment with Cl- and H2O2 caused
a loss of antibody recognition of the monomer (white arrow) and dimer bands (black
arrow) (Figure 6.3A). Addition of 20 µM of SCN- resulted in several notable fragments,
particularly those between the dimer (black arrow) and monomer bands (white arrow)
(Figure 6.3A). Increasing the concentration of SCN- led to a decrease in HOCl-induced
modifications, and were found to produce fragments and aggregates similar to those seen
with HOSCN (compared to figure 4.2 and 4.3) (Figure 6.3A). A notable modification
was observed when FN was treated with only 0.1 µM of MPO (in the absence of SCN-
and H2O2), with additional bands detected above and below the monomer bands (white
arrow); these were not detected with the lower concentration of MPO (Figure 6.3A).
Exposure of human plasma FN to only 0.1 µM of MPO caused a small increase in intensity
of the fragment band below the monomer bands (white arrow) (Figure 6.3B). The addition
of 0.02 µM of MPO and 800x molar excess (160 µM) of H2O2 to human plasma FN
were found to cause non-reducible aggregates and fragments at approximately 170-180
kDa (Figure 6.3B). Low concentrations of SCN- of 20-50 µM resulted in a decrease in
aggregate formation (black arrow and above), and also decreased in intensity of the 170-
180 kDa fragment band (Figure 6.3B). Higher concentrations of SCN- (100 to 500 µM)
resulted in the detection of lower intensity of aggregates compared to controls, but also
prevented the formation of the HOCl-specific fragments observed at approximately 170-
180 kDa (Figure 6.3B). With 0.1 µM of MPO, under the same treatment conditions, the
addition of 800x molar excess (160 µM) of H2O2 led to a greater smearing of FN and
greater intensity of fragments formed below the monomer bands (white arrow) at 170-180
kDa (Figure 6.3B). Moreover, it required > 100 µM of SCN- before these aggregates and
fragments were prevented from forming (Figure 6.3B).
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Examination of blots that were probed for the HBF epitope of FN showed similar
modifications under both non-reducing and reducing conditions (Figure 6.4). Fragments
and aggregates occurred upon exposure to MPO, 100 mM of Cl- and 800x molar excess
(160 µM) of H2O2 (Figure 6.4). Addition of SCN- was found to reverse the formation of
certain aggregates or fragments, however at higher concentrations of SCN-, the fragments
or aggregates that were detected were similar to those observed with MPO-derived
HOSCN (compare Figure 6.4 with 4.3).
Overall, these data indicate that there are interactions between MPO, H2O2, Cl-,
and SCN-, which may determine the relative yields of HOCl and HOSCN formed by
MPO have on the specific modifications that occur on FN. The following (discussion)
section describes the nature of these interactions between the enzyme and its mixture of
substrates in greater detail.
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Figure 6.3: Western blotting for CBF showing structural changes to human plasma FN treated with
the stated concentrations of MPO/Cl-/H2O2 and increasing concentrations of SCN-. Purified human
plasma FN (0.2 µM in 0.1 M phosphate buffer) was either left untreated (MPO only control) or treated
with MPO (0.02 or 0.1 µM), Cl- (100 mM), H2O2 (160 µM) and increasing concentration of SCN-,
and incubated for 2 hr at 37°C. Samples were electrophoresed on SDS-PAGE under A) non-reducing or
B) reducing conditions, transferred onto PVDF membranes and probed with a mouse monoclonal anti-
FN CBF antibody (A17; 1:10000), and conjugated with anti-mouse HRP secondary antibody (1:2000).
Blots were developed with ECL-plus reagent and data is labelled as follows: black arrow = dimer/higher
aggregates, and white arrow = monomer bands.
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Figure 6.4: Western blotting for HBF showing structural changes to human plasma FN treated with
MPO/Cl-/H2O2 and different concentrations of SCN-. Purified human plasma FN (0.2 µM in 0.1 M
phosphate buffer) was either left untreated (MPO only control) or treated with MPO (0.02 or 0.1 µM), Cl-
(100 mM), H2O2 (160 µM) and increasing concentration of SCN-, and incubated for 2 hr at 37°C. Samples
were electrophoresed on SDS-PAGE under A) non-reducing or B) reducing conditions, transferred onto
PVDF membranes and probed with a mouse monoclonal anti-FN HBF antibody (A32; 1:5000), and
conjugated with anti-mouse HRP secondary antibody (1:2000). Blots were developed with ECL-plus
reagent and data is labelled as follows: black arrow = dimer/higher aggregates, and white arrow =
monomer band.
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6.4 Discussion
MPO is important in the inflammatory response against invading pathogens and its
potential role is to generate reactive bactericidal species to kill pathogens. However,
excessive or inappropriate formation and amounts of oxidants can also be damaging to
host cells and their surrounding ECM. Within the body, Cl- concentrations are typically
in the range of 100-150 mM whereas SCN- fluctuates, with concentrations of 20-250 µM
reported for different individuals [95]. Hence, the relative concentrations of Cl- and SCN-
determine the amount of the two hypohalous acids, HOCl and HOSCN, generated by
MPO at a site of inflammation. With Cl- being more abundant than SCN-, it would be
expected that HOCl is the major species produced although SCN- is the more favoured
substrate for the enzyme [51]. Another known mechanism of HOSCN production is
through a non-enzymatic interaction between HOCl directly with SCN- [92, 93]. This
reaction occurs rapidly (k = 2.34 x 107 M-1 s-1) and spontaneously reducing highly reactive
HOCl concentrations and generating more specific, yet less reactive oxidant HOSCN with
the latter species being specific for thiols [26, 50, 92, 94]. By determining the nature
of interaction between MPO, Cl- and SCN-, in the presence of H2O2 to a biologically
important protein target FN, it was hoped that the extent and specificity of protein
modifications induced by HOCl vs HOSCN could be identified, and the nature of the
modifications induced by these species can be further elucidated.
In the previous Chapter, the modifications of FN induced by MPO/Cl-/H2O2 were
explored. The addition of SCN- at increasing concentrations resulted in the detection
of a greater number of apparent fragments or altered species together with a decreased
intensity of the aggregate bands (Figure 6.2). Previous studies have shown that MPO
has a greater specificity constant for SCN- over Cl- by 730 fold [26, 110]. Furthermore, it
has been reported that at least 40% of H2O2 consumed by MPO under some conditions
reacts with SCN- to generate HOSCN, with a small percentage being used to oxidise other
halides (Br- or I-), with the remaining H2O2 being converted to HOCl [26, 98]. Therefore,
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the presence of lower concentrations of SCN- in the samples is likely to produce small
amounts of HOSCN, which are likely to target Cys residues on FN. However, it is highly
likely that significant amounts of HOCl are still being generated.
In previous studies, MPO in the presence of physiological concentrations of Cl- and SCN-
combined, was found to have a synergistic effect leading to greater oxidation of TNB than
the sum of each separate species [110]. This suggestion was supported by data indicating
that the consumption of H2O2 was greater in the mixed Cl- and SCN- system, with the
rate of consumption proportionate to the concentration of SCN- [110]. The synergistic
generation of oxidant could suggest that in vivo, the mixture of halides is important in
generating a greater inflammatory response, which in turn could modify host proteins
more extensively. This hypothesis may potentially explain why there appears to be a
greater, or altered pattern of modifications on FN with the addition of SCN- to the
MPO/Cl-/H2O2 system.
Increasing the concentrations of SCN- (> 100 µM or approaching 1:1 ratio with 160 µM
of H2O2) resulted in less formation of fragments and aggregates. Furthermore, the loss of
antibody recognition also appears to be mitigated. There appears to be a shift in what
is assumed to be MPO/Cl-/H2O2-derived modifications to MPO/SCN-/H2O2-derived
modifications. The MPO/SCN-/H2O2 system does not seem to modify significantly the
functional CBF or HBF epitopes with no changes in antibody recognition seen in ELISA
or Western blots (Figure 6.1), nor affect the biological functions dependent on these
epitopes as found in previous chapters (Section 4 and 5). This suggests that although
MPO-derived HOSCN is modifying FN in a specific way, it is not targeting CBF or HBF
functional epitopes. HOSCN may target FN at different sequences or epitopes that are
rich in Cys residues which have not been investigated in this study; further investigations
are required to confirm this.
Exposure of FN to MPO, Cl-, and 1600x molar excess (32 µM) of H2O2 was observed to
decrease recognition to both the functional CBF and HBF epitopes, with a corresponding
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increase in presence of a HOCl-generated epitope (Figure 6.1). The addition of 20 µM
of SCN-, which is similar in concentration to the amount of H2O2 present, resulted in
a complete return of recognition to the CBF and HBF epitopes. Moreover, addition of
SCN- led to the disappearance of the HOCl-generated epitope recognised by 2D10G9
with the absorbance levels returning to those found in the controls (Figure 6.1). It may
be likely that MPO in the presence of 20 µM of SCN- and 1600x molar excess (32 µM)
of H2O2 is producing more HOSCN than HOCl, mitigating the damage to the functional
CBF and HBF epitopes, and reducing the formation of the HOCl-generated epitope.
The ELISA results repeated in this chapter in the presence of SCN- did not show a
greater modifications to these FN functional sites (as seen on the gels and by Western
blotting) but rather a return of epitope recognition with the addition of increasing
concentrations of SCN- (Figure 6.1), unlike what was observed earlier in the silver staining
and Western blotting results. There are several reasons why this may not be detected
with the ELISA treatment. Firstly, 1600x (32 µM) of H2O2 was used instead of 800x
molar excess (160 µM) of H2O2. Higher concentration of H2O2 will inevitably lead to a
greater formation of oxidant, and oxidation observed in the silver stain and Western
blot experiments, and less in the ELISA experiments despite the lower molar ratio.
Moreover the ratio of H2O2:SCN- was different between the two sets of experiments
thus the ratio of oxidants (HOCl:HOSCN) is likely to be different between the two sets of
experiments. Interestingly, a ratio of 5:8 (SCN-:H2O2) which was common for both ELISA
and silver staining/Western blotting experiments, a decreased MPO/Cl-/H2O2-derived
modifications, and a shift to what appears to be MPO/SCN-/H2O2-derived modifications
was observed. What may be happening in this case is that the presence of SCN- at a
concentration close to H2O2 is either diverting MPO production to HOSCN instead of
HOCl or SCN- is scavenging HOCl [26, 110]. This suggestion is supported by the presence
of a HOCl-generated epitope when FN was treated with MPO/Cl-/H2O2 in the absence
of SCN-, but the addition of 20 µM of SCN- led to a reduction in the levels of the HOCl-
generated epitope back to levels close to those levels observed in controls (Figure 6.1).
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This would suggest that at 0.02 µM of MPO, 100 mM Cl-, 20 µM of SCN-, 32 µM of
H2O2 the major oxidising agent that gives rise to the detectable modifications on FN
using the approaches examined here is HOSCN.
One limiting factor in these experiments was that it could not determine whether HOSCN
was produced or whether SCN- was scavenging HOCl. Due to time constraints, it
was difficult to create a larger set of experiments. In future experiments, the use of
monochlorodimedon would help to determine whether HOCl was generated in this process
[411]. The use of monochlorodimedon would decrease the reaction between MPO and Cl-,
and thus determine whether HOSCN was produced or whether HOCl was scavenged by
SCN-.
This chapter has shown that the modifications induced on FN by treatment with a
MPO/Cl-/H2O2 system can somewhat be attenuated by the addition of SCN-. The
addition of low concentrations of SCN- was found to potentially increase structural
damage on FN, possibly as a result of damage to a limited number of critical Cys
residues, whereas higher concentrations of SCN- resulted in the change from HOCl-
derived modifications to less damaging HOSCN-derived modifications. By elucidating
the relationship between MPO, Cl-, SCN-, and H2O2, a greater understanding can be
obtained as to the role of SCN- in the progression or prevention of atherosclerosis.
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Chapter 7
Discussion and future directions
7.1 Overview and Summary
FN is a key ECM protein in maintaining basement membrane homeostasis through
protein-protein and protein-cell interactions. FN dimeric protein consists of two nearly
identical monomers bound by two disulfide bonds present near the carboxy-termini [149,
195, 196]. There are two types of FN: soluble plasma FN and insoluble cellular FN, which
are both reported to be found within the arterial wall sub-endothelial matrix [149, 195,
196]. The two types of FN are similar, with the exception that cellular FN possesses
additional EDA and EDB domains, which have been proposed to play a role in matrix
assembly and atherogenesis [140, 273, 274]. FN possesses several functional domains that
interact with other ECM proteins and integrin binding sites on cells [149, 197].
Deposition of LDL in the sub-endothelial matrix is believed to initiate an inflammatory
response leading to the migration of leukocytes and a release of inflammatory species [1].
MPO, a heme-peroxidase that can be detected in plasma, has been shown to transcytosed
into the sub-endothelial matrix, or are released at this location by activated leukocytes
that have migrated into the site of inflammation [21, 270, 397]. High levels of circulating
MPO have been linked to an increased prevalence of CAD in the population [11, 396],
and a deficit was previously linked with a reduced rate of CVD [39]. MPO converts
H2O2 in the presence of physiological concentrations of Cl- and SCN- to generate HOCl
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and HOSCN, respectively [26]. High concentrations of these reactive oxidants have been
shown to modify and damage host lipids, DNA, peptides, and proteins [49, 50].
In Chapter 3, it was shown that exposure of human plasma FN to reagent HOCl caused
fragmentation and aggregation of FN, leading to a loss of antibody recognition of the
functional CBF and HBF epitopes, and increased detection of a HOCl-generated epitope.
HOCl was found to target Met, Trp, and free thiol residues with further oxidation of
MetSO occurring leading to subsequent by-products. Exposure of HCAEC to HOCl-
modified FN resulted in a loss of HCAEC adhesion and metabolic activity. Furthermore,
HCAEC incubated on HOCl-modified FN were found to modulate the expression of
several ECM and adhesion genes in response. Reagent HOCl was also found to damage
HCAEC-derived cellular FN CBF, HBF, and EDA epitopes leading to a loss of antibody
recognition to these functional sites. Furthermore, FN was shown to be present in
advanced Type II-III human atherosclerotic lesions, and were found to co-localise with a
HOCl-generated epitope as seen with IHC.
In Chapter 4, the results of analogous experiments reported in which human plasma FN
was exposed to reagent HOSCN (generated using an LPO/SCN-/H2O2 system). This
treatment resulted in minor modifications (when compared to those observed with HOCl
exposure) with limited fragmentation, aggregation or changes in gel mobility due to
protein unfolding. FN thiols were found to be modified upon exposure to HOSCN, which
is consistent with the known specificity for thiol residues by this oxidant. There were
limited modifications induced on the FN CBF epitope by HOSCN, and this treatment
did not cause any changes to HCAEC adhesion nor metabolic activity. However, HCAEC
incubated on HOSCN-modified FN were found to show altered expression of certain genes
which were different to those induced by HOCl-modified FN. Exposing HCAEC-derived
cellular FN to HOSCN did however induce small changes to the functional CBF, HBF,
and EDA epitopes. This may have arisen from HOSCN targetting key Cys residues in
other domains with this resulting in subsequent changes to these functional epitopes,
which are known to be lacking in these residues.
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In Chapter 5, human MPO/H2O2 with either 100 mM of Cl- or 20 or 500 µM of SCN-
was used to treat human plasma FN. This enzymatic reaction system should more
closely replicate the reaction that is occurring in vivo. Exposure of human plasma FN
to MPO/Cl-/H2O2 system was found to induce structural changes with formation of
fragments, aggregates, and altered mass species possibly arising from protein unfolding.
Moreover, exposure of FN to MPO/Cl-/H2O2 resulted in modifications to the functional
CBF and HBF epitopes causing a loss of antibody recognition, and subsequent exposure
of HCAEC to modified FN was found to decrease HCAEC adhesion and metabolic
activity. Exposure to MPO/SCN-/H2O2 was found to induce minor structural changes
to human plasma FN when compared to MPO/Cl-/H2O2. MPO/SCN-/H2O2 treatment
of FN resulted in minor modifications to the CBF and HBF epitopes, and when HCAEC
were incubated with this modified FN, HCAEC adhesion and metabolic activity was not
affected.
In Chapter 6, human plasma FN was exposed to MPO/Cl-/SCN-/H2O2 to investigate
the competitive generation of HOCl and HOSCN. As expected on the basis of the above
data, exposure to MPO/Cl-/H2O2 system resulted in extensive modifications to FN. The
addition of SCN- mitigated HOCl-derived modifications and at higher concentrations
of SCN-, modifications consistent with the MPO/SCN-/H2O2 system were detected.
Furthermore, the addition of SCN- was found to retrieve antibody recognition of the
functional CBF and HBF epitopes, with a corresponding decrease of the HOCl-generated
epitope recognised by 2D10G9, which was generated in samples where SCN- was absent.
These results are consistent with previous studies examining changes to ECM proteins
by reactive oxidants [22, 64, 65, 130, 260, 261]. The proximity of FN to the arterial
wall cells and the importance of FN for vascular ECM integrity makes it an interesting
target to investigate with respects to whether it is targeted and modified by HOCl and
HOSCN. Modifications to FN can lead to subsequent loss of biological function, and
particularly its ability to interact with other ECM proteins, and cells (ECs and SCMs)
[22, 130, 131, 261]. It would therefore be insightful to investigate changes to other ECM
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proteins, other functional epitopes on FN, the possible protective mechanism of SCN- or
other antioxidant species that may protect against modifications to FN.
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7.2 The implication of modifications to FN by HOCl or HOSCN, and
their interactions with other ECM proteins and cells
FN possesses functional epitopes including those that are important in interacting with
cells (e.g. via the CBF), collagen/gelatin, fibrin and heparin (the latter two have two
domains on FN) [196]. Modifications to the CBF on FN are known to have a drastic
effect on cellular adhesion [22, 130, 261], thus modifications to other functional epitopes
may identify what effect modified FN may have in vivo [130, 258, 318, 412].
The FN collagen binding fragment is known to bind to collagen [217, 218], with a greater
specificity to the denatured form (gelatin) than the native form [258]. This suggest that
FN may be binding with gelatin to initiate degradation of collagen peptides through
activation of collagenases [413]. Some studies have found that collagen triple helices
unfolds at physiological temperatures, which may increase the interaction between native
FN and collagen in vivo [414, 415]. The importance of collagen to FN assembly has
previously been shown in Mov13 mice, whereby inactivation of COL1A1 gene resulted in
sparse assembly of shorter FN fibrils [416]. Furthermore, FN and collagen have been
observed to co-localise, and when FN assembly in SMC culture was inhibited using
an anti-α5β1 integrin antibody, this subsequently inhibited collagen assembly [417].
Blocking the gelatin binding site on FN was also found to prevent deposition of both
collagen and FN fibrils in fibroblast cell culture [258]. These studies support the important
nature of the interactions between FN and collagen, and support the hypothesis that
modifications to the collagen/gelatin binding fragment by oxidants can have a profound
effect on collagen deposition and ECM assembly [418].
In previous studies, it has been proposed that procollagen, which can be cleaved
intracellularly to collagen may interact with FN prior to excretion into the ECM [419,
420]. If this were the case, the collagen/gelatin binding fragment may be occupied,
and FN may be in an altered or unfolded state, thus it may change what sequence is
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susceptible to HOCl or HOSCN modifications. In recent studies, investigations have
examined the mechanical forces between ECM proteins and cells; it has been shown that
FN-collagen interactions were important in reducing load-bearing on FN and decreased
cell mediated stretching of FN (compared to FN-only) [391]. The interaction between
FN and collagen would mean that FN would be less strained, which may modulate some
of the modifications generated by HOCl and HOSCN, which are dependent on protein
conformation and accessibility to epitopes. The amino acid sequence of the collagen
binding fragment is located between 308-608, which posses 23 Cys residues (Uniprot.
data; P02751). The reaction of oxidants in this region may be important due to the high
reactivity of HOCl and the specificity of HOSCN to thiol residues [50]. If this region
were to be modified by either HOCl or HOSCN, this may affect the interactions between
FN and collagen, resulting in improper FN-collagen (and subsequently matrix) assembly
[418].
The fibrin binding fragment in the Type I module of plasma FN plays an important role
in wound healing by binding to fibrin and platelets, providing a strong clot scaffold [197].
Formation of the fibrin-FN clot is mediated by coagulation factor XIII binding to the
N-terminus on FN [421]. Furthermore, the incorporation of FN into clots has been found
to be important in cellular function of platelets [422, 423], and activation of fibroblasts
[424]. Fibroblast binding and activation is mediated by the FN cell binding domain (type
III9-10), a variably spliced domain (type IIICS), in combination with HBF (which alone
does not result in cell adherence) [424]. Cellular FN is then deposited by cells, and both
plasma and cellular FN stimulate the deposition of collagen leading to granulation of
injured tissue and fibrosis [197, 425]. Plasma FN deficiency and FN+/- (expression of
half the amount of FN) in mice were observed to have delayed thrombus formation and
slower rate of arterial occlusion [426, 427]. Infusion of rat plasma FN in FN+/- mice was
found to retrieve the thrombotic defect [427]. The fibrin binding fragment is important in
initiating wound healing, and this may be important in the case of a plaque rupture [428,
429]. Furthermore, if this fragment were to be modified, it may affect the interaction
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between FN and fibrin and subsequent collagen formation for fibrosis (particularly in
plaque cap development).
The FN HBF plays in a myriad of roles, one of which is binding to cell-surface heparan
sulphate proteoglycans (HSPG) [164, 430]. There are two HBF domains in both forms
of FN, HBF I is located at the N-termini and has a weaker binding affinity than HBF
II which is located near the carboxy-termini on the type III12-14 module [196, 431]. This
type III13 domain is known to play a pivotal role in binding Syndecan-2 [207, 432]. Due
to its high binding affinity, it has been found to also bind to GAGs and particularly
CS, although perhaps not as strongly as to heparin [206]. Furthermore, it has been
previously found that the variable region can be alternatively spliced in the type IIICS
region in cellular FN [209]. The HBF in FN is important in matrix assembly and has
been found to increase the distribution of FN in Chinese Hamster Ovary cells (CHO)
[208]. Furthermore, binding of heparin to FN also increased the binding of collagen
[433]. Modifications on the FN HBF, as seen with exposure to HOCl (Section 3) or MPO
enzymatic system (Section 5), may lead to an inability of binding between FN to heparin
or GAG. This may cause impairment in collagen binding and subsequent loss of integrity
in matrix assembly.
Anastellin is a fragment located on the carboxy-termini of the type III1 domain (amino
acid sequence 627-702) and has been shown to regulate polymerization/fibril formation
of FN [434]. The binding of anastellin to FN is dependent on the protein unfolding
to give access to the binding site [435]. It acts on FN to initiate the formation of
superfibronectin (super-FN), which has increased cell adhesion properties, and suppresses
cell migration [436], and proliferation [434]. Moreover, anastellin has been found to elicit
an anti-angiogenic effect [437], although this mechanism is not fully elucidated. It has
been proposed that perhaps the conformational change may cover up certain domains
such as the EDA domain on cellular FN [438]. This suggest that there may be a
relationship between anastellin and the association between EDA and α4β1 integrin [439].
Modifications to this domain (which possesses 3 Trp, 4 Tyr, and no Met or Cys residues)
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by oxidants (HOCl) may have an implication on FN matrix assembly in vivo. The Tyr-
666 residue is known to be critical in binding for ananstellin and the deletion of Type
III1-3 (amino acid 614-901) was shown to have barely detectable levels of matrix fibrils
[440, 441]. Recent study by another member of the group, has identified that anastellin
Tyr-666 (and Tyr-687 ) residues were targets for chlorination upon exposure to HOCl
and MPO/Cl-/H2O2 system (Tina Nybo, 2018, Unpublished data). This may suggest
that modifications to this Tyr-666 residue would have an implication in the assembly of
FN and super-FN, and may play a minor role in disturbing cellular adhesion between FN
and HCAEC (as seen in Section 3 and 5).
Cellular FN is alternatively spliced during production and thus possesses the additional
EDA and EDB domains which are absent in plasma FN [196]. The EDA region, which
is the more extensively researched of these two domains, has been found to mediate
binding to α4β1 and α9β1 [439, 442]. EDA is particularly important during early
vascular development [443–445], and knock-out of both the EDA and EDB domains
(EDA-/-/EDB-/-) was found to be lethal to mice embryos with these observed to have
defects in embryonic cardiovascular development [446]. EDB-/- mice were observed to
develop normally, but fibroblasts derived from these animals were slow growing and
deposited lower levels of FN [447]. Atherosclerotic plaques have been observed to have
elevated levels of EDA containing FN, and these plaques were observed to be more stable
in apoE-/- mice [412]. Furthermore, apoE-/-/EDA-/- mice developed smaller plaques but
had higher levels of macrophage infiltration, lower levels of collagen deposits, and higher
levels of MMP expression and activity [412]. This suggests that EDA is required to
form thicker fibrous plaques that are likely to be more stable and less likely to rupture.
However, there are relatively few studies on the roles of the EDA and EDB domains, and
the extent of their function is not full understood. From the data available, it appears that
these extra domains are important in matrix assembly and mediating cellular functions.
Oxidation and modifications to these domains such as seen as part of these studies may
lead to the formation of more unstable plaques [318], which are commonly associated
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with decreased levels of collagen deposition, and high macrophage numbers.
The importance of FN in maintaining a healthy vasculature can be seen by how it
interacts with other proteins to form matrix and assist in cellular function. Certain
functional epitopes may be reactive with oxidants (HOCl or HOSCN), and can lead
to cellular dysfunction and also improper matrix assembly. There is current on-
going research investigating which amino acids are targets for HOCl on FN and what
peptides/domains are subjected to significant oxidation and chlorination (Tina Nybo,
2018, Unpublished data) [448]. This method is likely to be replicable in examining the
oxidative effects of HOSCN on FN. Further investigations of protein-protein interaction
can complement these findings by identifying whether particular modifications effect
the ability for FN to interact to other ECM proteins [449, 450]. Immunoprecipitation
or co-immunoprecipitation (Co-IP), which are used for strong or stable protein-protein
interactions may be favoured for well-known and categorised interactions [449]. Quartz
Crystal Microbalance (QCM) is a method that utilises a quartz crystal resonator
to measure changes in frequency; it has been used in determining protein-protein
interactions and also provides data on the affinity between two molecules [451]. Biacore is
another detection method that could be utilised to examine native and oxidant-induced
modifications of protein-protein interactions [452]. This method is based on surface
plasmon resonance (SPR), to measure affinity, kinetic rate constants and thermodynamics
of the interactions between proteins [452]. There are several other methods that can be
utilised, some of which are more preliminary (e.g. protein affinity chromatography or
affinity blotting) and others being more specific [449, 450].
Many of the FN domains have been implicated in playing a role in cellular function, and
these functions should be further examined using cells incubated on modified FN [453]. A
common technique employed for examining cell migration is a scratch test, where a surface
area is scratched free of cells and the migration of cells back into this area is monitored
[454]. A Boyden Chamber assay can also be employ to test cell migration, which is a
technique that utilises a porous membrane sitting within medium containing the species
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of interest such as modified FN [455]. Cells will migrate through the semi-permeable
membrane and are subsequently quantified.
As there are current research identifying sites of modifications induced by HOCl and
MPO/Cl-/H2O2 system (Tina Nybo, 2018, Unpublished data), it would be interesting to
expand this further and investigate the effects SCN-. MS analysis of sites of modifications
can be utilised to identify whether SCN- is able to be reduce or prevent the modifications
induced by HOCl and the MPO/Cl-/H2O2 system. Furthermore, it would be important to
elucidate whether HOSCN and MPO/SCN-/H2O2 targets and modifies specific residues
on FN. If HOSCN does target specific residues, then it can be identified whether these
modifications would lead to dysfunction or whether it may reducible by physiological
reductants such as GSH, or ascorbate [392, 393].
Protein-protein interaction is important in identifying whether particular FN functional
domains are more likely targeted than others. However, a mixture of proteins exist in
vivo with FN bound to other ECM proteins and cells (such as EC and SMC) [18, 196,
456]. This suggests that certain targets may be inaccessible to oxidative modifications
due to being bound to cells or other ECM proteins. In these studies, it was shown that
whole HCAEC-derived ECM exposed to HOCl resulted in cellular FN functional epitopes
(CBF, HBF, and EDA) were modified and less extensively by HOSCN. Examination of
other functional sites that are important in binding to other ECM proteins may elucidate
whether those sites are blocked or whether it is still targeted by these oxidants. Moreover,
examination of other ECM proteins, such as laminin, collagen and perlecan, in whole
HCAEC-derived ECM extract are also targeted by these oxidants and modified.
These future studies can further help to determine the role FN has during development of
atherosclerosis, and whether changes to FN can mediate certain responses. By elucidating
these effects, it would assist in identifying whether FN is a suitable target for developing
treatments or prevention of atherosclerosis.
192
7.3 Interaction between fibronectin and cells in healthy and
atherosclerotic blood vessels
Cellular FN, which contains alternatively spliced EDA, EDB, and type IIICS domains
are known to express different types of integrins that can interact with receptors from
different types of cells [196]. In this study, it was observed that the CBF and EDA domain
on FN was modified by MPO-derived oxidants, subsequently leading to loss of adhesion
by HCAEC. Other cells also play a role in the progression of atherosclerosis including
SMC, fibroblasts, and a number of leukocytes. The interactions between FN and cells
may change depending on the structural integrity of FN and their corresponding binding
sites and should be further investigated.
Vascular SMC have been known to play an important role in plaque stability and
subsequent prevention of plaque rupture [14]. It is also known that vascular SMC
both interact and produce FN within the vascular wall [14]. During the development of
blood vessels, SMC has been observed to co-localise with α4β1 receptors on cellular FN,
located on one of the alternatively spliced domains [227]. Mechanical stress and elasticity
within the vascular wall are known to be modified by FN [457], and activate arteriole
SMC response via surface integrins to initiate vasodilation or vasoconstriction [458].
Interactions with FN integrin sites have been shown to mediate SMC migration [459,
460], and proliferation [461, 462]. SMC has been found to interact with β1-containing
integrins (e.g. α5β1), which mediate migration and mobility [459, 460]. Furthermore, the
migration of SMC was observed to occur with αVβ3, both in vivo and in vitro [463–465].
Migration of vascular SMC into the injury site is important in synthesising matrix to
form a strong structural fibrous cap [14]. Inhibition of α5β1 by blocking with an RGD
peptide or mimetic has been shown to cause a reduction in vessel wall thickening in mice
models [466, 467], which may indicate a decrease in fibrotic fibres.
Mechanical stress and stiffness of FN was found to also mediate SMC migration, but not
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so in a FN and laminin mixture [468]. It is known that FN is important in regulating
matrix stiffness by interacting with other ECM proteins and cells [457, 469]. FN has
been observed to regulate SMC cell cycle, whereby SMC incubated on FN remained in
the G0/G1 phase for 6 days with increased cycle D1 expression [470]. The addition of
serum activated the S phase in the cell cycle and these processes were found to be absent
in SMC incubated on laminin [470]. These past studies support the interactions between
native FN and the cellular functions of SMC in blood vessels. Modified FN may lead to
changes in this relationship affecting the ability for SMC to migrate, initiate cell cycle
and respond to new stimulus within the blood vessels.
Another cell type that has been observed to interact with FN are fibroblasts, which
resides in the adventitia of arteries and known to function in angiogenesis [471, 472].
Migration of REF52 fibroblasts has been previously observed to be dependent on the CBF,
HBF, EDA domains, and in particular the α5β1 and αvβ3 integrin on FN [473]. Inter-
and intramolceular cross-linked FN (by glutaraldehyde) resulted in decreased directional
persistence in REF52 fibroblast migration, lower spread area, and an inability to form
polarized protrusions [473], indicating that the access to epitopes was important for
fibroblast migration and cell shape. FN mechanical gradient was observed to mediate
durotaxis of NIH 3T3 fibroblasts, which was found to be absent with laminin or mix FN-
laminin experiments [474]. This indicates that FN plays a role in migration of fibroblasts
but in vivo, this may differ depending on the interaction of ECM proteins between each
other and the availability of epitopes to attract fibroblasts.
Previous studies have observed that interactions between α4β1 and EDA domain on FN
promote stress fibre formation and initiation of fibrosis through FN synthesis, deposition
of matrix, and actin assembly [473, 475]. This suggests that fibroblasts play a role in
the generation of fibrotic fibres at injury sites. This may be important when fibroblasts
differentiate into myofibroblasts in response to injury to initiate fibrosis. The phenotype
of myofibroblast differentiation was found to be determined by the EDA and EDB FN
domains, whereby EDA deposition mediated increased α-SM actin and myofibroblasts
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formation via Transforming Growth Factor β1 (TGF-β1) conversion [476, 477]. This
may indicate that fibroblast migration and differentiation is dependent on FN functional
domains, especially in terms of formation of fibrotic tissue at an area of injury such as
the necrotic core of an atherosclerotic plaque. In this study, it was observed that the
EDA domain was modified by reagent HOCl, thus the dependence of fibroblasts on the
cellular-derived EDA domain and the integrins present on the CBF may suggest improper
migration and differentiation of fibroblasts [473, 476, 477]. This may subsequently lead
to reduced fibrosis and smaller plaque cap formation [473, 475].
Inflammatory cells (such as leukocytes, monocytes, and macrophages) have also
previously found to bind to certain ECM proteins during their adhesion and subsequent
transmigration through the EC layer. The type IIICS domain of FN has been found to
bind monocytes via an α4 integrin in a similar fashion to VCAM-1 [478]. Deamidation
of NGR motifs in FN, was observed to increase U937 monocyte adhesion, and binding
of primary human monocytes mediated by the αvβ3 integrin [479]. Blocking of the type
IIICS domain was found to reduce monocyte adhesion by approximately 20%, suggesting
it may be a minor regulator of monocyte recruitment compared to blocking of VCAM-1
which reduced monocyte adhesion by approximately 80% [480]. Furthermore, inhibition
of α4β1 attenuated recruitment of leukocytes (neutrophils and macrophages) and reduced
neointimal formation in apoE-/- mice [481]. Inhibition of β1 integrin with an antibody
decreased αDβ2 integrin (CD11d/CD18) mediated monocyte adhesion by approximately
50% on FN [482]. EDA deficiency in apoE-/- mice was observed to result in lower levels
of lipid accumulation in macrophages suggesting that the FN EDA domain may also
play a role in foam cell formation [272]. Neutrophils incubated on stiff FN fibres showed
stronger adherence and greater cell spreading than those incubated on looser fibres [483,
484]. Stiffness of FN fibres was determined with different concentrations of FN. Therefore,
FN appears to be important in the binding of inflammatory leukocytes to integrins, but
also in determining different macrophage responses via the EDA domain. These studies
suggest that FN may play a role in the recruitment of inflammatory cells into the injury
195
area by providing integrin binding sites. Modifications to the EDA (and possibly other
functional sites), as seen in these studies, may suggests changes to foam cell formation
and recruitment of inflammatory cells [272].
Interactions between cells and ECM proteins are complex, and the interactions between a
mixture of proteins in vivo and purified proteins can differ greatly. Further investigations
are clearly needed to examine the relationships between different cell types and native and
modified FN. Cell adhesion, cell metabolic activity, and migration can be tested utilising
the methods described in Sections 2 and 7.2. Since there are limited studies examining
gene expressions, such investigations may contribute greatly to the understanding
of cellular response to blood vessel changes such as modifications to FN or other
ECM proteins. Gene expression by HCAEC adhered on modified FN generated by
MPO/Cl-/H2O2 or MPO/SCN-/H2O2 systems would contribute to our understanding
of possible changes and comparison of the data obtained to what has shown in the
studies reported here with reagent HOCl and HOSCN could be very informative. The
competitive system using MPO/Cl-/H2O2 with the addition of SCN- may expose different
gene regulations, perhaps to a lesser degree than in the absence of SCN-, and this should
be examined further. Gene expression, such as conducted in this study (Section 3.3.6),
could be complemented by investigating protein expression. Gene expression and protein
expression are not always proportionately up- or down-regulated and thus should be
examined. Protein expression can be examined by probing for specific proteins with
specific antibodies using Western blotting or ELISA. This will assist in visualising the
relationship and pathways between gene expression and protein expression, as inhibition
or stimulation may occur upstream of protein expression.
196
7.4 Protective and damaging effects of thiocyanate and other
therepeutics
Lifestyle changes have been used as the first stage of treatment for early and advanced
atherosclerosis. This includes healthier eating habits, increased physical activity, control
of body weight, cessation of smoking, and dealing with any underlying mental health
problems, such as chronic stress. A healthy lifestyle in young adults has been found
to significantly decrease the risk of developing atherosclerosis during middle age [485].
Dietary changes are a factor in implementing these changes. This includes reducing
consumption of fatty foods, and shift to a low-fat vegetarian diet, which can reduce LDL
and cholesterol content and results in regression of atherosclerosis [486]. Previous studies
have reported that antioxidant supplementation does not give rise to any changes in the
risk of CVD in patients [133, 487]. It has been then proposed that diverting conversion
of a highly reactive oxidant such as HOCl, to a more specific and often reversible oxidant
such as HOSCN may help in the treatment of atherosclerosis [99, 114, 410]. The studies
reported previously have shown conflicting results, where a small elevation in plasma
levels of SCN- showed a protective effect, decreasing HOCl-induced modifications [99,
114, 410]. However other studies have reported that highly elevated plasma levels of
SCN- led to irreversible modifications induced by HOSCN [99, 114, 410].
The levels of HOSCN in an individual have been proposed to be highly dependent on the
presence of SCN- substrate. Non-smoking individuals have plasma SCN- levels of 20-40
µM, whereas plasma concentration of SCN- in smokers have been reported to be up to
80-400 µM [96–99]. This is a result of smokers having elevated levels of cyanide (CN-),
which the body detoxifies to form SCN- [98, 488, 489]. Smokers have been shown to have
a higher deposition of apoE and an earlier development of atherosclerosis when compared
to non-smokers [490]. These depositions were accompanied by an increased population
of foam cells (lipid-laden macrophages) in the area of injury compared to non-smoking
counterparts [490]. These effects have been linked to elevated levels of plasma SCN-
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[94]. Aside from smoking, elevated plasma levels of SCN- can also occur as a result of
consumption of food products such as cassava, stone fruits, lima beans, and flaxseed [368].
Certain cyanogenic plants, such as broccoli, cabbage, and sprouts can also give rise to
elevated levels of CN- which is detoxified to SCN- in the body [368].
MPO has a higher specificity for SCN- when compared to Cl- by almost 730 fold,
with studies proposing that up to 50% of H2O2 is converted to HOSCN [98, 110].
However, smokers also have high levels of H2O2 [491], therefore higher SCN- may not
be protective as a higher conversion of H2O2 to HOSCN would be expected compared to
HOCl [98, 110]. Elevated plasma SCN- have been linked to accelerated development
of atherosclerosis in younger people, with these individuals presenting with greater
deposition of oxidised LDL and increased formation of fatty streaks in the aortae [111]. As
previously discussed, individuals with higher concentrations of plasma SCN- have been
suggested to enzymatically convert this to HOSCN, which targets thiols and cysteine
residues, and results in MPO-induced depletion of thiols [99]. Reaction of HOSCN with
certain key Cys residues can lead to enzyme inhibition e.g. of protein Tyr phosphatase
enzymes, and modulate cell signalling [108, 410]. In a previous study, high SCN- levels
were not shown to be correlated with atherosclerosis but rather showed correlation with
increased carbamylation [112]. This process is linked to increased levels of OCN-, which
is formed by decomposition of HOSCN [112, 492]. Carbamylation has been found to
target lysine residues leading to formations of homocitrulline, and found to have several
detrimental effects during the development of atherosclerosis (e.g. dysfunction of HDL)
[112, 113].
Reaction of high levels of HOSCN with thiols has been reported to cause high levels
of irreversible products, such as cysteic acid, via over-oxidation of thiols [106]. High
levels of HOSCN has also been shown to be particularly detrimental by inducing protein
thiol depletion and promoting apoptosis in murine macrophage cells with corresponding
increased levels of cytochrome c being released into the cytosol [374]. Furthermore,
treatment with HOSCN led to a higher number of necrotic cells in comparison to controls
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and treatment with the same concentration of HOCl or HOBr [374]. Plasma SCN- levels
have been reported to be inversely proportionate to 3-chloroTyr concentrations on plasma
proteins, which is a common biomarker for HOCl oxidation [367]. This coincided with
a reduction in di-Tyr levels, and this was found to be significant in both smokers and
non-smokers [367]. It is known that HOCl is converted to HOSCN when there is a high
concentration of SCN- [92], this may lead to a skewing of oxidative biomarker levels such
as 3-chloroTyr, where humans or animals with elevated levels of SCN- would have lower
plasma levels of 3-chloroTyr biomarker [367].
Although SCN- has been found to detrimentally impact certain proteins and enzymatic
processes [94, 371], there have been studies showing that certain concentrations of SCN-
can have a somewhat protective mechanism [22, 98, 367]. This protective mechanism of
SCN- has been linked to low levels of MPO, and results in a decreased mortality rate
[99]. Low levels of MPO were found to produce lower levels of oxidation overall with high
levels of SCN- favouring the generation of HOSCN, a less reactive oxidant, over the more
reactive HOCl [99]. Low levels of HOSCN has been found to cause readily reversible
Cys-derived species, such as RS-SCN adducts, sulfenic acids, and disulfides [106, 370].
These species are repairable by GSH and redox enzymes including glutaredoxins and
thioredoxin reductase [106, 370]. Reversible thiols were more readily formed at low levels
of HOSCN in cells as they possess high levels of protein thiols and GSH [493]. However,
low levels of free thiols are present in the extracellular fluids with less than 10 µM of
low molecular mass, and as low as 600-700 µM on proteins [99, 367]. This may mean
that with higher concentrations of HOSCN, there is a greater likelihood that oxidation of
extracellular thiols may lead to irreversible products by over oxidation and also damage
to other amino acid side chains.
HOCl, a more reactive oxidant is known to target several amino acid chains leading
to highly modified peptides [50, 51]. Increased levels of SCN- and hence HOSCN have
been found to reduce damage on non-thiol targets on BSA, in comparison to HOCl at
physiological concentrations [367]. Met, Trp and Tyr residues, which are targets of HOCl,
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were found to be protected, along with Lys and His residues [367]. Increased HOSCN
formation has also been suggested to be biologically relevant, leading to reduced cell
cytoxicity (e.g. to EC, pancreatic cells, and a neuronal cell line) caused by HOCl, and to
protect against inflammatory diseases, such as cystic fibrosis [93]. Inhibition of apoptosis
and caspase 3 has been reported in human EC at low HOSCN doses, further supporting
the proposed protective mechanism afforded by this oxidant [494]. The protective
capability of HOSCN is highly reliant on the levels of MPO, SCN-, and redox enzymes that
are able to repair the reversible damage, such as glutaredoxin, thioredoxin reductase, and
protein disulfide isomerases [495]. SCN- supplementation may therefore help in decreasing
the necessity for invasive treatments such as percutaneous coronary intervention (PCI)
[496], or coronary artery bypass grafting (CABG) [497], and subsequently reduce the risk
of advanced atherosclerosis. However, these studies are preliminary and only show this
protective mechanism to be present at lower concentrations of SCN-. Elevated levels of
SCN- and long exposure to HOSCN were found to be detrimental rather than protective.
Therefore, further investigations are needed to define the appropriate range of SCN- that
is protective rather than damaging in humans.
There are also other possible therapeutics that are currently being studied such as I-
[128], which is another MPO substrate found at very low concentrations in the body [27],
and seleno-compounds [498]. The second-order rate constant of the reduction of MPO
compound I by I- is 7.2 ± 0.7 x 106 M-1 s-1, which is close to that of SCN- of 9.6 ± 0.5 x
106 M-1 s-1 [27]. These rates are much higher than for Cl-, which is 2.5 ± 0.3 x 104 M-1 s-1
[27]. There are few studies examining oxidation of I- to HOI by MPO and the subsequent
effects of HOI. One study examining the effects of HOCl and halides showed that the
MPO/Cl-/H2O2 system oxidised 2’-deoxyguanosine (dG) [128]. Addition of increasing
concentrations of I- (> 1 µM) attenuated this consumption of dG by MPO/Cl-/H2O2
[128]. However, the typical physiological concentration of I- within the body is < 1 µM,
so the relevance of these higher levels of I- is not known [27]. Ischemic reperfusion (IR)
injury occurs after a heart attack and is known to produce an inflammatory response and
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recruitment of MPO releasing leukocytes [499, 500]. A recent study has reported that
I- supplementation can significantly reduce heart damage, characterised by a reduction
in infarct volume and decreased myocardial infarct protein troponin-1 [501]. Elevated
levels of I- may therefore be a possible treatment that can modulate the development of
severity of atherosclerosis, but clearly further investigations are needed due to limited
studies thus far.
Another therapeutic approach that has been studied recently is seleno-containing
compounds [498]. Sulfur-containing side chains, such as thiols and thioethers residues,
are readily targeted by MPO-derived oxidants and downstream materials such as N -
chloramines [50]. It is known that HOCl and HOSCN have a greater reactivity with
selenium species compared to their sulfur analogues [138, 502], and the oxidation products
from these selenium species are more readily reversible than their sulphur counterparts
[137, 138, 503, 504]. It has been reported that seleno-methionine (SeMet) was effective at
scavenging HOCl, and was also reactive with N -chloramine species [498]. Furthermore,
the product from SeMet - the corresponding selenoxide (SeMetO) has been reported
to be readily reduced by endogenous thiols such as GSH [503, 505]. Selenocysteine
containing thioredoxin has been observed to be resistant to over-oxidation and are
readily reversible unlike their sulfur counterparts [137, 138]. This suggests that selenium-
containing compounds may play a role in scavenging biologically relevant HOCl and N -
chloramines and reduce cellular damage during inflammation in inflammatory diseases,
such as atherosclerosis.
High levels of MPO plays a major role in the progression of atherosclerosis [37], therefore
there has been recent studies investigating inhibition of MPO as possible therapeutics
[506, 507]. There are several types of MPO inhibitors but most aim to inhibit the active
sites and prevent the generation of more damaging oxidants [508, 509]. Hydroxamates
have been previously studied as a potential inhibitor of MPO activity but were found to
poorly inhibit MPO activity [510]. Recent studies investigated the effects of substituted
aromatic hydroxamates to examine their inhibitory performance on MPO [506]. It
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was observed that higher binding affinity between MPO and substituted aromatic
hydroxamates resulted in inhibition of the MPO halogenation cycle, thus inhibiting
generation of oxidants [506]. An irreversible target inhibitor currently being investigated
is PF-1355 (Pfizer), which has been found to decrease plasma MPO activity in peritonitis
and vasculitis [507]. These studies have primarily been conducted in vitro or in mice
models, thus further investigations are needed before human application.
There is on-going research investigating these possible therapeutics amongst others.
Perhaps a combination of life style changes based on these recent findings may help
to decrease the severity of CVD and subsequently reduce the risk of heart attacks and
strokes as a consequence of atherosclerosis.
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7.5 Concluding remarks
The studies in this Thesis provides an insight into the reaction between MPO-derived
oxidants, HOCl and HOSCN, on ECM protein, FN. It has been shown that human plasma
FN and HCAEC-derived whole ECM were structurally modified by what is believed to
be physiologically relevant concentrations of HOCl and HOSCN (reagent and within an
MPO/halide/H2O2 system) resulting in important functional domains becoming modified
and unrecognisable by specific antibodies. Moreover, exposure of human plasma FN
to reagent HOCl and MPO/Cl-/H2O2 system was observed to form a HOCl-generated
epitope recognised by antibody clone 2D10G9.
Structural modifications to human plasma FN exposed to MPO-derived oxidants were
observed to impair biological function. Reagent HOCl and MPO/Cl-/H2O2 were both
observed to modify the human plasma FN leading to a reduction in HCAEC adhesion and
HCAEC metabolic activity, likely due to changes to the functional CBF. Furthermore,
exposure of HCAEC to HOCl- and HOSCN-modified FN resulted in different gene
expressions compared to HCAEC exposed to non-treated (native) human plasma FN.
However, exposure of human plasma FN to HOSCN or enzymatic MPO/SCN-/H2O2
system also resulted in minor structural modifications but to a lesser extent compared
to the more reactive HOCl. In the competitive study, the addition of SCN- to
MPO/Cl-/H2O2 system was observed to attenuate some modifications and damage
occurring from exposure to HOCl likely generated from the MPO/Cl-/H2O2. This
suggests that FN is targeted and modified by MPO-derived oxidants with low to moderate
levels of SCN- possibly being capable of reducing the severity of modifications. It is clear
that further investigations are needed to fully elucidate the mechanism of damage and
the relationship between FN, HOCl, and HOSCN.
These studies contribute greatly to the current knowledge of oxidative damage to ECM
proteins by MPO-derived oxidants, HOCl and HOSCN. Developing an understanding of
the role of native and modified FN in mediating endothelial dysfunction, and the factors
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that modulate vascular remodelling could greatly expand the current knowledge about
the progression of atherosclerosis. Furthermore, by elucidating the role and relationship
between FN and MPO-derived oxidants, perhaps a novel therapeutic target could be
identified. This could subsequently lead to a decreased risk of vulnerable plaque rupture
or erosion by formation of more stable plaques, and thus reduction in the occurrences of
myocardial infarction and strokes.
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7.6 Appendix
Table 7.1: All gene expressions of HCAEC incubated on human plasma FN (0.04 µM) pre-treated
with a 1250x molar ratio (50 µM) of HOCl or HOSCN.
Genes Fold Regulation P-Value Fold Regulation P-Value
ADAMTS1 1.20 0.062 -1.24 0.138
ADAMTS13 -2.00 0.008* -1.52 0.009*
ADAMTS8 1.55 0.404 1.59 0.196
CD44 1.04 0.718 -1.01 0.861
CDH1 -3.06 0.263 1.04 0.781
CLEC3B 1.12 3.81 2.82 0.961
CNTN1 -2.47 0.353 -1.86 0.413
COL11A1 -1.29 0.913 1.79 0.345
COL12A1 -5.09 0.011*
COL14A1 1.89 0.320 -1.16 0.848
COL15A1 -1.07 0.526 1.37 0.26
COL16A1 -1.91 0.124 1.13 0.376
COL1A1 -1.07 0.526 1.37 0.426
COL4A2 1.08 0.912 1.25 0.539
COL5A1 -1.30 0.005* -1.23 0.009*
COL6A1 -1.86 0.022* 1.25 0.176
COL6A2 -1.10 0.588 1.42 0.634
COL7A1 1.02 0.960 1.60 0.652
COL8A1 -1.12 1.79 -1.12 0.147
CTGF -1.12 0.009* -1.12 0.147
CTNNA1 -1.24 0.020* -1.17 0.019*
CTNNB1 -1.39 0.018* -1.15 0.66
CTNND1 -1.21 0.048* -1.13 0.119
CTNND2 -1.07 0.526 -1.07 0.517
ECM1 -1.88 0.026* -1.08 0.560
FN1 -1.26 0.007* -1.25 0.002*
HAS1 -3.69 0.076 -1.44 0.295
ICAM1 -1.01 0.989 1.03 0.691
ITGA1 -1.26 0.162 -1.10 0.422
ITGA2 -1.24 0.026* -1.42 0.110
ITGA3 -1.09 0.084 -1.18 0.271
ITGA4 1.69 0.008* -1.17 0.549
ITGA5 -1.29 0.202 1.07 0.276
ITGA6 1.09 0.127 1.01 0.799
ITGA7 -3.90 0.046* -1.92 0.211
ITGA8 1.98 0.404 -1.22 0.389
ITGAL -2.01 0.388 1.62 0.814
ITGAM -3.71 0.126 -1.25 0.616
ITGAV -1.11 0.309 -1.25 0.127
ITGB1 -1.15 0.174 1.05 0.350
ITGB2 -1.34 0.583 -6.79 0.536
ITGB3 -1.81 0.003* -1.00 0.981
ITGB4 -3.10 <0.001* -1.05 0.703
ITGB5 -1.06 0.376 -1.06 0.481
ANOS1 7.86 0.0.333 -1.07 0.517
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Genes Fold Regulation P-Value Fold Regulation P-Value
LAMA1 -1.07 0.526 -1.07 0.517
LAMA2 -1.56 0.045* -1.47 0.451
LAMA3 -1.01 0.911 -1.19 0.407
LAMB1 -1.24 0.055 -1.19 0.064
LAMB3 -1.12 0.115 -1.17 0.192
LAMC1 -1.30 0.113 -1.13 0.435
MMP1 1.33 0.021* 1.02 0.583
MMP10 -1.05 0.454 1.07 0506.
MMP11 -1.89 <0.001* -1.20 0.212
MMP12 3.11 0.512 -1.07 0.392
MMP13 -10.12 0.150 -9.02 0.152
MMP14 -1.46 0.061 -1.35 0.226
MMP15 -1.51 0.259 -1.03 0.876
MMP16 -1.26 0.104 -1.19 0.159
MMP2 -1.35 0.002* 1.00 0.945
MMP3 -2.13 0.245 -3.60 0.112
MMP7 -1.58 0.771 -2.03 0.683
MMP8 -3.14 0.129 -9.58 0.050*
MMP9 -2.58 0.239 -2.27 0.316
NCAM1 2.36 0.553 -2.56 0.397
PECAM1 -1.08 0.393 1.16 0.280
SELE 1.91 0.004* -1.06 0.615
SELL -5.39 <0.001* -1.56 0.009*
SELP -5.37 <0.001 -1.44 0.039*
SGCE -1.03 0.693 1.17 0.069
SPARC -1.00 0.943 +1.18 0.045*
SPG7 -1.17 0.002* -1.06 0.479
SPP1 1.05 0.526 -1.07 0.517
TGFBI 1.05 0.781 1.02 0.972
THBS1 -1.03 0.834 -1.10 0.413
THBS2 -1.86 0.023* -1.11 0.679
THBS3 -1.76 0.016* -1.31 0.145
TIMP1 -1.58 0.002* -1.07 0.456
TIMP2 -1.52 0.004* -1.10 0.247
TIMP3 1.46 0.499 1.92 0.285
TNC 1.18 0.500 1.06 0.706
VCAM1 -1.22 0.348 -1.07 0.512
VCAN -1.47 0.021* -1.03 0.702
VTN -1.08 0.811 -2.79 0.171
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Table 7.2: Gene expressions that were up- or down-regulated of HCAEC incubated on human plasma FN (0.04 µM) pre-treated with a 1250x molar
ratio (50 µM) of HOCl or HOSCN.
Genes Function Fold Regulation P-Value Fold Regulation P-Value
ADAMTS13 von Willebrand factor-cleaving protease -2.00 0.008* -1.52 0.009*
COL12A1 Interaction between collagen I fibrils and matrix -5.09 0.011*
COL5A1 Type V collagen pro-α1(V) chain chain -1.30 0.005* -1.23 0.009*
COL6A1 Type VI α1(VI) chain -1.86 0.022*
CTGF Connective Tissue Growth Factor -1.12 0.009*
CTNNA1 Plays a role in cell adhesion -1.24 0.020* -1.17 0.019*
CTNNB1 Adherens conunctions protein -1.39 0.018*
CTNND1 Armadillo protein for signal transduction adhesion -1.21 0.048*
ITGA2 Integrin α2 partial chain receptor to ECM proteins -1.24 0.026*
ITGA4 Integrin α4 partial chain receptor for FN 1.69 0.008*
ITGA7 Integrin α7 partial chain laminin -3.90 0.046*
ITGB3 Integrin β3 partial chain for ECM & cell adhesion -1.81 0.003*
ITGB4 Integrin β4 partial chain for laminin -3.10 <0.001*
MMP1 Cleaves collagen 1.33 0.021*
MMP8 Degrades fibrillar type I, II, and III collagens. -9.58 0.050*
MMP11 Weakly degrades ECM; control of cell proliferation -1.89 <0.001*
MMP2 Degrades ECM and signal transduction molecules -1.35 0.002*
SELE CAM important in inflammation 1.91 0.004*
SELL CAM between ECs and lymphocytes -5.39 <0.001* -1.56 0.009*
SELP CAM on ECs -5.37 <0.001 -1.44 0.039*
SPG7 Paraplegin; regulator of cell and proteins -1.17 0.002*
THBS2 cell-cell & cell-matrix interactions -1.86 0.023*
THBS3 cell-cell & cell-matrix interactions -1.76 0.016*
TIMP1 MMP inhibitor -1.58 0.002*
TIMP2 MMP & EC proliferation -1.52 0.004*
ECM1 ECM formation & angiogenesis -1.88 0.026*
FN1 Formation of plasma & cellular FN -1.26 0.007* -1.25 0.002*
LAMA2 Laminin α2 chain -1.56 0.045*
VCAN Versican protein -1.47 0.021*
SPARC Regulates cell growth via interaction with ECM and cytokines +1.18 0.045*
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